



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12P 1/00, 1/25, 1/68 C12P 21/00		A1	(11) International Publication Number: WO 92/13083 (43) International Publication Date: 6 August 1992 (06.08.92)
<p>(21) International Application Number: PCT/US92/00437</p> <p>(22) International Filing Date: 17 January 1992 (17.01.92)</p> <p>(30) Priority data: 643,982 18 January 1991 (18.01.91) US</p> <p>(71) Applicant: JOSLIN DIABETES CENTER, INC. [US/US]; One Joslin Place, Boston, MA 02215 (US).</p> <p>(72) Inventors: KAHN, C., Ronald ; 64 Valentine Park, West Newton, MA 02165 (US). WHITE, Morris, F. ; 14 Grettter Road, West Roxbury, MA 02131 (US). ROTHEN-BERG, Paul, Louis ; Oak Hill Condominiums, West 212, 1604 Oakwood Drive, Narberth, PA 19072 (US).</p>		<p>(74) Agent: FREEMAN, John, W.; Fish and Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).</p> <p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: NUCLEIC ACID ENCODING INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN, DISEASES, THERAPY ASSOCIATED WITH THE METABOLISM OF IRS-1</p> <p>(57) Abstract</p> <p>A purified nucleic acid consisting essentially of nucleic acid encoding IRS-1, Insulin Receptor Substrate-1; a purified polypeptide preparation of IRS-1; diagnosing an insulin-related disease comprising measuring an aspect of IRS-1 metabolism; diagnosing an insulin-related disease in a patient comprising determining the structure of the gene IRS-1; assaying an effect of a therapeutic agent which alters the ability of a tyrosine kinase to phosphorylate a substrate; a method of treating mammal suffering from a disease caused by IRS-1 metabolism; treating a mammal suffering from a disease caused by the phosphorylation of a substrate of a tyrosine kinase.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		

- 1 -

NUCLEIC ACID ENCODING INSULIN RECEPTOR SUBSTRATE-1 (IRS-1), IRS-1 PROTEIN,
DISEASES, THERAPY ASSOCIATED WITH THE METABOLISM OF IRS-1

Background of the Invention

The invention relates to insulin metabolism and
5 more specifically to the insulin receptor substrate (IRS-
1) and the gene that encodes it.

Insulin initiates its metabolic and growth
promoting effects upon binding to its tetrameric receptor
(Kahn et al., 1988, J. Clin. Invest. 82:1151-1156, hereby
10 incorporated by reference; Freychet et al., 1976, Proc.
Natl. Acad. Sci. (USA), 68:1833-1837, hereby incorporated
by reference; Cuatrecasas, 1972, Proc. Natl. Acad. Sci.
(USA) 69:1277-1281, hereby incorporated by reference)
thereby activating a kinase in the β -subunit to catalyze
15 the intramolecular autophosphorylation of specific
tyrosine residues of its own β -subunits (Roth, R.A.,
1990, in Handbook of Experimental Pharmacology, Vol. 92,
Cuatrecasas, P., and Jacobs, S., eds., Springer-Verlag,
hereby incorporated by reference; Kasuga et al., 1982,
20 Nature 298:667-669, hereby incorporated by reference;
Kasuga et al., 1982, Science 215:185-189, hereby
incorporated by reference). Autophosphorylation enhances
receptor tyrosine kinase activity toward other protein
substrates (Avruch et al., 1982, J. Biol. Chem.
25 256:15162-15169, hereby incorporated by reference; Roth
et al., 1983, Science, 219:299-301, hereby incorporated
by reference, Rosen et al., 1983, Proc. Natl. Acad. Sci.
(USA) 80:3237-3240, hereby incorporated by reference).
Considerable evidence demonstrates that insulin receptor
30 tyrosine kinase activity is essential for many, if not
all of the biological effects of insulin (Odawara et al.,
1989, Science 245:66-68, hereby incorporated by
reference; Taira et al., 1989, Science, 245:63-66, hereby
incorporated by reference; Moller et al., 1988, New Engl.
35 J. Med., 319:1526-1529, hereby incorporated by reference;

- 2 -

Ellis et al., 1986, Cell, 45:721-732, hereby incorporated by reference; Chou et al., 1987, J. Biol. Chem. 262:1842-1846, hereby incorporated by reference; Ebina et al., 1987, Proc. Natl. Acad. Sci., (USA), 84:704-708, hereby incorporated by reference; Maegawa et al., 1988, J. Biol. Chem., 263:12629-12637, hereby incorporated by reference; Morgan et al., 1987, Proc. Natl. Acad. Sci. (USA) 84:41-45, hereby incorporated by reference). However, the exact biochemical mechanisms linking receptor kinase mediated tyrosine phosphorylation to the regulation of cellular metabolic pathways are undefined.

Tyrosine phosphorylation of several cellular proteins and enzymes has been observed during the initial cellular response to some receptor tyrosine kinase-linked polypeptide growth factors, e.g., PDGF-induced phosphorylation of phospholipase C (Meisenhelder et al., 1989, Cell 57:1109-1122, hereby incorporated by reference), 3'-phosphatidyl-inositol (PI-3) kinase (Kaplan et al., 1987, Cell 50:1021-1029, hereby incorporated by reference), and the raf-1 kinase (Morrison et al., 1989, Cell 58:649-657, hereby incorporated by reference). However, the nature of the physiologically relevant cellular protein substrates of the insulin receptor kinase has remained elusive.

Although many purified proteins and synthetic peptides can be phosphorylated in vitro by isolated insulin receptors (reviewed in, Rothenberg et al., 1990a, in Handbook of Experimental Pharmacology, Vol 92, Cuatrecasas, P., Jacobs, S. eds., Springer-Verlag, hereby incorporated by reference), these reactions do not occur in vivo. When anti-phosphotyrosine antibodies are used to immunoprecipitate phosphotyrosine-containing proteins which appear in intact cultured cells during insulin stimulation, a protein of approximately $M_r=185$ kDa, designated pp185, appears in extracts of several cell

- 3 -

types (White et al., 1987, J. Biol. Chem. 262:9769-9777, hereby incorporated by reference; White et al., 1985, Nature 318:183-186, hereby incorporated by reference; Izumi et al., 1987, J. Biol. Chem. 262:1282-1287, hereby
5 incorporated by reference; Beguinot et al., 1988, Biochemistry 27:3222-3228, hereby incorporated by reference; Kadokawa et al., 1987, J. Biol. Chem. 262:7342-7350, hereby incorporated by reference; Condorelli et al., 1989, J. Biol. Chem. 264:12633-12638,
10 hereby incorporated by reference). Additional phosphotyrosyl proteins of lower M_r have also been described in some cell lines (Rothenberg et al., 1990a, *supra*; Madoff et al., 1988, Biochem. J. 252:7-15, hereby incorporated by reference; Rees-Jones et al., 1985, J.
15 Biol. Chem. 260:4461-4467, hereby incorporated by reference; Bernier et al., 1987, Proc. Natl. Acad. Sci. (USA) 84:1844-1848, hereby incorporated by reference; Heffetz et al., 1989, J. Biol. Chem. 264:10126-10132, hereby incorporated by reference; Levenson et al., 1989,
20 J. Biol. Chem. 264:19984-19993, hereby incorporated by reference). The majority of these putative substrates are unidentified, and of all such putative insulin receptor kinase substrates no clear role in insulin signalling has yet been assigned.

25 Summary of the Invention

In general, the invention features a purified nucleic acid encoding IRS-1. In preferred embodiments the purified nucleic acid is from a mammal, e.g., a rat or a human, the purified nucleic acid is present in a
30 vector, and the purified nucleic acid is present in a cell, the purified nucleic acid is under the transcriptional control of a heterologous promoter. The invention also includes a homogeneous population of cells, preferably eukaryotic cells, wherein each of the
35 cells contains cloned nucleic acid encoding IRS-1.

- 4 -

In another aspect, the invention features a purified preparation of IRS-1, preferably produced from nucleic acid encoding IRS-1. The invention also includes a method of producing IRS-1, including the steps of:

- 5 culturing a cell which contains purified nucleic acid which encodes IRS-1 in medium to form a population of cells which expresses IRS-1 and purifying IRS-1 from the cells or from the culture medium.

In another aspect the invention features a method 10 of purifying a phosphoprotein including in the following order: (a) providing a sample containing the phosphoprotein in the phosphorylated state; (b) contacting the sample with denaturant and a reducing agent under conditions, e.g., heating, or boiling, that 15 inhibit the removal of phosphate groups from the phosphoprotein; (c) decreasing the concentration of the denaturant sufficiently to allow an antiphospho-amino antibody e.g., an anti-phosptyrosive antibody, to bind to the phosphoprotein; and (d) contacting the phosphoprotein 20 with an anti-phosphoamino antibody and purifying the phosphoprotein by virtue of its affinity for the antibody. In preferred embodiments, in step (d), the antibody is bound to a substrate, the sample is contacted with the bound antibody, and the phosphoprotein is eluted 25 from the bound antibody.

In another aspect the invention features a method of diagnosing a disease, e.g., insulin-related disease, e.g., an insulin resistant insulin-related disease, e.g., Type II diabetes, in a mammal, e.g., in a human. In 30 preferred embodiments the disease is characterized by an abnormality in IRS-1 structure or metabolism. The method includes measuring an aspect of IRS-1 metabolism in the mammal, an abnormal level of IRS-1 metabolism being diagnostic of the disease. The metabolism of a 35 substance, as used herein, means any aspect of the

- 5 -

metabolism, expression, function, or action of the substance. Preferred embodiments include those in which: the measurement includes measuring the level of IRS-1 in a tissue sample (a tissue sample as used herein means any suitable sample e.g., a sample including classic insulin sensitive tissue, e.g., muscle, fat or liver tissue, or a sample including more easily accessible tissue, e.g., circulating blood cells or fibroblasts), taken from the mammal; the measurement includes measuring the level of phosphorylation of the IRS-1 in a tissue sample taken from the mammal; the measurement includes measuring the level of kinase activity of IRS-1; and the measurement includes measuring the amount of IRS-1 encoding RNA in a tissue sample taken from the mammal. An insulin-related disease, as used herein, is a disease, disorder, or condition in which some aspect of insulin expression metabolism, or action is disrupted or, a disease in which insulin action contributes to the disease. An insulin resistant insulin-related disease, as used herein, is any disease, disorder, or condition in which a normal amount of insulin results in a less than normal biological response. Examples of insulin resistant diseases include Type II diabetes, obesity, aging related insulin resistance, and insulin resistance that arises secondary to infections, hormonal disorders, or other causes.

The invention also features a method of diagnosing, preferably prenatally, an insulin-related disease, e.g., an insulin resistant insulin-related disease, e.g., Type II diabetes, in a mammal, e.g., a human, including determining the structure of the gene which expresses IRS-1, an abnormal structure being diagnostic of the disease.

The invention also includes a method of assaying an effect of a therapeutic agent on IRS-1 metabolism, e.g., an agent used to treat an insulin-related disease

- 6 -

in a mammal, e.g., a human. (A therapeutic agent, as used herein, can be any substance or treatment.) The method includes administering the agent to a test organism e.g., a cultured cell or a mammal, and measuring
5 the effect of the drug on an aspect of IRS-1 metabolism, e.g., measuring the level of IRS-1 expression, the cellular or intra-cellular distribution of IRS-1, or the level of the IRS-1 phosphorylation. A change in an aspect of IRS-1 metabolism indicates an effect of the
10 agent. In preferred embodiments the insulin-related disease is an insulin resistant disease and the change in an aspect of metabolism is a change in the level of IRS-1 phosphorylation.

The invention also includes a method of assaying
15 an effect of a therapeutic agent which mimics a first effect of insulin, the first effect mediated by IRS-1, without mimicking a second effect of insulin. The method includes administering the agent to a test organism, e.g., a cell grown in culture or a mammal, and measuring
20 a change in an aspect of IRS-1 metabolism, e.g., the level of IRS-1 expression, the kinase activity of IRS-1, the cellular or intra-cellular distribution of IRS-1, or the level of the IRS-1 phosphorylation. A change in an aspect of IRS-1 metabolism indicates an effect of the
25 agent.

The invention also features a method of assaying an effect of a therapeutic agent which alters the ability of a tyrosine kinase to phosphorylate a substrate which includes the amino acid sequence YM XM (Seq. I.D. No. 1).
30 The method includes administering the drug to a test organism, e.g., a cultured cell or a mammal, and measuring the level of phosphorylation of a substrate, which includes the amino acid sequence YM XM (Seq. I.D. No. 1), e.g., a naturally occurring substrate of the
35 tyrosine kinase or a synthetic substrate.

- 7 -

The invention also includes a method of treating a mammal e.g., a human, suffering from a disease, disorder, or condition caused by the phosphorylation of a substrate of a tyrosine kinase, the substrate including 5 the amino acid sequence YM XM (Seq. I.D. No. 1). The tyrosine kinase may be, e.g., a receptor tyrosine kinase, e.g., insulin receptor, epidermal growth factor (EGF) receptor, platelet derived growth factor, (PDGF) receptor, or insulin-like growth factor (ILG) receptor, 10 or an oncogene product, e.g., the src, abl, or fms gene product. The method includes administering a therapeutically effective amount of a therapeutic agent, e.g., IRS-1, which includes the amino acid sequence YM XM (Seq. I.D. No. 1). In preferred embodiments the 15 substance blocks phosphorylation of the naturally occurring substrate by competitive or non-competitive inhibition of the naturally occurring substrate.

The invention also features a method of treating a mammal e.g., a human, suffering from a disease caused by 20 IRS-1, e.g., by an abnormality of IRS-1 metabolism. The method includes administering to the mammal a therapeutically effective amount of a therapeutic agent, e.g., IRS-1, agent which alters an aspect of the metabolism of IRS-1, e.g., the level of IRS-1 25 phosphorylation. In preferred embodiments the abnormality includes the inability of the insulin receptor to respond to insulin by phosphorylating IRS-1. In other preferred embodiments the agent increases the phosphorylation of IRS-1, e.g., by increasing the 30 activity of a kinase or decreasing the activity of a phosphatase.

In other preferred embodiments the agent decreases the phosphorylation of IRS-1, e.g., by decreasing the activity of a kinase or increasing the activity of a 35 phosphatase.

- 8 -

The invention also features a method of treating a mammal, e.g., a human, suffering from a disease caused by a tyrosine kinase. The method includes administering to the mammal a therapeutically effective amount of a 5 therapeutic agent which modifies the ability of IRS-1 to alter the phosphorylation of the tyrosine kinase, thereby altering the activity of the tyrosine kinase. In preferred embodiments the tyrosine kinase is the product of an oncogene.

10 The invention also features a method of treating a mammal, e.g., a human, suffering from a disease characterized by abnormal cell proliferation. Abnormal cell proliferation, as used herein, includes both neoplastic and non-neoplastic diseases, and thus includes 15 diseases such as cancer and atherosclerosis. The method includes administering to said mammal a therapeutically effective amount of a therapeutic agent, e.g., IRS-1, which alters an aspect of IRS-1 metabolism. In preferred embodiments the aspect of IRS-1 metabolism is IRS-1 20 phosphorylation. In other preferred embodiments the aspect of IRS-1 metabolism is the level of kinase activity of IRS-1.

IRS-1, as used herein, means insulin receptor substrate, e.g., mammalian insulin receptor substrate, 25 e.g., rat or human insulin receptor substrate.

Purified nucleic acid, as used herein, means nucleic acid which is separated from other nucleic acid with which it is naturally joined covalently.

A vector, as used herein, is an autonomously 30 replicating nucleic acid molecule.

A heterologous promoter, as used herein is a promoter which is not naturally associated with a gene or a purified nucleic acid.

A nucleic acid encoding IRS-1, as used herein, is 35 a nucleic acid, preferably a DNA molecule, which encodes

- 9 -

a protein which, in its natural state, is phosphorylated by the insulin receptor, preferably in an insulin dependent fashion, and which has at least 70%, preferably 80%, and more preferably 90% homology to IRS-1 or which 5 hybridizes to IRS-1 under conditions of high stringency.

An anti-phosphoamino antibody, as used herein, is an antibody directed against a phosphorylated amino acid, e.g., an antibody directed against phosphotyrosine or phosphoserine.

10 A denaturant, as used herein, is an agent, e.g., a detergent, e.g., SDS, which disrupts the tertiary structure of a protein and thereby inhibits the enzymatic activity of the protein.

A reducing agent, as used herein, is an agent 15 which disrupts S-S bonds.

A phosphoprotein, as used herein, is a phosphorylated protein or polypeptide.

A purified preparation of IRS-1, as used herein, means IRS-1 that has been separated from other proteins, 20 lipids, and nucleic acids with which it naturally occurs.

Preferably, the IRS-1 is also separated from substances, e.g., antibodies or gel matrix, e.g., polyacrylimide, which are used to purify it. Preferably, the IRS-1 constitutes at least 10% dry weight of the purified 25 preparation. Preferably, the preparation contains sufficient IRS-1 to allow protein sequencing.

The method of the invention can be used to diagnose the presence of diseases characterized by an abnormality in the structure or metabolism of IRS-1 or 30 the insulin receptor. The invention allows for the analysis of various aspects of insulin metabolism, e.g., for the determination of insulin receptor function, e.g., the detection of insulin-stimulated substrate phosphorylation. The invention also provides useful

- 10 -

tools for the testing and development of therapeutic agents used to treat insulin or IRS-1 related diseases.

Methods of the invention allow for rapid and high yield purification of phosphoproteins. The denaturation 5 step prevents dephosphorylation and thus allows efficient anti-phosphoamino antibody based purification.

Methods of the invention also allow the treatment of a variety of diseases, e.g., insulin related diseases, insulin resistant diseases, diseases characterized by 10 abnormal cellular proliferation, and diseases caused by the phosphorylation of a substrate by a tyrosine kinase, by intervening in aspects of IRS-1 metabolism.

Other features and advantages of the invention will be apparent from the following description of the 15 preferred embodiments and from the claims.

Description of the Preferred Embodiments

The drawings are first described.

Drawings

Fig. 1 is a graph of the effect of insulin on 20 phosphorylation of pp175 and the β -subunit of the insulin receptor.

Fig. 2 is a diagram of two dimensional phosphopeptide maps of pp175 and the β -subunit of the insulin receptor.

25 Fig. 3 is a graph of the effect of vanadate on blood glucose levels in ob/ob mice.

Fig. 4 is a graph of the effect of vanadate on blood glucose level in ob/ob mice.

30 Fig. 5 is a graph of the effect of vanadate on blood glucose level in db/db mice.

Fig. 6 is a comparison of PTPase activity in the cytosolic liver fraction of ob/+ and ob/ob mice.

35 Fig. 7 is a comparison of the PTPase activity in the particulate and WGA purified fractions of livers from ob/ob and ob/+ mice.

- 11 -

Fig. 8 is a comparison of the PTPase activity in cytosolic liver fraction from db/db and control mice.

Fig. 9 is a comparison of the PTPase activity in the particulate fraction from the livers of db/db and 5 control mice.

Fig. 10 is graph of the effects of vanadate treatment on PTPase activity in particulate fractions from ob/ob mouse livers.

Fig. 11 is a map of probes 138 (Seq. I.D. No. 2) 10 and 80 (Seq. I.D. No. 3).

Fig. 12 is the sequence of rat IRS-1 (Seq. I.D. No. 4).

Fig. 13 is a diagram of overlapping cDNA inserts from two rat liver cDNA libraries.

15 Fig. 14 is a map of three mRNA molecules.

Fig. 15 is a diagram of structural features of rat IRS-1.

Fig. 16 is a map of the putative phosphorylation sites in IRS-1.

20 Fig. 17 is a graph of the effect of insulin stimulation of phosphorylation of synthetic peptides.

Fig. 18 is a graph of the effect of insulin stimulation on phosphatidyl inositol 3-kinase.

Purification and Partial Sequence Analysis of pp185, the 25 Major Cellular Substrate of the Insulin Receptor Tyrosine Kinase

Preparative Purification of pp185

pp185 was purified from liver using SDS denaturation/TCA precipitation, coupled with preparative-30 scale anti-phosphotyrosine antibody immunoaffinity chromatography. Following infusion of insulin total liver extracts of denatured proteins were prepared from SDS-homogenates. After dissolution in base and neutralization, each liver extract was passed through a 35 column of immobilized anti-phosphotyrosine antibody. The

- 12 -

column was washed, and the adsorbed phosphotyrosyl proteins were eluted from the affinity matrix with p-nitrophenyl phosphate (pNPP). (The method is described in detail below).

5 The eluted phosphotyrosyl proteins were analyzed by anti-phosphotyrosine Western blotting and by direct silver-staining, as described below. The pNPP-eluted proteins in the Western blot contain a $M_r=120$ kDa insulin-insensitive protein, and also the insulin-
10 stimulated pp185 and the 95 kDa insulin receptor β -subunit. When these same pNPP-eluted phosphotyrosyl proteins were visualized with a sensitive silver-stain, intense broad bands appear which correspond to the $M_r=120$ kDa protein, and to the insulin-receptor β -subunit.
15 However, at the position corresponding to pp185 there appear two co-migrating bands: one broad band which stains weakly, the other quite narrow. This latter band is also equally evident in the absence of insulin. The broad, poorly staining band detected only after insulin
20 stimulation appears to be authentic pp185. The narrow band, co-migrating at $M_r=185$ kDa, appear to be co-purifying contaminant (not containing phosphotyrosine) which partially and non-specifically eluted from the anti-phosphotyrosine antibody column together with the
25 authentic phosphotyrosyl proteins. This is supported by the presence of this same sharp contaminant band at 185 kDa among those other proteins which were non-specifically absorbed to the affinity column matrix and were not removed by the column washing procedures, but
30 which were dissociable from the affinity matrix by directly heating the matrix in Laemmli sample buffer.

35 To estimate recoveries of the phosphotyrosyl proteins, total amino acid analysis (described below) was performed on a portion of each of the phosphotyrosyl bands. After separation by 1D-SDS PAGE, the

- 13 -

phosphotyrosyl bands were electrotransferred to PVDF membranes, located by Coomassie Blue stain, and each band excised. The total amino acid content and composition of each band was obtained, following *in situ* hydrolysis, on 5 an automated amino acid analyzer. From 50 insulin-stimulated livers, 340 picomoles of the 95 kDa insulin receptor β -subunit, 196 pmoles of the 120 kDa band, and 108 pmoles of the combined $M_r=185$ kDa bands were removed. Based on silver-stained gels and colloidal gold-stained 10 nitrocellulose electroblots it is estimated that about half of the protein in the combined $M_r=185$ kDa band was pp185.

Details of the purification procedure are as follows. SDS-denatured protein extracts were prepared 15 from whole livers of 3-day fasted (preliminary experiments showed that prolonged fasting increased the insulin-stimulated tyrosine phosphorylation of pp185 about 2.5 fold) male rats (200-300 gram initial body weight), following an intraportal infusion of insulin 20 (10^{-6} M) or 0.9% NaCl vehicle for 30 seconds, as described below. 60 grams of dry liver protein precipitate (from a total of 50 livers) was quickly dissolved in 1200 mls of 0.1 N NaOH with vigorous agitation for 5 minutes at 22 C°, and the base neutralized by addition of 4800 mls of 25 100 mM Tris-HCl, to a final pH of 7.4 (The preparation of dry liver protein precipitate is described below). The following additions were made to this solution: EDTA, 1 mM; NaN₃, 0.02%; leupeptin and aprotinin, 1 ug/ml each; PMSF, 0.1 mM.

30 After centrifugation (143,000 x g at r_{max}) for 1 hour at 18 C° in a Beckman Type 35 rotor, the clear supernatant was filtered (0.45 uM cellulose/PVC, Miller-HA), and then passed over a 15 x 1 cm column containing 12 mls of immobilized anti-phosphotyrosine antibody (aPY- 35 Ab) Protein A-TrisAcryl matrix (described below), at 0.8

- 14 -

mls/min., at 4 C°. The column was sequentially washed at 1 ml/min. with 30 bed volumes of 1% Triton X-100, 0.1% SDS, 100 mM NaCl, 50 mM Tris, pH 7.3 at 22 C°, and then with 30 bed volumes of the same buffer lacking NaCl, and 5 finally at 22 C° with 1 bed volume of 50 mM Tris, pH 7.2. The adsorbed proteins were eluted at 22 C° for 2 hours with 4 bed volumes of 100 mM pNPP in 0.025% SDS, 50 mM Tris, pH 7.2. The eluate was made 5 mM in DTT, and then simultaneously dialyzed (against 0.05% SDS, 5 mM DTT, 10 50 mM Tris, pH 7.2) and concentrated 125-fold in vacuo at 22 C° in a Micro-ProDiCon apparatus using PA-15 membranes (Bio-Molecular Dynamics Co., Beaverton, Oregon). The concentrated sample was made 10% in sucrose, 50 mM DTT, and heated at 100 C° for 3 minutes. Since only about 15 half of the phosphotyrosyl protein content of the original liver extract was removed by a single pass over the aPY-Ab column under the conditions just described, the liver extract was therefore recycled through the column, and the adsorption, column washing, hapten 20 elution, dialysis and concentration procedure was repeated, and the final sample combined with the first, and stored at -70 C°.

Dry liver protein precipitate was prepared as follows. Male rats (100 to 250 g) were fed ad libitum 25 with Purina Laboratory Rodent Chow, except where indicated. Rats were injected with sodium amobarbital (150 mg/kg body weight, intraperitoneal) and were used in experiments 10 to 15 minutes later as soon as anesthesia was assured by loss of pedal and corneal reflexes. The 30 abdominal cavity was opened, the portal vein or inferior vena cava exposed, and normal saline (0.9% NaCl) with or without hormone (10^{-6} M insulin) was infused through a 27 g needle connected to a mechanical syringe pump driven at 1 cc/min for 0.5 minutes. Following infusion, the liver or 35 other tissues were rapidly excised, coarsely minced and

- 15 -

immediately disrupted for 45 seconds in 35 cc of solubilization buffer maintained at 100 C° in a water bath with a Polytron PTA 20S generator (Brinkmann Inst. Co., Model PT10/35) operated at maximum speed (Setting 5 10). The solubilization buffer was composed of 2% SDS, 100 mM HEPES (pH 7.8 at 22 C°), 100 mM NaCl, 10 mM EDTA and 50 mM DTT. The homogenate was further heated to boiling with gentle stirring for 2 minutes, and then left to cool to 22 C°. After centrifugation at 35,000 rpm for 10 2 hours at 18 C° in a Beckman Type 35 rotor (143,000 x g at r^{\max}), the supernatant was acidified with 100% TCA, added slowly dropwise at 22 C° with vigorous stirring, to a final TCA concentration of 10%. The mixture was then cooled on ice for 30 minutes. Under these conditions 15 protein and nucleic acids form a copious, flocculent, pink precipitate while SDS remains largely soluble. Preliminary tests indicated that TCA concentrations of 5 and 15% gave identical results. The precipitate was collected by centrifugation at 5,000 rpm in a Sorvall SS- 20 34 rotor at 4 C° for 5 minutes. The precipitate was washed once with 25 volumes of 10% TCA at 4 C°, and the TCA was then extracted by three washes, each with 25 volumes of ethanol:diethyl ether (1:1, v/v) at 4 C°. The precipitate was dried in vacuo for 4 to 18 hours. The 25 final yield of dry precipitate was about 0.05 gram per gram of liver (wet wt.). The precipitate was thoroughly pulverized to a fine powder in a porcelain mortar. In this form the extracted proteins can be stored for at least 1 year at -70 C° without apparent degradation or 30 significant loss of phosphotyrosine content.

Alternate methods of removing the SDS from the initial tissue extracts were evaluated. These include: precipitation of the insoluble potassium salt of SDS by KCl addition (Suzuki et al., 1988, Anal. Biochem.

35 172:259-263, hereby incorporated by reference, Zaman et

- 16 -

al., 1979, Anal. Biochem. 100:64-69, hereby incorporated by reference), dilution of the SDS with an excess of Triton X-100 (Clarke, 1981, Biochem. Biophys. Acta 670:195-202, hereby incorporated by reference), selective precipitation of proteins with cold organic solvents (Hager et al., 1980, 109:76-86, hereby incorporated by reference), and ion-pair extraction of the SDS with triethylamine (Konigsberg et al., 1983, Methods Enzymol. 91:254-259, hereby incorporated by reference). These treatments were unsatisfactory because of much lower yields of phosphotyrosyl proteins and/or formation of intractable protein precipitates which could not be redissolved. Use of different lots of SDS obtained from different manufacturers altered the recovery of phosphotyrosyl proteins, perhaps due to variable contamination with hexadecyl sulfates which have higher protein binding affinity and are less readily removed (Lacks et al., 1979, Anal. Biochem. 100:257-363, hereby incorporated by reference).

For the immunoprecipitation of phosphotyrosyl proteins, 0.1 gram of dry tissue powder was dissolved in 0.1 N NaOH (0.05 g powder/ml) with vigorous stirring at 22C° for 3 minutes. The resulting solution was then rapidly neutralized to pH 8 with 2 volumes of 100 mM Tris-HCl. EDTA (1 mM), NaN₃ (0.1%) and the protease inhibitors PMSF (1mM), leupeptin (1 ug/ml), aprotinin (1 ug/ml) were added, and the slightly turbid solution clarified with a 0.45 um pore diameter cellulose/PVC filter (Millex-HA, Millipore Corp.). Control experiments demonstrated that once resolubilized, the phosphotyrosine content of the extracted proteins was stable for at least 3 days at 4C°. In later experiments omission of the protease inhibitors was without effect. Protein concentrations were determined with the Bradford dye binding assay (Bradford, 1976, Anal. Biochem. 72:248-

- 17 -

254, hereby incorporated by reference) using dye reagent and immunoglobulin protein standards from BioRad, or alternatively by optical density as described by Whitaker and Granum (Whitaker et al., 1980, Anal. Biochem.

5 109:156-159, hereby incorporated by reference). Anti-phosphotyrosine antibodies were added to a final concentration of 3-4 ug IgG/ml and incubated at 4C° with gentle agitation. The immunocomplexes were washed twice by resuspension and brief centrifugation in 1 ml of wash
10 buffer (1% Triton X-100, 0.1% SDS, 100 mM NaCl, 50 mM Tris, pH 7.3 at 22°C) and once further in the same buffer lacking NaCl. After aspirating excess wash buffer, the immunoprecipitated proteins were solubilized in 50 ul of SDS-PAGE sample buffer (Laemmli) with 50 mM DTT at 100°C
15 for 3 minutes. For some experiments, the immunoprecipitated phosphotyrosyl proteins were competitively eluted from the antibody-bead pellet by incubating with 100mM pNPP, 50 mM Tris, pH 7.4, 0.05% SDS for 1 hour at 22°C. The eluate was desalted by
20 centrifugal passage (Helmerhorst et al., 1980, Analytical Biochemistry 104:130-135, hereby incorporated by reference) over a micro-column of G-25 Sephadex, pre-equilibrated with Laemmli sample buffer.

The anti-phosphotyrosine antibody affinity-matrix
25 was prepared as follows. 38 milligrams of affinity-purified rabbit anti-phosphotyrosine antibody (aPY Ab) was adsorbed to 12 mls (settled gel volume) of Protein A TrisAcryl, by slow mixing at 4 C° overnight in 150 mM NaCl, 50 mM HEPES, pH 7.8. The gel matrix was washed
30 three times with 100 mls of 0.2 M sodium borate, pH 9.0 at 22 C°, and resuspended in 45 mls of 0.2 M sodium borate, pH 9.0 also containing 2 mM pNPP (to bind and protect the antibody combining site) for 2 hours at 22 C°. Dimethylpimelimidate was then added (20 mM final
35 concentration), and the matrix gently mixed at 22 C° for

- 18 -

30 minutes to covalently link the antibody to Protein A (Simanis et al., 1985, *Virology* 144:88-100, hereby incorporated by reference). The antibody-matrix was then washed with excess 0.2 M ethylamine, pH 8.0 at 22 C° and 5 incubated 2 hours further in the same buffer to quench unreacted dimethylpimelimidate. The cross-linked matrix was washed extensively and stored at 4 C° in 10 mM Tris, pH 7.5, 150 mM NaCl, 0.02% NaN₃. Use of a tris-acryl matrix for this affinity column was essential, as the 10 relatively hydrophilic nature of this material (Dean et al., *Affinity Chromatography*, IRL Press, Washington, DC pp. 11-14, 1985, hereby incorporated by reference) minimized non-specific adsorption of denatured proteins.

To estimate the yield of purified phosphotyrosyl 15 proteins, the samples were resolved on 5% SDS-PAGE, 0.5 mm thick gels, then electrotransferred to PVDF membranes at 95 volts for 2 hours at 35 C° in 10 mM CAPS, pH 11.0, 10% methanol, as described by Matsudaira (Matsudaira, 1987, *J. Biol. Chem.* 262:10035-10040, hereby incorporated 20 by reference). The PVDF membranes were incubated in 0.1% Coomassie Blue R-250, 50% methanol, for 5 minutes, and following destaining (in 50% methanol, 10% acetic acid), the visible protein bands were individually excised.

Proteins blotted onto PVDF membranes were placed in 6 x 25 50 mm tubes previously baked at 1000 F for 16 hours. The tube(s) were placed in a Waters hydrolysis vial, 200 ul of constant boiling HCl added, and the vial evacuated and flushed with argon. After a final exposure to vacuum, the vial was sealed and heated at 110 C° for 22 hrs.

30 Following hydrolysis, the samples were dried in vacuo, and the resultant amino acids analyzed as follows. The PVDF membrane was wet with 10 ul MeOH, then extracted twice with 100 ul of 0.1 M HCl/20% MeOH. This extract was taken to dryness, dissolved in 4 mM EDTA, and loaded 35 onto an Applied Biosystems 420A derivatizer/analyzer for

- 19 -

amino acid analysis. Phosphotyrosyl protein yields were also estimated by direct silver staining of SDS-PAGE gels (Heukeshoven et al., 1985, Electrophoresis 6:103-112, hereby incorporated by reference), or alternatively by 5 colloidal-gold staining of nitrocellulose electroblots (Li et al., 1989, Analytical Biochemistry 182:44-47, hereby incorporated by reference), (Hunter et al., 1987, Analytical Biochemistry 164:430-433, hereby incorporated by reference) with comparison of band intensities to 10 those of standard reference proteins included in the same gel or blot.

Electrophoresis and immunoblotting were performed as follows. Immunoprecipitated proteins were separated on 0.5 mm thick, 1-D SDS-PAGE (5% T acrylamide) using the 15 formulations of Laemmli (Laemmli, 1970, Nature 227:680-685, hereby incorporated by reference) in a BioRad miniature slab gel apparatus (Mini-Protean) at 175 V (constant). Standard molecular weight protein markers were: myosin (200 kDa), β -galactosidase (116 kDa), 20 phosphorylase b (97.4 kDa) BSA (66.2 kDa) and ovalbumin (42.7 kDa). Electrotransfer of proteins from the gel to nitrocellulose was performed for 2 hours at 100 V (constant) at 5-15°C in the BioRad miniature transfer apparatus (Mini-Protean), as described by Towbin (Towbin 25 et al., 1979, Proc. Natl. Acad. Sci. USA 76:4350-4354, hereby incorporated by reference), but with 0.05% SDS added to the transfer buffer to enhance elution of high molecular weight proteins. Preliminary experiments using alternate transfer buffers (Szewczyk et al., 1985, Anal. 30 Biochem. 150:403-407, hereby incorporated by reference) or transfer times varying from 0.5 to 4 hours gave qualitatively identical results. Non-specific protein binding to the nitrocellulose was reduced by pre-incubating the filter overnight at 4°C in blocking buffer 35 (5% BSA, 1% ovalbumin in TNA [10 mM Tris, pH 7.2, 0.9%

- 20 -

NaCl, 0.02% NaN₃]). The nitrocellulose blot was incubated with anti-phosphotyrosine antibodies diluted in blocking buffer (2 ug/ml) for 2 hours at 22°C and then washed twice for 10 min in TNA, once for 10 minutes in 5 TNA containing 0.05% NP-40, and twice further for 10 minutes each in TNA. The blots were then incubated with 50 uCi of ¹²⁵I-Protein A (6-30 uCi/ug) in 10 mls of blocking buffer for 1 hour at 22°C, and then again washed as described above. Bound anti-phosphotyrosine 10 antibodies were detected by autoradiography using pre-flashed (Laskey et al., 1975, Eur. J. Biochem. 56:335-342, hereby incorporated by reference) Kodak XAR film with Cronex Lightning Plus intensifying screens at -70°C for 12 to 72 hours. Band intensities were quantitated by 15 optical densitometry (Hoefer Instruments Model GS300) of the developed autoradiogram or by direct gamma scintillation spectrometry of bands excised from the nitrocellulose blots.

PMSF, leupeptin, aprotinin, p-nitrophenyl-phosphate, ovalbumin, DTT, dimethylpimelimidate and NP-40 were purchased from Sigma. Sodium amobarbital (Amytal) and porcine insulin and human recombinant insulin (Humulin R) were from Eli Lilly Co. BSA (Fraction V) was from Armour. SDS (protein chemistry special grade), Tris-HCl and HEPES (ultrapure grade) were 25 from Boehringer Mannheim. ¹²⁵I-Protein A was from ICN. Immobilized Protein A beads (Trisacryl) and Triton X-100 (purified grade) were obtained from Pierce. TCA and diethyl ether (anhydrous) were from Fisher Scientific. 30 Wheat germ agglutinin-agarose was from Vector Labs. Male Sprague-Dawley rats were from Charles River, Wilmington, MA. Nitrocellulose (BA85, 0.2um) was from Schleicher and Schuell. PVDF membranes were from Millipore. Reagents for SDS-PAGE, including molecular weight standards were 35 from BioRad. Silver-stain reagent kit was from Sigma,

- 21 -

and colloidal gold-stain from Janssen. Sequencing grade bovine trypsin was obtained from Boehringer Mannheim. HPLC grade trifluoroacetic acid was obtained from Applied Biosystems, Inc.; HPLC grade acetonitrile and water from 5 Burdick and Jackson; and Vydac HPLC columns from The Nest Group. Automated sequencer and analyzer reagents were provided by the manufacturer. All other reagents were of at least analytical grade purity. Polyclonal anti-phosphotyrosine antibodies were raised in rabbits and 10 affinity-purified on phosphotyramine columns as described by Pang et al., 1985, Arch. Biochem. Biophys. 242:176-186, hereby incorporated by reference).

Validation of methods

Phosphotyrosyl proteins are susceptible to rapid 15 phosphatase-mediated dephosphorylation both in vivo (Lau et al., 1989, Biochem J. 257:23-36, hereby incorporated by reference) and during cell extraction procedures (Kamps et al., 1988 Oncogene 2:305-315, hereby incorporated by reference). To assay hormone-stimulated 20 tyrosine phosphorylation in intact organs of the live animal under conditions which block dephosphorylation, tissues were rapidly homogenized at 100 °C in 2% SDS solution also containing 50 mM DTT reductant. These conditions denature all cell proteins, eliminating 25 enzymatic dephosphorylation and proteolysis of phosphotyrosyl proteins. However, attempts at analysis of such SDS extracts from animal tissues by direct, conventional anti-phosphotyrosine antibody immunoblotting yielded only poorly resolved bands of very low intensity.

30 To selectively concentrate cellular phosphotyrosyl proteins by antiphosphotyrosine antibody immunoprecipitation, the SDS denaturant was first removed by precipitation of proteins with TCA - under conditions where SDS remains soluble (Weber et al., in The Proteins, 35 Vol. I, Chapter 3, Neurath and Hill, eds. Academic Press,

- 22 -

1975, pp. 179-223, hereby incorporated by reference). TCA was removed by organic extraction, the protein precipitate redissolved in 0.1N NaOH (conditions where phosphotyrosine is stable, (Cooper et al., 1983, Methods 5 Enzymol. 99:387-402, hereby incorporated by reference), and following neutralization, the phosphotyrosyl proteins were quantitatively precipitated with anti-phosphotyrosine antibodies. The immunoprecipitated proteins were then resolved by 1-D SDS-PAGE, 10 electrophoresed to nitrocellulose, and detected with additional anti-phosphotyrosine antibody and ¹²⁵I-Protein A.

The validity of this method was tested by examining the insulin response of FaO hepatoma - a cell 15 line (Deschartrette et al., 1979, Somatic Cell Gen. 5:697-718, hereby incorporated by reference) with well characterized insulin receptor tyrosine autophosphorylation and endogenous protein phosphorylation (Crettaz et al., 1984, Diabetes 33:477- 20 485; White, et al., 1987, J. Biol. Chem. 262:9769-9777, hereby incorporated by reference). Experiments were performed to compare the recovery of phosphotyrosyl proteins from control and insulin stimulated FaO cells using either the boiling SDS denaturation/TCA 25 precipitation method or using the generally employed, nondenaturing detergent (Triton X-100) extraction method at 0 °C with phosphatase inhibitors (10 mM Na₄P₂O₇, 100 mM NaF, 2mM Na₂VO₄, 10 mM EDTA) (White et al., 1987, J. Biol. Chem. 262:9769-9777, hereby incorporated by reference). 30 Under non-denaturing extraction conditions, in the absence of insulin, FaO cells contain a major phosphotyrosyl protein at M_r=120 kDa. Upon insulin stimulation (10⁻⁶M) for 1 minute, only one new phosphotyrosyl protein appears at M_r=95 kDa, consistent 35 with the autophosphorylated β-subunit of the insulin

- 23 -

receptor. Use of denaturing SDS extraction demonstrates the same $M_r=120$ kDa phosphotyrosyl protein and upon insulin stimulation the appearance of receptor β -subunit phosphorylation. In addition, SDS extraction permits
5 detection of a distinct, insulin stimulated phosphotyrosyl protein at $M_r=185$ kDa. This band has been previously designated pp185 (White et al., 1987, J. Biol. Chem. 262:9769-9777, hereby incorporated by reference; White et al., 1985, Nature 318:183-186, hereby
10 incorporated by reference; Izumi et al., 1987, J. Biol. Chem. 262:1282-1287, hereby incorporated by reference; Beguinot et al., 1988, Biochemistry 27:3222-3228, hereby incorporated by reference; Kadowaki et al., 1987, J. Biol. Chem. 262:7342-7350, hereby incorporated by
15 reference; Condorelli et al., 1989, J. Biol. Chem. 264:12633-12638, hereby incorporated by reference), and is likely an endogenous, cellular substrate of the insulin receptor tyrosine kinase (Tashiro-Hashimoto et al., 1989, J. Biol. Chem. 264:6879-6885, hereby
20 incorporated by reference). The attenuated band intensities and the apparent lack of pp185 in the Triton X-100 extracts compared to the SDS extracts is attributed to incomplete inhibition of phosphotyrosyl phosphatase activity under non-denaturing conditions-despite
25 inclusion of phosphatase inhibitors. When non-denaturing Triton X-100 buffers were used to solubilize animal tissues in preliminary experiments, virtually no phosphotyrosyl proteins could be observed. In contrast, the SDS denaturation/TCA precipitation technique makes
30 possible analysis of insulin receptor tyrosine kinase activity in organs and tissues of the intact animal under physiological conditions, as described herein.
FaO hepatoma cells (Deschัtrette et al., 1979, Somatic Cell Gen. 5:697-718, hereby incorporated by
35 reference) were cultured in Falcon 150 mm diameter

- 24 -

plasticware dishes in Dulbeccos Modified Essential Medium supplemented with 10% heat-inactivated fetal calf serum (Gibco) and penicillin/streptomycin (Crettaz et al., 1984, Diabetes 33:477-485, hereby incorporated by reference) at 37 C in a 5% CO₂ incubator. For experiments, 90% confluent cultures (10⁷ cells) were serum deprived for 16-18 hours prior to hormone stimulation, extraction and analysis. In some experiments, cultures were metabolically labelled with 10 mCi of ³²P-orthophosphate in P_i-free medium for 4 hours prior to analysis by methods described elsewhere (White et al., 1987, J. Biol. Chem. 262:9769-9777, hereby incorporated by reference). Solutions containing sodium orthovanadate were prepared at neutral pH to avoid loss of phosphatase inhibitory activity, as previously described (Kadota et al., 1987, J. Biol. Chem. 262:8252-8256, hereby incorporated by reference).

Proteolytic digestion and sequencing of pp185

Because soluble proteins often have blocked N-termini which prevent Edman degradation (Brown et al., 1976, J. Biol. Chem. 251:1009-1115; Moos et al., 1988, J. Biol. Chem. 263:6005-6008, hereby incorporated by reference) and since pp185 was contaminated by an unknown protein of the same M_r, the amino acid sequencing strategy depended on analysis of both basal and insulin-stimulated bands. The M_r=185 kDa proteins eluted from the anti-phosphotyrosine affinity column were separated by 1D-SDS PAGE, transferred to nitrocellulose, and then digested with trypsin in situ. The resulting tryptic polypeptide fragments were then resolved on a reverse phase C18 HPLC column, and the basal and insulin-stimulated tryptic peptides compared.

Close comparison of the two peptide maps revealed 8 distinct peaks which were present only in the insulin-treated sample (Peaks 42, 43, 58, 72, 73, 76, 80, and 98)

- 25 -

and these were provisionally assigned to pp185. These peak fractions were subjected to direct amino acid sequence analysis in an automated sequenator. In addition, three peaks common to both the control and the 5 insulin-treated maps were sequenced. The amino acid sequence data for all peptides is summarized in Table I.

Table I
SUMMARY OF SEQUENCE DATA FOR pp185 POLYPEPTIDES

- 10 Tryptic peptides were subjected to amino terminal protein sequence analysis as described above. Designations for tryptic fragments correspond to the column peaks described above. Where multiple sequences were identified in a given peak fraction the sequences are designated primary (1•), then secondary (2•), etc., in order of 15 decreasing molar yield. The number in parenthesis after a sequence indicates the position of that sequence in IRS-1.

<u>Fragment</u>	<u>Sequence</u>	<u>Identity</u>
<u>From + Insulin Sample</u>		
42	1• LEYYENEK(44) (Seq. I.D. No. 5)	IRS-1
20 43a	1• EQQQQQQQQqqSILXPpE(871) (Seq. I.D. No. 6)	IRS-1
43b	2• LSSETFSAPXp(1098) (Seq. I.D. No. 7)	IRS-1
58	1• VVAVDXGIK (Seq. I.D. No. 8)	CPS@220
72 ¹ a	1• EETGSTXYMNMDLGPGea(932) (Seq. I.D. No. 9)	IRS-1
72b	2• XLPDAemgXspaXT(484) (Seq. I.D. No. 10)	IRS-1
25 76 ² a	1• <u>SVSAPQQIINPI</u> (635) (Seq. I.D. No. 11)	IRS-1
76b	2• NLIGIY(173) (Seq. I.D. No. 12)	
	3• GQXLTMAN (Seq. I.D. No. 13)	CPS@91
80	1• YIPGATMGTSPALTGDEAr(489) (Seq. I.D. No. 14)	IRS-1
	2• SFAFvS (Seq. I.D. No. 15)	CPS@1263
30 98	1• XISHAISEHVEDSGVHS (Seq. I.D. No. 16)	CPS@1187
98b	2• XL <u>GASPPNAXTAPXXXr</u> (Seq. I.D. No. 17)	IRS-1
98c	3• XPPXTFQXVXXP (Seq. I.D. No. 18)	IRS-1
138 ³	1• SAVTGPGEFWMQVDDSVVAQNmXe(223) (Seq. I.D. No. 19)	None
	2• QADAVYFLPITPQFVTEVIX (Seq. I.D. No. 20)	CPS @478

- 26 -

From - Insulin Sample

53	1. TFEESFQk (Seq. I.D. No. 21)	CPS
115	1. LFATEATSDW (Seq. I.D. No. 22)	CPS@1388
	2. TADDSXIXll (Seq. I.D. No. 23)	CPS@1455

5 Notes:

1 Residues clearly observed at positions 6 and 7 could not be assigned unambiguously to the major vs. minor sequence, as they were of equal yield.

2 Relative molar yield of PTH-derivatives for 1•:2•:3• sequences approximately 2:2:1. Therefore, residues clearly observed at positions 1 through 5 of the 1• and 2• sequences could not be assigned unambiguously to the major versus minor sequence, as they were of equal yield.

3 Equimolar abundance of 1• and 2• sequences. Deduced CPS tryptic peptide @ 478 listed as 2•.

Residues in lower case letters represent assignments of less than full confidence. Positions where no assignment was possible are indicated by X. A = alanine; R = arginine; N = asparagine; D = aspartic acid; C = cysteine; Q = glutamine; E = glutamic acid; G = glycine; I = isoleucine; L = leucine; K = lysine; M = methionine; F = phenylalanine; P = proline; S = serine; T = threonine; Y = tyrosine; and V = valine.

Peak 42 yielded a single, 8 residue sequence.

25 Searching of gene and protein sequence registries reveals this sequence is not identical to any previously reported sequence. Peak 43 yielded an interesting sequence of 18 residues, beginning with Glu, followed by 10 consecutive Gln residues. Peak 43 also contained a secondary (less abundant) sequence of 11 residues. Neither the primary nor the secondary sequence of Peak 43 is identical with reported sequences. Novel sequences were also derived from Peaks 72, 76, 80, 98, and 138. Although Peak 58 appeared in the tryptic map of the insulin-treated sample, the sequence of this peak matched that of an

- 27 -

internal tryptic fragment of carbamyl phosphate synthetase (CPS) (Nyunoya et al., 1985, J. Biol. Chem. 260:9346-9356, hereby incorporated by reference). CPS is an inner mitochondrial matrix protein which is abundant 5 in fasted rat liver (Schimke, 1963, J. Biol. Chem. 237:1921-1924, hereby incorporated by reference). This result suggested that CPS was the protein which non-specifically co-purified with pp185. Additional sequence data supporting this identification of CPS as the 10 contaminant was provided by the sequencing of Peak 53, and Peak 115 from the control sample. CPS was also present in the secondary and tertiary sequences of Peaks 80, and 76, respectively, and also as the primary sequence in Peak 98. Control experiments with anti-CPS 15 antiserum confirmed that CPS is not tyrosine phosphorylated in liver following insulin stimulation.

As evidenced by these results, any individual tryptic peak is not necessarily homogenous and may contain more than a single polypeptide species. To 20 assess possible peak heterogeneity, the ultraviolet absorbance of each peak was monitored with a diode array detector, allowing simultaneous detection at 210 nm, 277 nm and 292 nm. Absorbance at 210 nm and 277 nm monitors for peptide bonds and aromatic residues, respectively, 25 while detection at 292 nm distinguishes peptides containing tyrosine from those containing tryptophan. Tyrosine containing peptides have a low 292/277 nm absorbance ratio, whereas tryptophanyl peptides have a high 292/277 nm ratio. One tryptic peak, 138, was 30 present in the peptide maps of both control and insulin-treated material, absorbing at 210 nm and 277 nm. However, this peak lacked absorbance at 292 nm in the control map but did absorb significantly at 292 nm in the insulin-treated map. Automated Edman degradation of peak 35 138 (from the insulin-treated map) resulted in

- 28 -

identification of two different residues at each of the first 19 sequenator cycles. These residues were of equal yield, thus precluding direct assignment of residues to a primary or secondary sequence. However, analysis of the 5 predicted tryptic cleavage products of CPS revealed one CPS peptide sequence (at CPS residue 478) which uniquely matched one of each pair of residues present in the first 19 sequencer cycles of peak 138. Therefore, it was possible to subtractively deduce the second, novel 10 peptide sequence (which contained the predicted tryptophan) from the data obtained from peak 138, and assign this sequence to pp185.

Enzymatic cleavage of pp185 was performed as follows. Anti-phosphotyrosine affinity-purified liver 15 proteins, concentrated by vacuum-dialysis into a solution containing 3% SDS, 50 mM Tris, pH 7.2, 50 mM DTT, 10% sucrose, were made 5% in SDS, then preparatively separated by reducing 1-D SDS-PAGE (5.5% T -0.8% C°) in a BioRad miniature slab gel apparatus, using 1.2 mm thick 20 gels, run at 150 Vests, with electrophoresis buffers as described by Laemmli (Laemmli, 1970, Nature 227680-685, hereby incorporated by reference). After electrophoresis, the proteins were electro-transferred to BA 85 nitrocellulose in transfer buffer (10 mM Tris, pH 25 8.0, 192 mM glycine, 20% methanol, 0.02% SDS) for 2 hours at 4 C°, and then for an additional 15 minutes in transfer buffer lacking SDS. To locate the protein bands, the nitrocellulose was stained for 2 minutes in 0.1% Ponceau S, 1% acetic acid, and destained for 4 30 minutes in 1% acetic acid. The lightly stained bands were excised with a scalpel, washed three times with HPLC-grade water, and stored moist at -20 C°.

Peptide fragments of the electrophoretically separated proteins were generated by in situ proteolytic 35 digestion of the nitrocellulose-bound proteins with

- 29 -

trypsin, as described by Aebersold (Aebersold et al., 1987, Proc. Natl. Acad. Sci. USA 84:6970-6974, hereby incorporated by reference), but omitting the NaOH wash to minimize the loss of protein. After digestion the
5 solution was immediately stored at -20 C° until separation of the resultant peptides by narrow-bore reverse phase HPLC.

Reverse phase HPLC separation of peptides was performed as follows. Peptides were separated by narrow-
10 bore reverse phase HPLC on a Hewlett-Packard 1090 HPLC equipped with a 1040 diode array detector, using a Vydac 2.1 mm x 150 mm C18 column. The gradient employed was a modification of that described by Stone et al. (Stone et al., 1989 Techniques in Proteins Chemistry, Hugli ed.,
15 pp. 377-391 Academic Press). Briefly, where buffer A was 0.06% trifluoroacetic acid/H₂O and buffer B was 0.055% trifluoracetic acid/acetonitrile, a gradient of 5% B at 0 min, 33% B at 63 min, 60% B at 95 min and 80% B at 105 min with a flow rate of 0.15 ml/min was used.
20 Chromatographic data at 210, 277 nm and ultraviolet spectra from 209 to 321 nm of each peak were obtained. While monitoring absorbance at 210 nm, fractions were manually collected by peak into microfuge tubes and immediately stored without drying at -20 C° in
25 preparation for sequence analysis.

Amino terminal peptide sequence analysis was performed as follows. Samples for amino terminal sequence analysis were applied directly to a polybrene pre-cycled glass fiber filter and placed in the reaction
30 cartridge of an ABI Model 477A protein sequencer. The samples were subjected to automated Edman degradation using the program NORMAL-1, which was modified using the manufacturer's recommendations for faster cycle time (36 min) by decreasing dry-down times and increasing reaction
35 cartridge temperature to 53 C° during coupling. The

- 30 -

resultant phenylthiohydantoin amino acid fractions were subsequently identified using an on-line ABI Model 120A HPLC and Shimadzu CR4A integrator. Computerized protein and gene sequence database searches were performed using 5 the Intelligenetics FASTDB program. Anti-peptide antibody studies

If the novel peptide sequences we assigned to pp185 are contained within the primary structure of this insulin receptor substrate, then antibodies to these 10 peptides should recognize a protein with properties expected of pp185. To test this prediction, polyclonal antibodies to a synthetic peptide containing the first 15 residues of the primary sequence of Peak 80 (Table I) were raised. Anti-peptide 80 antibodies clearly reacted 15 on immunoblots with a single $M_r=185$ kDa band which had first been immunoprecipitated with anti-phosphotyrosine antibodies from extracts of insulin-stimulated liver. Anti-peptide 80 antibodies do not recognize such a band 20 in the anti-phosphotyrosine immunoprecipitate obtained from control (no insulin treatment) liver extracts. This result is consistent with the presence of phosphotyrosine in pp185 only after the insulin receptor tyrosine kinase has been activated. Anti-peptide 80 antibodies also 25 immunoprecipitate from both control and insulin-stimulated liver extracts a single 185 kDa protein which is recognized equally well on immunoblots by anti-peptide 80 antibodies, but which is reactive with anti-phosphotyrosine antibodies only when precipitated from insulin-stimulated livers. Additional control 30 experiments demonstrated that anti-peptide 80 antibody immunoprecipitation of the $M_r=185$ kDa protein was completely blocked when 1 uM synthetic peptide 80 was added to the original liver extract. These results strongly support the derivation of the novel peptide 35 sequences of Table I from authentic pp185.

- 31 -

Anti-pp185 antibodies were prepared as follows. Polyclonal antibodies to peptide segments of pp185 were raised in young adult New Zealand White rabbits.

Synthetic peptides were prepared by solid phase peptide synthesis and purified by reverse-phase high pressure liquid chromatography. Peptides were coupled to RSA carrier by the bis-diazobenzidine method (Gordon et al., 1958, J. Exptl. Med. 108:37-51, hereby incorporated by reference) and by glutaraldehyde (Reichlin, 1980, Methods Enzymol. 70:159-165, hereby incorporated by reference), and a mixture of these conjugates used to immunize three rabbits. Immunoglobulin fractions of the sera were prepared by ammonium sulfate precipitation and DEAE-Sephadex chromatography (Harlow et al., 1988, Antibodies Lab Manual, pp. 302-305, Cold Spring Harbor Laboratory Press, hereby incorporated by reference). Antibodies were further affinity-purified on a column prepared by coupling synthetic peptide to Affigel 10 (according to the manufacturers directions), with antibody elution using 100 mM glycine, pH 2.5 and rapid neutralization.

To assess anti-peptide immunoreactivity with non-denatured pp185, whole rat liver cytosolic extracts were prepared by homogenizing 1 gram of liver in 25 cc of homogenization buffer (0.25 M sucrose, 5mM EDTA, 5 mM EGTA, 10 mM Na₄P₂O₇, 20 mM NaF, 50 mM HEPES, pH 7.5, 1 mM PMSF, 5 ug/ml leupeptin, 5 ug/ml aprotinin, 1 mg/ml bacitracin, 0.1 mg/ml benzamidine) at 0°C, and clarified by centrifugation at 100,000 x g) for 1 hr.

Insulin Metabolism and pp185

30 Hepatic insulin response

To determine the rate of insulin receptor autophosphorylation and its relationship to tyrosine phosphorylation of cellular proteins in vivo, insulin (10^{-5} M) was infused into the portal vein of anesthetized rats. In the absence of insulin only one major,

- 32 -

phosphotyrosyl protein ($M_r=120$ kDa) is present. At the earliest time point sampled after initiating insulin infusion the insulin receptor β -subunit appeared at $M_r=95$ kDa and was already maximally autophosphorylated.

5 Similarly, at $t=0.5$ min the endogenous substrate of the insulin receptor (pp185) was also maximally tyrosine phosphorylated. Despite continuous insulin infusion, the level of insulin receptor β -subunit tyrosine phosphorylation slowly decreased, with a $t_{\frac{1}{2}}=6$ minutes
10 (determined by densitometry of autoradiographs from 3 replicate experiments). Under these same conditions, pp185 was even more rapidly dephosphorylated, and reduced to nearly baseline intensity after only 2-3 minutes. No additional insulin-stimulated phosphotyrosyl proteins
15 were detected in liver over this time period, even when gel electrophoresis conditions were adjusted to resolve low M_r proteins (%T acrylamide=10-15%), or when autoradiographs were over exposed, or when the insulin-stimulated liver was initially quick frozen and powdered
20 in liquid N₂ prior to further processing, or when two alternate preparations of anti-phosphotyrosine antibodies were used. Essentially identical patterns of tyrosine phosphorylation of the $M_r=185$ kDa and 95 kDa bands were observed in hindlimb skeletal muscle and epididymal fat
25 pads, following acute insulin infusion into the inferior vena cava. However, in rat fat pads, an additional, insulin-sensitive phosphotyrosyl protein of $M_r=60$ kDa is also readily detected. No consistent, insulin-related change in the tyrosine phosphorylation of the $M_r=120$ kDa
30 band has been observed.

The in vivo insulin sensitivity of hepatic insulin receptor kinase activation and substrate phosphorylation was examined by varying the concentration of insulin infused into the portal vein from 10^{-12} to 10^{-6} M. With
35 increasing insulin, the intensity of insulin receptor β -

- 33 -

subunit and pp185 tyrosine phosphorylation increased in parallel, although the pp185 band was 30% as intense as the β -subunit band. Half-maximal phosphorylation occurred at $1-5 \times 10^{-8}$ M insulin. Based on dilution of 5 the infusate by portal blood flow (portal flow in 200 g, anesthetized rat: 8.9 cc/min, (Vidt et al., 1959, Circ. Res. 2:759-768, hereby incorporated by reference); insulin infused at 0.2 cc/min.) the effective insulin concentration within the hepatic sinusoids and at the 10 cell surface is at least 45-fold lower than the infused concentration. Thus, the insulin sensitivity is in good agreement with the reported binding constant of the hepatic insulin receptor (Kahn et al., 1974, J. Biol. Chem. 240:2249-2257, hereby incorporated by reference). 15 The observed results are not dependent on the anti-phosphotyrosine antibody immunoprecipitation/immunoblotting assay, as control experiments demonstrated the linearity of the method over the range of antibody concentrations used.

20 Regulation of insulin-stimulated tyrosine phosphorylation in vivo

To investigate whether physiological states which modulate tissue insulin sensitivity might be associated with altered patterns of in vivo protein tyrosine phosphorylation experiments were performed with rats subjected to prolonged fasting, streptozotocin-diabetes, and hypophysectomy. Fasting diminishes pancreatic insulin secretion and also includes peripheral tissue insulin resistance (DeFronzo et al., 1978, J. Clin. Invest. 62:204-212, hereby incorporated by reference; Cech et al., 1980, Biochem. J. 188:839-845, hereby incorporated by reference). In these experiments male Sprague-Dawley rats, initial body weight 200-250 grams, were deprived of food for 1, 2, or 3 consecutive days, 35 anesthetized, and saline without or with 10^{-6} M insulin

- 34 -

was infused into the portal vein at 1 cc/min for 0.5 min. The entire liver of each animal was excised and processed for anti-PY antibody immunoprecipitation and immunoblotting as described in above. Results are 5 representative of three replicate experiments. Control animals infused with saline alone contain only the Mr=120 kDa phosphotyrosyl band and that this band did not change with prolong fasting nor was it influenced by acute insulin infusion. After a 1 day fast, insulin did 10 promote tyrosine phosphorylation of the insulin receptor β -subunit (Mr=95 kDa) and pp185 with a pattern similar to that in fed animals. Over the next two days of fasting the β -subunit band increased slightly compared to the 1 day fasting condition (26%, mean of 3 experiments). 15 However, a much greater increase occurs over this same period in the pp185 band with a 100% increase after only 2 days and a 146% increase after 3 days fasting, relative to day 1. At day 3, the intensity of the pp185 band is nearly equal to the β -subunit band intensity. Whether 20 this relative increase in the pp185 band results from induced expression of the pp185 protein or whether it is related to increase phosphorylation (or decreased dephosphorylation) of a constant level of pp185 remains to be determined. 25 Another condition of insulin deficiency and hepatic insulin resistance occurs in diabetes induced by the islet cell toxin streptozotocin (Dall'aglio et al., 1985, Amer. J. Physiol. 249:E312-316, hereby incorporated by reference). Adult Sprague-Dawley rats were injected 30 with streptozotocin (55 mg/kg b.w.) or vehicle alone and the development of diabetes monitored by assay of blood and urine glucose levels. In these experiments male Sprague-Dawley rats were injected on Day 0 via tail vein with saline-citrate buffer, pH 4.5 without (control) or 35 with streptozotocin (STZ-diabetic), at 55 mg STZ/kg body

- 35 -

weight. On Day 3 when the diabetic condition was confirmed by blood glucose levels greater than 300 mg/dl, some diabetic animals (Ins Tx'd STZ) received once daily subcutaneous insulin injections (6 units Humulin R) and 5 the experiment shown above performed on Day 10. Blood glucose was 116 ± 20 mg/dl (mean \pm S.D.; n=10) in control rats, 377 ± 51 mg/dl (n=10) in STZ-diabetic rats, and 70 ± 54 mg/dl (n=6) in insulin-treated diabetic rats. Body weights at sacrifice were 304 ± 19 g (mean \pm S.D.) in 10 control rats, 250 ± 7 g in diabetic rats, and 314 ± 7 g in insulin-treated diabetic rats. Anesthetized animals received intraportal infusion of saline without (-) or with 10^{-6} M insulin (+) for 0.5 min and the entire liver 15 excised and processed for anti-PY immunoprecipitation and immunoblotting as described in above.

In the euglycemic control rats the hepatic response is essentially the same as previously described, without and with acute insulin stimulation. In the streptozotocin-treated, diabetic animals, the activated 20 insulin receptor β -subunit underwent tyrosine autophosphorylation to an extent only 33% (mean, n=3) greater than control rats, while pp185 tyrosine phosphorylation increased by 142% (mean, n=3) relative to control rats. When the diabetic rats were treated with 25 daily subcutaneous insulin injections to normalize their blood glucose levels, the intensity of insulin receptor β -subunit and pp185 tyrosine phosphorylation also normalized.

Another state of relative insulin deficiency and 30 impaired glucose tolerance is induced in the rat by hypophysectomy (Penhos et al., 1971, Endocrinology 88:1141-1149, hereby incorporated by reference). Following hypophysectomy, insulin receptor β -subunit autophosphorylation was not significantly altered, 35 increasing only 33% (mean, n=2) compared to controls,

- 36 -

whereas the level of pp185 tyrosine phosphorylation was markedly increased (315%) compared to sham-operated controls.

In these experiments control (sham-operated) or 5 hypophysectomized male Sprague-Dawley rats (100-125 gram initial body weight) were fed ad libitum, and used 3-5 weeks after surgery. Anesthetized rats received an intraportal infusion of saline without or with 10^{-6} M insulin for 0.5 min. The entire liver was excised and 10 processed for anti-PY immunoprecipitation and immunoblotting as described in above. The results are representative of the same experiment repeated twice.

Tissue distribution studies

If insulin receptor kinase mediated tyrosine 15 phosphorylation of endogenous cellular proteins is an obligatory component of the metabolic regulatory effects of insulin in vivo, then this process should occur in organs besides the liver. To determine the tissue distribution of phosphotyrosyl proteins male Sprague- 20 Dawley rats were anesthetized and saline without or with 10^{-6} M insulin was infused into the portal vein (for liver) or the inferior vena cava (other tissues) for 1 minute at 1 cc/min. Tissues were excised and phosphotyrosyl proteins analyzed by anti-PY antibody 25 immunoprecipitation and immunoblotting as described above. Liver, kidney, spleen, brain, and hindlimb skeletal muscle, and epididymal fat pads were examined under basal and insulin-stimulated conditions. In both the absence or presence of insulin, all tissues examined 30 contain an Mr=120 kDa phosphotyrosyl protein and as noted above in the liver, the intensity of this band is unaffected by insulin. In skeletal muscle, a major insulin target tissue, insulin clearly stimulates insulin receptor β -subunit autophosphorylation together with the 35 appearance of a prominent phosphotyrosyl protein at

- 37 -

Mr+185 kDa, comparable in intensity to the muscle insulin receptor and to hepatic pp185. An analogous pattern of receptor and pp185-like protein phosphorylation is also observed in rat epididymal fat pads. In this tissue an 5 additional, distinct phosphotyrosyl protein at Mr=60 kDa also appears after acute insulin stimulation. This band is more clearly resolved by a 10% gel and no bands of lower Mr are evident. The Mr=60 kDa phosphotyrosyl protein has been reported previously (Mooney et al., 10 1989, Endocrinology 124:422-429, hereby incorporated by reference; Momomura et al., 1988, Biochem. Biophys. Res. Comm 155:1181-1186, hereby incorporated by reference) in insulin-treated, isolated adipocytes and may be a unique substrate of the insulin receptor kinase specific to the 15 fat cell. Kidney, without insulin contains an Mr=195 kDa phosphotyrosyl protein and after insulin stimulation this band either disappears or broadens and migrates at a slightly lower Mr. Spleen and brain do not contain detectable tyrosine phosphorylated insulin receptors and 20 no new phosphotyrosyl proteins appeared following insulin infusion. There is an intense insulin-insensitive band in brain at Mr=190 kDa.

Coordinate Phosphorylation of the Insulin Receptor Kinase and Its 175 kDa Endogenous Substrate in Rat

25 Hepatocytes

Overview To investigate the early events in insulin signal transmission in liver, isolated rat hepatocytes were labeled with ^{32}P , and proteins phosphorylated in response to insulin were detected by 30 immunoprecipitation with anti-phosphotyrosine and anti-receptor antibodies and analyzed by SDS-PAGE and autoradiography. In these cells insulin rapidly stimulated tyrosine phosphorylation of two proteins: the 95 kDa β -subunit of the insulin receptor and a 175 kDa 35 phosphoprotein (pp175). Both proteins were precipitated

- 38 -

by anti-phosphotyrosine antibody, whereas only the insulin receptor was recognized using anti-insulin receptor antibody. In the insulin-stimulated state, both pp175 and the receptor β -subunit were found to be 5 phosphorylated on tyrosine and serine residues. Based on precipitation by the two antibodies, receptor phosphorylation was biphasic with an initial increase in tyrosine phosphorylation followed by a more gradual increase in serine phosphorylation over the first 30 10 minutes of stimulation. The time course of phosphorylation of pp175 was rapid and paralleled that of the β -subunit of the insulin receptor. pp175 was clearly distinguished from the insulin receptor as it was detected only when boiling SDS was used to extract 15 cellular phosphoproteins, whereas the insulin receptor was extracted with either Triton X-100 or SDS. In addition, the tryptic peptide maps of the two proteins were distinct. The dose response curve for insulin stimulation was shifted slightly to the left of that of 20 the insulin receptor, suggesting some signal amplification at this step. These data suggest that pp175 is a major endogenous substrate of the insulin receptor in liver and that this may be a cytoskeletal-associated protein. Both serine and tyrosine sites are 25 involved in insulin stimulated phosphorylation in hepatocytes.

In hepatocytes, insulin stimulates the rapid tyrosine phosphorylation of the β -subunit of the insulin receptor, which is followed by a slower rise in 30 serine/threonine phosphorylation of the receptor. During the initial response to insulin, an endogenous substrate of M_r - 175 kDa (pp175) is also phosphorylated on tyrosine residues in an insulin-dependent manner. This protein has a similarity to pp185, but also has some 35 apparent differences in its properties, suggesting a

- 39 -

family of related high molecular weight receptor substrates. This work is described in detail below.

Characterization of insulin receptor phosphorylation in rat hepatocytes ³²P-labeled

5 hepatocytes were stimulated with or without 1 µg/ml of insulin for different periods of time and extracted with 1% Triton X-100 as described below. Extract supernatants were immunoprecipitated with either anti-phosphotyrosine antibodies or with anti-insulin receptor antibodies and 10 analyzed by SDS-PAGE. Using anti-phosphotyrosine antibody, in the basal state, phosphotyrosine containing proteins of M_r - 200, 120 and 55 kDa were observed, but there was no tyrosine phosphorylation of the insulin receptor. Following insulin stimulation, there was 15 appearance of a 95 kDa band corresponding to the insulin receptor β -subunit, Bernier et al., 1987, Proc Natl Acad Sci USA 84:1844-48, hereby incorporated by reference, White et al., 1985, J Biol Chem 260:9470-78, hereby incorporated by reference, and labeling of pp120 20 increased slightly, whereas phosphorylation of pp200 and pp55 was not affected. Both of the latter proteins could be absorbed by precipitation with protein A alone indicating the non-specific nature of their immunoprecipitation. The increase in tyrosine 25 phosphorylation of the β -subunit of the insulin receptor reached a maximum after 1 min, plateaued for at least 20 min and then gradually declined.

Using anti-insulin receptor antibody, phosphorylation of the β -subunit of the insulin receptor 30 could be detected in the basal state, consistent with the presence of serine and threonine phosphate before insulin stimulation, Kasuga et al., 1982, Science 215:185-87, hereby incorporated by reference. Total phosphate incorporation was increased within 1 min after insulin 35 stimulation due to the increase in tyrosine

- 40 -

phosphorylation. However, with anti-receptor antibody the level of phosphorylation of the β -subunit gradually increased throughout the 30 min stimulation. The different results using the two antibodies suggest that 5 during the first minute following insulin stimulation, the β -subunit of the insulin receptor becomes phosphorylated mainly on tyrosine residues, and this is followed by a more gradual increase in phosphorylation on serine and threonine residues.

10 To further study the relationship between serine and tyrosine phosphorylation on the insulin receptor, the band representing the receptor immunoprecipitated by anti-insulin receptor antibody (B-9) was eluted from the gel by trypsinization and subjected to phosphoamino acid 15 analysis. Without insulin, the receptor contained primarily phosphoserine and a small amount of phosphothreonine, but no phosphotyrosine. After one minute of insulin stimulation, there was no significant change in phosphoserine or phosphothreonine, but 20 phosphotyrosine appeared. These results are consistent with previous studies demonstrating that the insulin receptor in the basal state contains mainly phosphoserine and that phosphotyrosine appears only after insulin stimulation, Kasuga et al., 1982, supra, Pang et al., 25 1985, J Biol Chem 260:7131-36 hereby incorporated by reference.

Hepatocytes were isolated and 32 P-labeled as follows. Hepatocytes were isolated from male Sprague-Dawley rats weighing 160-200 g fed ad libitum using a 30 modification, Okamoto et al., 1982, Endocrinol Jpn 29:263-7, hereby incorporated by reference, of the method of, Berry et al., 1969, J Cell Biol 43:506-20, hereby incorporated by reference. The cells were washed with 137 mM NaCl supplemented with 2.7 mM KCl and 20 mM HEPES, 35 pH 7.4, and resuspended in phosphate-free RPMI 1640 to

- 41 -

give a final cell concentration of 2×10^6 /ml. Cell viability was 80-90% as judged by trypan blue exclusion. Labeling of the hepatocytes with [32 P]orthophosphate was accomplished by incubating 0.5 ml aliquots of the cell suspension for 90 min with 1 mCi of [32 P]orthophosphate at 37°C in a humidified atmosphere composed of 95% air and 5% CO₂.

Phosphorylation and immunoprecipitation of labeled proteins were performed as follows. After stimulation by insulin for 1 min (except as otherwise indicated), the reaction was stopped using one of two methods. For Triton X-100 extracts, the reaction was stopped by adding 0.5 ml of ice cold stopping solution composed of 50 mM HEPES, pH 7.4, 1% Triton X-100, 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 2 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride (PMSF) and 0.1 mg/ml aprotinin. The mixture was vigorously vortexed, cooled on dry ice-methanol until minimal ice was detected in the bottom of the tube, vortexed again and kept on ice for 30 min. For SDS extraction, 0.5 ml of boiling stopping buffer was added to give the same concentrations as described above except that 1% SDS replaced the 1% Triton, and PMSF and aprotinin were omitted. After boiling for 15 min, the sample was cooled in an ice bath for 60 min. After both extraction procedures, the samples were centrifuged at 200,000 x g for 45 min at 0-4°C, and the supernatant was used for immunoprecipitation.

Immunoprecipitation with anti-insulin receptor antibody B-9 and anti-phosphotyrosine antibody were performed at dilutions of 1:200 and 1:100, respectively, Kasuga et al., 1985, Methods of Enzymol 109:609-621, hereby incorporated by reference. Immunoprecipitated proteins were solubilized in Laemmli buffer with 100 mM dithiothreitol (DTT) and were separated in 7.5%

- 42 -

polyacrylamide gels by electrophoresis. The gels were stained with Coomassie blue in 50% trichloroacetic acid, destained in 7% acetic acid, dried and autoradiographed with Kodak X-Omat film. Molecular weights of proteins 5 were calculated by using standard proteins (BioRad). The incorporation of ^{32}P into individual bands was quantitated by scanning densitometry of the film.

Phosphoamino acid analysis was performed as follows. Tryptic phosphopeptides were obtained from the 10 protein bands in polyacrylamide gel fragments as previously described, White et al., 1985, J Biol Chem 260:9470-78, hereby incorporated by reference. The positions of the phosphorylated proteins were determined by autoradiography, the gel fragments containing the 15 proteins was excised from the gel, washed for 12 h at 37°C in 20% methanol, dried at 80°C for 2 h and digested with 2 ml of 50 mM NH_2HCO_3 , containing 100 μg of trypsin, pH 8.0. After a 6 h incubation at 37°C, another 100 μg of trypsin was added, and the digestion was continued for 20 an additional 16 h. The supernatant was lyophilized, and the phosphopeptides were dissolved in 100 μl of 6 N HCl and hydrolyzed for 2 h at 110°C. The phosphoamino acids were separated in one dimension by high voltage electrophoresis on thin layer plates (Avicel, Analtech, 25 Newark, DE; 250 μm) using a solution of H_2O :acetic acid:pyridine (89:10:1). Unlabeled phosphoserine, phosphothreonine, and phosphotyrosine standards (1 μl) were added to all samples and identified by reaction with ninhydrin, and the radioactivity was located by 30 autoradiography.

Sprague-Dawley rats were purchased from Charles River. Collagenase (Type IV) was obtained from Cooper Biomedical; [^{32}P]orthophosphate and Triton X-100 from New England Nuclear; phosphoamino acids from Sigma; porcine 35 insulin from Elanco; reagents for SDS-PAGE from Bio-Rad;

- 43 -

Pansorbin from Calbiochem; and cellulose thin-layer plates from Analtech; RPMI 1640 tissue culture medium from GIBCO. Polyclonal anti-phosphotyrosine antibody was prepared in rabbits as previously described and affinity 5 purified on phosphotyramine Sepharose, Pang et al., 1985, J Biol Chem 260:7131-36, hereby incorporated by reference. Anti-insulin receptor antibody was from the serum of patient B-9, Kasuga et al., 1981, J Biol Chem 256:5305-8, hereby incorporated by reference.

10 Phosphorylated proteins in SDS extracts of hepatocytes Although autophosphorylation of the β -subunit insulin receptor was easily detected in Triton X-100 extracts of intact rat hepatocytes using anti-phosphotyrosine antibodies, no other insulin-stimulated 15 phosphorytrosine-containing proteins were detected. To further pursue potential substrates, SDS extracts of the hepatocytes were prepared as described above. Experiments were performed to compare the phosphoproteins solubilized from hepatocytes with Triton or SDS and 20 precipitated with anti-phosphotyrosine antibody. Only the β -subunit of the insulin receptor was immunoprecipitated from Triton extracts as an insulin-stimulated phosphotyrosyl protein. However, when cells were extracted with 1% SDS and boiling and 25 immunoprecipitated with anti-phosphotyrosine antibody, a new protein of M_r - 175 kDa was observed in the basal state which was not present in the Triton extract. After insulin stimulation, ^{32}P incorporation into pp175 was increased 10-fold, resulting in a labeled band which was 30 more prominent than the β -subunit. No other phosphotyrosyl proteins were detected by SDS-PAGE using 15% and 5% gel.

35 Characterization of pp175 Phosphoamino acid analysis was performed on pp175 before and after insulin stimulation. In these experiments isolated rat

- 44 -

hepatocytes were labeled with [³²P]orthophosphate and treated with insulin (1 µg/ml) for various time intervals. The cells were extracted with 1% SDS, immunoprecipitated with anti-phosphotyrosine antibody, reduced with DTT, and analyzed by SDS-PAGE with a 7.5% resolving gel. In the basal state, the major phosphoamino acid in pp175 was phosphoserine with a small amount of phosphotyrosine. After insulin stimulation, both phosphoamino acids increased. Whether the increase 10 in phosphoserine arises from de novo phosphorylation of this protein stimulated by insulin or is only apparent due to increased recovery of the protein during immunoprecipitation with the anti-phosphotyrosine antibody is unknown.

15 The time course of phosphorylation of pp175 closely paralleled that of the insulin receptor β-subunit. In these experiments isolated rat hepatocytes were labeled with [³²P]orthophosphate and treated with insulin (1 µg/ml) for the indicated time intervals. The 20 cells were extracted with 1% SDS, immunoprecipitated with anti-phosphotyrosine antibody, reduced with DTT, and analyzed by SDS-PAGE with a 7.5% resolving gel. Autophosphorylation of the β-subunit of the receptor and phosphorylation of pp175 were almost maximal within 1 25 min, remained elevated for 10 min and decreased at 30 min. As noted above, the phosphorylation of pp120 exhibited little or no stimulation by insulin.

The dose-response curves for insulin stimulation of pp175 and for the insulin receptor β-subunit are shown 30 in Fig 1. In Fig. 1 isolated rat hepatocytes were labeled with [³²P]orthophosphate, and the cells treated with the indicated concentrations of insulin for 1 min. The cells were extracted with 1% SDS, immunoprecipitated with anti-phosphotyrosine antibody, reduced with DTT, and 35 analyzed by SDS-PAGE with a 7.5% resolving gel.

- 45 -

Autoradiogram of the SDS gels were subjected to densitometry scanning to quantitate the amount of ^{32}P incorporated in the proteins. Data are presented as the percent increase above basal. Some increase in ^{32}P incorporation into these proteins was observed with an insulin concentration of 5 nM after only 1 min of stimulation, and the effect was maximal at 100 nM. The dose-response curves for stimulation of both proteins were similar, although the ED_{50} for pp175 (open circles) was slightly to the left of that of the β -subunit (closed circles) of the insulin receptor suggesting some signal amplification at this step. Both curves were about one order of magnitude less sensitive than insulin stimulation of amino acid transport in isolated hepatocytes, but similar to the curve for insulin binding to its receptor. It is important to emphasize the fact that the phosphorylation data were obtained only one minute after insulin addition, and at the lower insulin concentrations, insulin binding to its receptor probably had not come to equilibrium. This accounts, in part, for the apparent insensitivity of the cells to insulin.

Peptide mapping of pp175 and the insulin receptor

The insulin receptor is synthesized via a proreceptor of $M_r \sim 180$ kDa. Thus, pp175 could be the precursor of the insulin receptor. This seemed unlikely, however, since pp175 was not detected in Triton X-100 extracts of cells or precipitated by anti-receptor antibody, and it contained trace amounts of phosphotyrosine in the basal state (both characteristics different from those of insulin receptor). To confirm their different origin, pp175 and the 95 kDa β -subunit of the insulin receptor were subjected to two dimensional phosphopeptide mapping, Fig. 2. In Fig. 2 hepatocytes were stimulated by insulin (1 $\mu\text{g}/\text{ml}$), and the tyrosine phosphorylated proteins in hepatocytes were immunoprecipitated and separated with

- 46 -

SDS-PAGE. The gel fragments containing the proteins were incubated with trypsin, and the eluted phosphopeptides were separated on cellulose thin-layer plates by electrophoresis (ph 1.9) and ascending chromatography (pH 5.3.5) as described above. Fig 2 shows schematic diagrams of the autoradiograms. The phosphoamino acid in individual peptides was also determined. These are indicated as Y for phosphotyrosine and S for phosphoserine. When both amino acids were present the size of the letters represents the relative amount of each phosphoamino acid in the spot.

The peptide map of the β -subunit of the insulin receptor and the peptide map from pp175 showed a completely different pattern. This different peptide map was also confirmed using reverse phase HPLC (data not shown). Thus, pp175 is distinct from the insulin receptor β -subunit and not likely to represent the precursor of the insulin receptor.

HPLC separation of the tryptic phosphopeptides was performed as follows. The phosphopeptides were eluted from the gel fragments as described above with 95% efficiency and were analyzed in two ways. Two-dimensional peptide mapping was performed as described by Ellis et al., 1981, Nature (Lond) 292:506-511, hereby incorporated by reference. Peptide mapping was also performed with high performance liquid chromatography system (Waters) equipped with a wide-pore C₁₈ column (Bio-Rad, RP-0318) as previously described, White et al., 1985, J Biol Chem 260:9470-78, hereby incorporated by reference, Carpentier et al., 1987, J Cell Biol 105:2751-2752, hereby incorporated by reference. Phosphopeptides were applied to the column which was washed with 5% acetonitrile and eluted with an acetonitrile gradient increasing linearly to 25% during 85 min.

35 The Effects of Insulinomimetic Agents on pp185

- 47 -

Vanadate is a trace element which has been shown to be a potent insulinomimetic agent in isolated adipocytes (reviewed in Shechter et al., 1988, Biochem. Pharmac. 37:1891-1896, hereby incorporated by reference).

5 In streptozotocin (STZ) treated diabetic rats, vanadate normalizes blood glucose, Heyliger et al., 1985, Science, 227:1474-1476, hereby incorporated by reference; Meyerovitch et al., 1987, J. Biol. Chem., 262:6658-6662, hereby incorporated by reference; and restores liver 6-

10 10 phosphofructose-2-kinase glucokinase activity toward normal, Gil et al., 1988, J. Biol. Chem., 263:1868-187, hereby incorporated by reference. Vanadate has been shown to be a potent inhibitor of phosphotyrosyl protein phosphatase (PTPase) activity in vitro at concentrations

15 15 which do not inhibit phosphoserine and phosphothreonine phosphatase activity, Swarup et al., 1982, J. Biol. Chem., 257:7298-7301, hereby incorporated by reference; Swarup et al., 1982, Biochem. Biophys. Res. Commun., 107:1104-1109, hereby incorporated by reference.

20 Under certain conditions, vanadate may also directly stimulate β -subunit tyrosine autophosphorylation and in vitro phosphotransferase activity of purified insulin receptors, Tamura et al., 1984, J. Biol. Chem., 259:6650-6658, hereby incorporated by reference; but this

25 25 action has not been observed in all studies, Machicao et al., 1983, FEBS Lett., 163:76-80, hereby incorporated by reference. Vanadate increases glucose transport in trypsin-treated adipocytes and in cells where the insulin receptor concentration is reduced 60% by receptor down-

30 regulation, Green, 1986, Biochem. J., 238:663-669, hereby incorporated by reference; suggesting a post-receptor mechanism of vanadate action.

Two well studied rodent models of Type II diabetes are ob/ob and db/db mice. These homozygous mice are

35 characterized by obesity, hyperglycemia, hyperinsulinemia

- 48 -

and a blunted response to insulin at the receptor and post-receptor levels, Mordes et al., 1985, Animal models of diabetes mellitus, In Joslin's Diabetes Mellitus, Marble et al., editors, Lea and Febiger, Philadelphia,
5 110-137, hereby incorporated by reference; Seidman et al., 1970, Diabetologia, 6:313-316, hereby incorporated by reference; Belefioire et al., 1987, Int. J. Obesity, 11:631-646, hereby incorporated by reference; Coleman et al., 1967, Diabetologia, 3:238-248, hereby incorporated
10 by reference; Stengard et al., 1987, Biomed. Pharmacother., 41:389-396, hereby incorporated by reference; Soll et al., 1980, J. Clin. Invest., 56:769-780, hereby incorporated by reference; Chang et al., 1970, Diabetologia, 6:274-278, hereby incorporated by
15 reference; Tannti et al., 1986, Diabetes, 35:1243-1248, hereby incorporated by reference; Vicario et al., 1987, Life Sci., 41:1233-1241, hereby incorporated by reference; Marchand-Brustel et al., 1985, Nature, 315:676-679, hereby incorporated by reference;
20 Meyerovitch et al., 1989, J. Clin. Invest., 84:976-983, hereby incorporated by reference. The exact etiology of the two syndromes has not been elucidated, although several glycolytic and gluconeogenic enzymes are elevated in the livers of these animals. Both models demonstrate
25 several metabolic defects consistent with peripheral insulin insensitivity, including decreased binding to liver plasma membranes and hepatocytes, Soll et al., 1980, *supra*; increased nonsuppressible gluconeogenesis, Coleman et al., 1967, *supra*; Chang et al., 1970, *supra*;
30 and failure of exogenous insulin to ameliorate the syndrome, Coleman et al., 1967, *supra*. In spite of the decreased number of insulin receptors in the ob/ob and db/db mice, the kinase activity per receptor had been reported to be normal, Tannti et al., 1986, *supra*;
35 Vicario et al., 1987, *supra*. However, in one study the

- 49 -

insulin receptor kinase in the muscle of ob/ob mice was reported to be defective, Marchand-Brustel et al., 1985, *supra*.

The experiments presented below examine
5 alterations in hepatic phosphotyrosyl protein phosphatase (PTPase) activity and the effects of oral administration of vanadate, an insulinomimetic agent and potent inhibitor of PTPases in vitro, in two rodent models of non-insulin dependent diabetes mellitus (NIDDM). PTPase
10 activity was measured using a ³²P-labeled peptide corresponding to the major site of insulin receptor autophosphorylation. In obese hyperglycemic ob/ob mice both cytosolic and particulate PTPase activity in liver were decreased by about 50% (p , 0.01), whereas in db/db
15 diabetic mice, PTPase activity in the cytosolic fraction was decreased to 53% of control values (p < 0.02) with no significant difference in the particulate PTPase activity.

Oral administration of vanadate (0.25 mg/ml) in
20 the drinking water to ob/ob mice for 3 weeks lowered blood glucose level from 236 ± 4 to 143 ± 2 mg/dl without effect on body weight. Administration of vanadate to db/db mice produced a similar effect. The onset of the vanadate effect was relatively slow, reaching a maximum
25 after 15-20 days of therapy. When the vanadate was discontinued, the hypoglycemic effect was slowly reversible over a similar time course. Electron microscopic examination revealed no signs of hepatotoxicity after 47 days of treatment. When tested
30 by immunoblotting with antiphosphotyrosine antibody, after in vivo stimulation, there was a slight reduction in insulin receptor autophosphorylation and the phosphorylation of the endogenous substrate of the insulin receptor, pp 185, was markedly decreased in the
35 ob/ob mice. Vanadate pretreatment increased the

- 50 -

phosphorylation of the pp 185 in control, but not in the ob/ob mice. The treatment with vanadate, however, did not alter hepatic PTPase activity as assayed in vitro. These data indicate that oral administration of vanadate 5 is an effective hypoglycemic treatment in NIDDM states, and support a post insulin receptor mechanism of action of vanadate.

Data concerning blood glucose, body weight and plasma insulin levels in ob/ob and db/db mice and their 10 matched controls are presented in Table II. Blood glucose and serum insulin levels, as well as the body weights, were markedly increased in the both diabetic models compared to the control mice. These experiments are described in more detail below.

15 Effect of Vanadate Treatment on ob/ob mice: After 47 days of treatment with vanadate, the blood glucose levels of the treated ob/ob mice was 143 ± 2 mg/dl compared to 276 ± 3 mg/dl in the control untreated ob/ob mice ($p < 0.001$, Table II and Fig. 3).

20 Fig. 3. shows the effect of oral administration of vanadate on ob/ob mice on blood glucose level. Ob/ob mice (upper panel) and their matched controls ob/+ (lower panel) were treated with vanadate (NaVO_3 , 0.25 mg/ml and 25 80 mmol/l NaCl) in the drinking water (solid lines) or with 80 mmol/l NaCl alone (dashed lines). Each point is the mean of 5 animals. the S.E.M. was 2-3 mg/dl.)

- 51 -

TABLE II
CHARACTERISTICS OF MICE

Groups	n	Body Weight (g)	Blood Glucose (mg/dl)	Insulin (μ U/ml)
ob/+	6	32.4 \pm 0.1	64 \pm 2	44 \pm 7
ob/ob	6	45.0 \pm 0.1*	406 \pm 2	170 \pm 30*
db/+	6	32.2 \pm 0.2.	70 \pm 2	27.2 \pm 2
db/db	6	36.8 \pm 0.4*	319 \pm 2	410 \pm 24*

The data are represented as the mean \pm S.E.M. * = p < 0.001 for ob/ob vs ob/+ and db/db vs db/+.

The vanadate treatment also lowered the blood glucose level of lean ob/+ mice from 170 \pm 4 mg/dl to 114 \pm 1 mg/dl (p < 0.001). In both the ob/ob and the ob/+ groups, there was no difference in body weight in the vanadate-treated mice as compared to their appropriate saline-treated controls (Table II).

TABLE III
EFFECT OF VANADATE TREATMENT ON ob/ob MICE

Groups	Treatment	Body Weight (g)	Blood Glucose (mg/dl)	Insulin (μU/ml) (8/10μg)	Binding (μU/ml) (8/10μg)
10	Control	35.3 ± 0.1	170 ± 4	57±10	17.3 ± 3.8
	Vanadate	34.9 ± 0.2	114 ± 1	68 ± 15+	10.3 ± 1.9
	Control	40.0 ± 0.1*	276 ± 3*+	272 ± 25*	8.1 ± 1.8#
	Vanadate	40.0 ± 0.2*	143 ± 2+	398 ± 40+	7.3 ± 1.3#

The vanadate treatment was for 47 days, controls received saline only in their drinking water.

15 The data are represented as the mean ± S.E.M. Sample size is 5 per group.

* p < 0.001 compared to ob/+ mice.

+ p < 0.001 compared to non treated mice.

p < 0.05 compared to ob/+ mice.

- 53 -

Circulating levels of vanadate were $5.2 \pm 0.9 \mu\text{M}$ and $2.7 \pm 0.5 \mu\text{M}$ in the ob/+ mice after 3 weeks of treatment. These levels are similar to vanadate levels previously reported by us and others, Meyerovitch et al., 5 1987, *supra*; Gil et al., 1988, *supra*. Untreated mice have no detectable (< 7 nM) serum vanadate, Stoop et al., 1982, *Clin. Chem.*, **28**:79-82; hereby incorporated by reference. The effect of vanadate was reversible and 20 days after withdrawal of the vanadate, the blood glucose 10 returned to the initial hyperglycemic levels, Fig. 4. Fig. 4 shows that the effect of vanadate is reversible. The vanadate drinking water was changed to control after 20 days. The ob/ob mice are shown in the upper panel and the ob/+ mice in the lower panel. Each point is the mean 15 of 5 animals. The S.E.M. was 2-3 mg/dl.) To determine the possible mechanism of one vanadate effect, we evaluated serum insulin levels, insulin receptor function and some post-receptor sites of hormone action.

Vanadate treatment increased plasma insulin levels 20 from 254 ± 29 to $338 \pm 49 \mu\text{U/ml}$ in the ob/ob, and from 66 ± 10 to 92 ± 20 in the ob/+ group ($p < 0.001$). Insulin binding to WGA purified insulin receptors was reduced in the untreated ob/ob mice, ($8.7 \pm 1.8 \% / 10 \mu\text{g}$ protein compared to $17.3 \pm 3.8 \% / 10 \mu\text{g}$ protein, in untreated 25 controls, $p < 0.05$) (Table II). After 47 days of vanadate treatment there was still a decrease in the insulin binding in the ob/ob mice ($8.7 \pm 1.8 \% / 10 \mu\text{g}$, $p < 0.05$), while the vanadate treatment down regulated the level of insulin binding in the ob/+ mice to $10.3 \pm 30 1.9 \% / 10 \mu\text{g}$ proteins, although this change did not reach statistical significance, Table III.

At the ultrastructural level, the livers of obese mice were heavily laden with glycogen and lipid droplets, with much variability from cell to cell. There was an 35 increasing gradient in the number of lipid droplets from

- 54 -

the portal triad to the central vein. For this reason hepatocytes from the protal triad from all groups were compared. With both the ob/ob or lean ob/+, there was no apparent difference between vanadate-treated and control 5 mice, thus demonstrating a lack of major toxicity to the liver by vanadate.

Effect of Vanadate Treatment on db/db mice

Treatment of db/db mice with vanadate lowered the blood glucose levels from 228 ± 6 to 141 ± 1 mg/dl ($p < 0.001$).
10 This effect was maximal after 55 days of treatment, with half the effect observed after 23 days, Table IV and Fig. 5. Fig. 5 shows the effect of oral administration of vanadate on blood glucose level in db/db mice. Db/db mice (solid line) and their matched controls db/+ (dashed
15 line) were treated with vanadate as described in Figs. 3 and 4. Sixty days after treating the mice, the vanadate had been changed into the control solution. Each point is the mean of 5-6 mice. The S.E.M. was 2-3 mg/dl.)

TABLE IV
EFFECT OF VANADATE TREATMENT ON db/db MICE

Groups	Treatment	n	Body Weight Change (g/day)	Blood Glucose (mg/dl)	Insulin (μU/ml)
db/+	Vanadate	6	0.6 ± 0.02	104 ± 1	48 ± 5
db/+	Control	5	0.05 ± 0.003	106 ± 1	42 ± 3
10	db/db	Vanadate	6	0.06 ± 0.003	167 ± 1#
db/db	Control	5	0.06 ± 0.002	191 ± 2	198 ± 10*+
					339 ± 52

The vanadate treatment was for 60 days, controls received saline only in their drinking water.

15 The data are represented as the mean ± S.E.M.

*p < 0.025 compared to db/db with control treatment

+p < 0.001 compared to db/+.

#p < 0.001 compared to non treated db/db and db/+ mice.

- 56 -

The vanadate treatment also lowered the blood glucose level of the db/+ mice from 126 ± 2 to 81 ± 1 mg/dl. There was no difference in body weight gain treatment with vanadate or with saline for either the 5 db/db or the db/+ groups (Table IV). The effect of vanadate was reversible, and 25 days after withdrawal of the vanadate the blood glucose returned to the initial hyperglycemic levels, Fig. 5.

Effect of Diabetes and Vanadate on PTPase Activity

- 10 PTPase activity present in cytosolic extracts of liver from the 8 week old ob/ob mice was 55% that of the ob/+ (0.18 ± 0.02 U/mg and 0.33 ± 0.03 U/mg, $p < 0.01$) when assessed in vitro using the phosphorylated 1142-1153 peptide as substrate Fig. 6.
- 15 Fig. 6 shows PTPase activity in cytosolic fractions and Fig. 7 shows particulate and WGA purified fractions from livers of ob/ob and ob/+ mice. Liver fraction derived from ob/ob and ob+ mice were fractionated using isotonic sucrose differential 20 centrifugation. The particulate fraction was than further fractionated on WGA columns. The 1142-1153 peptide was phosphorylated at 4°C in the presence of 100 nM insulin using WGA purified insulin receptor as described in the methods. The ^{32}P labeled peptide was 25 separated from the ^{32}P ATP by chromatography on AG 1-X2 acetate column and by SEP-PAK cartridge and lyophilized. Aliquots from each fraction were assayed for PTPase activity towards the phosphorylated peptides ($0.14 \mu\text{M}$) in the presence of 2 mM EDTA and 1mM DTT for 5 min at 30°C .
- 30 The reaction was stopped by precipitation with 10% TCA, and $^{32}\text{P}_i$ release was measured by organic extraction of P_i (27). The results represent the mean \pm S.E.M. of six mice in each group assayed in duplicate. Fig. 6: Cytosolic PTPase activity on ob/ob mice and their 35 controls. * = < 0.01 . Fig. 7: Particulate and WGA

- 57 -

purified PTPase activity in ob/ob mice and their controls. * = < 0.02.

PTPase activity associated with the particulate fractions was similarly decreased in the ob/ob mice 5 versus the ob/+ controls (1.43 ± 0.2 U/mg and 2.1 ± 0.3 U/mg, $p < 0.02$), Fig. 7. The glycoprotein fraction of the membrane had 5- to 8-fold higher specific activity than the particulate fraction, however, specific activities of the PTPase in the WGA purified particulate 10 fractions were not different between ob/ob and ob/+ mice (16.1 \pm 1.3 U/mg versus 16.8 \pm 1 U/mg, Fig. 7).

In the 8 week old db/db mice, the cytosolic PTPase activity was also decreased by about 50% (0.25 ± 0.03 U/mg versus 0.47 ± 0.07 U/mg, $p < 0.02$), Fig. 8. No 15 significant difference was found in the PTPase activity associated with the particulate fraction, Fig. 9, and thus activity in the glycoprotein fraction-enriched fraction was not determined. Fig. 8 shows activity in cytosolic fractions and Fig. 9 shows activity in 20 particulate fractions from db/db mice livers. PTPase activity was assayed in cytosolic and in particulate fractions. Liver fractionation and PTPase assay methods were as described in Fig. 3. * = < 0.2.

After 9 weeks of treatment, vanadate did not 25 significantly alter particulate PTPase activity in the 17 week old ob/ob mice compared to the age-matched untreated ob/ob mice, Fig. 10.

Fig. 10 shows the effects of vanadate treatment on PTPase activity in particulate fractions from ob/ob mice 30 liver. Left panel; ob/ob mice, right panel; ob/1⁺ mice. Forty-seven days after oral administration of vanadate (hatched bars) or solution (empty bars). Particulate PTPase activity from the ob/ob mice livers was assayed as described in Figs. 6 and 7. The results represent mean \pm

- 58 -

S.E.M. of five mice in each group assayed in duplicate.

* = $p < 0.02$.

The specific activity of the PTPase activity in the particulate fraction of the ob/ob mice was 55% of 5 ob/+ (2.93 ± 0.4 U/mg versus 5.3 ± 0.9 U/mg, $p < 0.02$), Fig. 10. Vanadate treatment did result in a decrease in PTPase activity in the ob/+ mice (3.9 ± 0.5 U/mg in the treated versus 5.3 ± 0.5 in the control animals); however, the change was not statistically significant, 10 Fig. 10. No significant differences in cytosolic PTPase activity were observed in this age groups (data not shown).

Effect of Vanadate Treatment on Phosphorylation of 95 kDa and 185kDa To determine whether administration of 15 vanadate produced insulinomimetic metabolic effects in the liver of ob/ob through increased tyrosine phosphorylation of the insulin receptor β -subunit or other cellular substrates of the insulin receptor kinase, such as pp 185, the phosphotyrosyl proteins in intact 20 mice liver were analyzed by immunoblotting with anti-phosphotyrosine antibodies before and after acute insulin stimulation in vivo.

In these experiments ob/ob and control mice were treated for 9 weeks with vanadate or control solutions. 25 Phosphotyrosyl proteins from the liver were isolated as described in above. Briefly, mice were anesthetized, the abdominal wall was incised to expose the viscera. Normal saline or 10^{-6} M insulin was infused for 20 seconds, after 30 when the liver excised and homogenized in 1% SDS, 100 mM HEPES pH 7.5 50 nM DTT at 100°C for 5 min. The denatured proteins were precipitate with TCA, and immunoprecipitated with polyclonal antiphosphotyrosine antibodies. The immunoprecipitated phosphotyrosyl proteins were resolved on 6% SDS-polyacrylamide gels, 35 transferred to nitrocellulose and detected with

- 59 -

antiphosphotyrosine antibodies and [I^{125}]-Protein A and subject to autoradiography. The experiment was preformed twice with similar results.

In the absence of insulin, only a single, major 5 constitutive phosphotyrosyl protein at Mr = 120 kDa was present in all animals. The identity and function of this protein is not known, and its phosphotyrosine content is not altered by vanadate or insulin treatment. After insulin infusion into the portal vein, the insulin 10 receptor β -subunits (Mr = 95 kDa) become tyrosine phosphorylated. The extent of receptor autophosphorylation is similar in all animals. Vanadate treatment did not significantly increase receptor autophosphorylation. Insulin infusion also induced 15 tyrosine phosphorylation of the endogenous substrate of the insulin receptor, or protein with an Mr about 185 kDa. The phosphorylation level of the putative endogenous substrate of the insulin receptor, pp 185, was markedly decreased in the ob/ob compared to the ob/+.

20 Vanadate treatment significantly augmented pp 185 phosphorylation in control mice, however, vanadate did not increase the phosphorylation of the pp 185 in the ob/ob mice. There were no new phosphotyrosyl proteins detected in the vanadate treated mice compared with 25 control treated mice.

Materials and methods [γ - ^{32}P]ATP (3000 Ci/mmol) was obtained from New England Nuclear (Boston, MA); wheat germ agglutinin agarose (WGA) was from Vector Laboratories (Burlingame, CA); sodium orthovanadate was 30 from Aldrich Chemical Company, Inc. (Milwaukee, WI). Streptozotocin, HEPES, phenylmethylsulfonyl fluoride (PMSF), N $^{\alpha}$ -P-tosyl-L-lysine chlormethyl ketone (TLCK), N $^{\alpha}$ -tosyl-L-phenylalanine chlormethyl ketone (TPCK), aprotinin, N-acetyl-D-glucosamine were from Sigma 35 Chemical (St. Louis, MO). Silicotungstic acid was from

- 60 -

J.T. Baker Chemical Co. (Phillipsburg, NJ). Dithiothreitol (DTT), Coomassie blue Triton X-100 and AG 1-X2 acetate were purchased from Bio-Rad Laboratories, (Richmond, CA). The synthetic peptide, Thr-Arg-Asp-Ile-
5 Tyr-Glu-Thr-Asp-Tyr-Tyr-Arg-Lys (Seq. I.D. No. 24), which contains the amino acid sequence between residues 1142-1153 of the insulin receptor β -subunits, Ullrich et al., 1985, *Nature*, 313:756-761, hereby incorporated by reference; was purchased from Dr. David Coy, Tulane
10 University (New Orleans, LA). 3-[(3-cholamidopropyl) dimethylammonio]-2 hydroxyl-1-propanesulfonate (CHAPSO) was purchased from Pierce Chemicals (Rockford, IL).

Female obese-hyperglycemic mice (C57B1/6J ob/ob) and the obese diabetic mice (C57B1/KsJ db/db) and their
15 lean matched controls (ob/+) and (db/+) were purchased from Jackson Laboratory (Bar Harbor, ME) and used at 6-8 weeks of age. Mice were fed ad libitum a standard laboratory chow. The fed mice were anesthetized by ether and then bled through the orbital venous plexus. Venous
20 blood and liver sample were taken between 9-11 a.m. As noted in the figure legends and text, some mice were treated with vanadate (0.25 mg/ml) included in the drinking water. 80 mM NaCl was also included to reduce vanadate toxicity, as previously described, Heyliger et
25 al., 1985, *supra*; Meyerovitch et al., 1987, *supra*. For these experiments, control mice were treated with 80 mM NaCl alone.

^{32}P -labelled peptide 1142-1153 was prepared as follows. Wheat germ agglutinin purified insulin
30 receptor, Kasuga et al., 1984, *Methods Enzymol.*, 109:609-621, hereby incorporated by reference; was incubated with 100 nM insulin for 30 minutes at 4°C after which 100 μM [ν - ^{32}P] ATP (specific activity 14.2 Ci/mol), 5 mM Mn $^{2+}$ and 2 mM 1142-1153 peptide were incubated with the receptor
35 overnight at 4°C. ^{32}P -peptide was separated from ^{32}P -ATP

- 61 -

by chromatography on AG1-X2 acetate column (29) and on a C-18 SEP-PAK cartridge (Waters Associates, Milford, MA) and lyophilized.

Tissue extractions were performed as follows.

- 5 Mice were sacrificed by cervical dislocation, and livers were rapidly removed. All tissue extractions were performed at 4°C. Livers were homogenized using a Potter-Elvehjem type homogenizer rotating at 1300 rpm for 20 seconds in three columns of buffer A (20 mM Tris-HCL, pH 7.5, 50 mM 2-mercaptoethanol, 250 mM sucrose, 2 mM EDTA, 10 mM EDTA, aprotinin 10 µg/ml, leupeptin 25 µg/ml, 0.1mM TLCK, 0.1 mM TPCK, 0.5 mM benzamidine, 0.2 mM phenylmethylsulfonyl fluoride and 5 µg/ml each of pepstatin A, antipain and chymostatin). Homogenates were 10 centrifuged at 10,000 x g for 20 minutes, and the supernatant was further centrifuged at 100,000 x g for 45 minutes. The final supernatant was designated the cytosolic fraction. The pellet resulting from the 15 100,000 x g spin was solubilized using a Potter-Elvehjem type homogenizer rotating at 1300 rpm for 5 minutes in buffer A containing 1% (W/V) CHAPSO and was then 20 centrifuged 45 minutes at 100,000 x g to remove insoluble material. The solubilized material in the supernatant was designated the particulate fraction. In some 25 experiments, this fraction was further fractionated by chromatography on WGA-agarose columns. After application, the column was washed with 50 bed volumes of 10 mM HEPES buffer, pH 7.6, 0.1% (v/v) Triton 100, 5 mM EDTA, 0.5 mM benzamidine and 0.2 mM PMSF and 2 30 mercaptoethanol 0.1% (v/v) (buffer B) and eluted with two bed volumes with 0.3 M N-acetyl glucosamine in buffer B. The WGA purified fractions were designated the glucoprotein-enriched fractions. All preparations were stored at -70°C prior to use.

- 62 -

- PTPase assays were performed as follows. The dephosphorylation reaction was carried out at 30°C in a final volume of 50 μ l of 50 mM HEPES, pH 7.0, 2 mM EDTA and 1 mM DTT, and was terminated by the addition of 30 μ l 5 10% trichloroacetic acid and 20 μ l 1% (w/v) bovine serum albumin (BSA). Following incubation at 4°C for 10 minutes and centrifugation to remove precipitated proteins, 32 P_i released from 32 P-peptide was measured using organic extraction of P_i, Shacter, 1984, Anal.
- 10 Biochem, 138:416-420, hereby incorporated by reference. Reaction rates were linear when under 20% of the phosphate was released from the peptide; therefore, the extent of dephosphorylation was kept within this limit. Concentrations of phosphotyrosyl peptide were calculated
- 15 from the 32 P content and the specific activity of [ν - 32 P]ATP. One unit of PTPase was defined as the amount of enzyme hydrolyzing 1 pMol of phosphate per minute.
- 125 I-insulin binding to solubilized insulin receptor was assayed as follows. An insulin receptor 20 preparation was prepared as previously described, Kasuga et al., 1984, *supra*; and diluted in 50 mM HEPES, pH 7.6, 0.1% Triton X-100. Aliquots (5-9 μ g protein) of wheat germ agglutinin eluate were incubated with 125 I-insulin (0.1 ng/ml, 2,000 Ci/mmol) in the absence or presence of 25 1 μ mol unlabeled insulin at 4°C for 10 hours in a medium of 150 mM NaCl and 50 mM HEPES at pH 7.4 containing 0.1% BSA. Separation of receptor-bound and free insulin was performed by the polyethylene glycol method using bovine gamma globulin as carrier protein, Desbuquois et al., 30 1971, J. Clin. Endocrinol. Metab., 33:732-738, hereby incorporated by reference.
- Hepatic phosphotyrosine containing proteins were identified *in vivo* as follows. A recently developed procedure was employed to measure *in vivo* phosphorylation 35 involving the analytical isolation of phosphotyrosine

- 63 -

containing proteins which appear in response to hormonal stimulation of intact tissues. Mice were anesthetized with sodium amobarbital (200 mg/kg body weight, intraperitoneal). The abdominal wall was incised to expose the viscera. Normal saline with or without 10^{-6} M insulin (Humulin R, Eli Lilly) was infused into the portal vein for 20 seconds at a rate of 0.2 ml/minutes. The entire liver was then excised and homogenized in 1% sodium dodecyl sulfate, 50 mM dithiothreitol, 100 mM HEPES, 2mM EDTA, pH 7.5 at 100°C for 5 minutes. The denatured proteins were precipitated with TCA (10% w/v). The TAC was removed using 3 washings with 1:1 (v/v) ether: ethanol. The proteins were resuspended in 50 mM TRIS buffer, pH 7.5, and immunoprecipitated with rabbit polyclonal anti-phosphotyrosine antibodies. Immunoprecipitated phosphotyrosyl proteins were resolved on 6% SDS polyacrylamide gels, transferred to nitrocellulose and detected with anti-phosphotyrosine antibodies and [125 I]-Protein A. The nitrocellulose membranes were then subjected to autoradiography.

Electron microscopy was as follows. After cervical dislocation, the right lobe of the liver was rapidly excised, minced in cold 2.5% glutaraldehyde, 0.1 M phosphate buffer, pH 7.4 and fixed in fresh fixative at 4°C overnight. Tissue was rinsed in the same buffer, fixed with osmium, dehydrated in graded alcohols and embedded in Araldite. Ultrathin sections were picked up on copper grids and stained with uranyl acetate and lead citrate. Areas adjacent to portal triads were viewed using a Phillips 301 electron microscope.

Analytic methods were as follows. Blood glucose levels were determined using ACCU-CHEC II (Boehringer Mannheim Diagnostics Division, Indianapolis, IN). Plasma immunoreactive insulin concentration was determined by radioimmunoassay using the polyethylene glycol method,

- 64 -

Desbuquois et al., 1971, *supra*. Serum concentrations of vanadate were determined by flameless atomic absorption spectroscopy, Stoop et al., 1982, *supra*. The lower limit of detection was 7 nM concentration. Protein 5 concentrations were determined by the method of Bradford, Bradford, 1976, *Anal. Biochem.*, 72:248-254, hereby incorporated by reference; using IgG immunoglobulin as a standard.

Data are presented as mean \pm S.E.M. The unpaired 10 student's t-test (two tailed) was used to compare two groups, and analysis of variance was used to compare more than two groups.

The Molecular Structure of the Insulin Receptor Substrate
Partial amino acid sequence of IRS-1 and
15 preparation of cDNA probes

Phosphotyrosine-containing proteins were partially purified from extracts of basal or insulin-stimulated rat liver by affinity chromatography on immobilized anti-phosphotyrosine antibodies, as described above. The 20 eluted proteins were separated by 1-dimensional SDS-PAGE and transferred to nitrocellulose, from which the pp185 band was excised and digested with trypsin. Tryptic peptides eluted from the nitrocellulose were separated by reverse-phase HPLC, as described above. Several peptide 25 fractions were subjected to amino acid sequence analysis revealing two classes of peptide sequences. Class I peptides were found only in the insulin-stimulated extracts, whereas Class II peptides were found in both the basal and insulin-stimulated extracts. Based on a search of the translated Genebank, the Class I peptide 30 sequences were unique and attributed to the insulin receptor substrates in the pp185 band, whereas Class II peptide sequences were identical to rat liver carbamyl phosphate synthase which apparently binds nonspecifically 35 to the affinity matrix. It was assumed provisionally

- 65 -

that the Class I peptides were derived from a single 175 kDa phosphotyrosine-containing substrate in the pp185 band which termed IRS-1; however, the actual relationship between each peptide was unknown.

5 The unique Class I peptide sequences obtained from the tryptic digest of the pp185 band are listed in Table I. Pep-80 and Pep-138 were the longest and most reliable amino acid sequences obtained, and they were used to prepare two long "optimal" cDNA probes according to the
10 rules for codon usage developed by Lathe, 1985 J. Mol. Biol. 183:1, hereby incorporated by reference. The nucleotide sequence of each probe is shown in Fig. 11. Double-stranded [³²P]phosphate-labeled probes were prepared by synthesizing partially overlapping
15 complementary oligonucleotides corresponding to each sequence, and then filling the 3'-overhanging ends with Klenow using high specific activity [α -³²P]dCTP and [α -³²P]dGTP. The resulting radioactive double-stranded probes (2 mCi/pmol) were used simultaneously to detect
20 cognate coding sequences in rat liver cDNA libraries.

Isolation of the cDNA for IRS-1

The complete cDNA sequence of rat liver IRS-1 is shown in Fig. 12. It was constructed from overlapping cDNA fragments obtained from two rat liver cDNA libraries
25 (Lib-1, Stratagene #936507 and Lib-2, Stratagene #936512, see below). Approximately 1.5x10⁶ clones from Lib-1 were screened with the oligonucleotide probes (Fig. 11). Two positive recombinant phages were identified and labeled C18 and C19 (Fig. 13). (Fig. 13 is a diagram of
30 overlapping cDNA inserts obtained from the rat liver cDNA libraries. The first two inserts obtained from Lib-1, C-18 and C-19, were identified with probe-138 (see Fig. 11). The remaining fragments were identified by two additional screenings of Lib-1 and Lib-2 using specific
35 cDNA probes prepared with the 3200 bp EcoRI insert of C-

- 66 -

18, or the 1300 bp EcoRI fragment from P2-2. The overlapping fragments define a contiguous piece of cDNA indicated in the black box. The cDNA is 5365 bp long and contains an open reading frame which extends from
5 nucleotide 589 to 4293. The start and end of translation is indicated, and the relative locations of the tryptic peptides listed in Table I are shown. EcoRI sites used during the analysis are shown; only the EcoRI site at the end of the C-18 insert and in the overlapping region of
10 the other fragments is actually found in the cDNA.)

The phages were purified, the Bluescript vector containing the cDNA insert was excised, and the inserts were characterized by EcoRI digestion and Southern blot hybridization (data not shown). C18 contained a single
15 EcoRI insert of 3200 bp which hybridized with probe-138, but not with probe-80. The structure of C19 is shown in Fig. 13. A fragment from the C19 insert hybridized during Southern analysis with probe-138, whereas no fragment from of C19 hybridized with probe-80. Thus,
20 probe-138 identified 2 cDNA molecules, whereas probe-80 identified none.

Nucleotide sequence analysis revealed that more than half of the C19 insert overlapped C18 (Fig. 13). However, the sequence of the 5'-end of the C19 insert
25 corresponded to rat albumin up to the EcoRI polylinker; beyond this site, the sequence corresponded exactly to the C18 insert as indicated (Fig. 13). The C18 insert contained an open reading frame beginning with an ATG codon which matched Kozak's criteria for a translation
30 initiation site Kozak, 1985, J. Mol. Biol. 183:1, hereby incorporated by reference; moreover, three in frame stop codons exist on the 5'-side of the ATG (Fig. 12). The amino acid sequence of both Pep-80 and Pep-138 were found in the open reading frame, even though probe-138, but not
35 probe-80, hybridize with the cDNA. Comparison of the

- 67 -

probe sequences with the actual cDNA sequence revealed that the "optimal" sequence of probe-80 contained 13 errors and no long stretches of identity, whereas probe-138 contained only 5 mismatches and two stretches of at least 18 matching nucleotides (Fig. 11).

Four other class I tryptic peptides attributed to a major component of the pp185 band were found in the open reading frame encoded by the C18 insert, including Pep-42, Pep-43a, Pep-76a and Pep-76b (Fig. 13). However, several peptides were not found, and no inframe stop codons were present, suggesting that only a partial cDNA clone of IRS-1 was obtained from the first screening. *Lib-1* was replated and screened with the 3200 bp EcoRI fragment from C18 as the probe. Additional clones were identified (C16, C7), but these fragments overlapped entirely with the sequence of C18, and did not extend the sequence in the 3' direction (Fig. 13). A third plating and screening of *Lib-1* identified two additional clones with unique inserts, P9 and P2-2 (Fig. 13). The insert of P9 overlapped with that of C18, confirming the putative initiation codon. In addition, this clone extended the sequence in the 5'-untranslated region. The P2-2 insert contained two internal EcoRI sites, which yielded three fragments, see Fig. 13. Sequence analysis of the entire P2-2 insert demonstrated that it contained three regions: 1) a non-overlapping sequence at the 5'-end that did not contain an open reading frame, nor did it encode Pep-80 as predicted by the sequences of C18 and C19; 2) a region which overlapped with the 3'-end of C18 fragment and contained a 1300 bp EcoRI fragment which extended the cDNA clone of IRS-1 in the 3'-direction to an inframe stop codon, TAG; and 3) the partial sequence of rat albumin that began at a junction between EcoRI polylinkers used for the library construction, indicating

- 68 -

that it was a likely artifact and unrelated to IRS-1 (Fig. 13).

Inframe translation of the 1300 bp EcoRI fragment from P2-2-cDNA revealed the presence of two additional 5 tryptic peptides, Pep-72 and Pep-43b, before a stop codon (Fig. 13). The EcoRI site at the 5'-end this open reading frame was not due to polylinkers used for library construction, suggesting that it is a real site in the cDNA of IRS-1. Thus, all of the class I peptide 10 sequences (Table I), except 2 peptides with poor quality sequence (Pep-98b and Pep-98c) were found in a contiguous cDNA molecule, suggesting that the pp185 band from rat liver contains a single insulin receptor substrate, IRS-1.

15 The open reading frame encoded by the unique overlapping inserts of C18, C19 and P2-2 encodes a 131 kDa protein (Fig. 13). The complete deduced amino acid sequence is shown in Fig. 12. To verify that neither some intervening sequence, nor the true start site, were 20 missed, an additional rat liver cDNA library, Lib-2, was screened. Nine additional overlapping clones were obtained from over 2 million plaques which confirmed the original cDNA sequence (Fig. 13). In addition, these clones extended the cDNA sequence in the 3'-direction and 25 revealed 13 inframe stop codons preceding a polyadenylation signal (AATAAA); sequencing was not extended to locate the poly-A tail. Furthermore, a consensus sequence, ATTTA, was identified three times in the 3'-untranslated region that is thought to play a role 30 in destabilization of mRNA. This may be partially responsible for the low level of the IRS-1 in cells.

35 cDNA cloning was performed as follows. Two bacteriophage cDNA libraries, Stratagene #936507, or #936512, prepared with oligo dT and random primed cDNA synthesized from rat liver mRNA and inserted into the λ-

- 69 -

Zap-II vector using EcoRI linkers were screened with optimal oligonucleotide probes. Approximately 10^6 plaques were plated at a density of 30,000 plaques per 150 mm plate, transferred to nylon filters (New England Nuclear), and screened with an equimolar mixture of probe-80 and probe-138 ($2-6 \times 10^8$ cpm/pg). Hybridizations were performed in solutions containing 30% formamide, 10% dextran sulfate, 5x NaCl/citrate (1x NaCl/citrate is 0.15 M NaCl/0.015 M trisodium citrate), 2x Denhardt's solution, and 1% SDS at 42°C. The filters were washed with 0.2% SDS, 0.5x NaCl/citrate at 42°C and exposed to Kodak XAR-5 film with a Quanta 111 intensifying screen at -60°C. The Bluescript KS⁻ plasmid containing the cDNA inserts that remained positive after plaque purification were liberated from the λ-Zap-II vector by *in vivo* excision as described in the manufacturer's instructions (Stratagene, Inc.). The inserts were sequenced on both strands as described previously (Williams and Birnbaum, 1989), and aligned into contiguous sequence. The sequence was confirmed by sequencing the coding strand of independent cDNA inserts which contained all the translated sequences. The sequences were aligned and analyzed using the EUGENE and SAM (Molecular Biology Computing Research Resource, Dana Farber Cancer Institute and Harvard School of Public Health).

[³²P]Phosphate, [γ -³²P]ATP (3000 Ci/mmol), [α -³²P]dCTP (3000 Ci/mmol), [α -³²P]UTP (800 Ci/mmol), and [¹²⁵I]protein A were from New England Nuclear (Boston, MA). Restriction enzymes and other DNA modifying enzymes were purchased from either New England Biolabs (Beverly, MA) or United States Biochemicals (USB, Cleveland, OH). Other common materials were commercial products of the highest grade available.

Identification of the mRNA for IRS-1

- 70 -

Northern blot hybridization analysis using poly(A)⁺ RNA from the liver of normal and streptozotocin-induced diabetic rats revealed a faint doublet band about 9.5 kbp in length. The doublet was detected with two probes, one derived from the C18 insert and encoding the 5'-end of the cDNA, and the other derived from the 1300 bp EcoRI fragment of the P2-2 insert which encodes the 3'-end of the cDNA. Although other bands were also detected with each probe, a 9.5 kbp doublet was common to both probes suggesting that it was the major species encoding IRS-1. The smaller species may represent degradation products that are differentially recognized, as the 1.3 kbp and 2.0 kbp fragments are too small to encode IRS-1.

RNA analysis was performed as follows. Total RNA was isolated by guanidinium isothiocyanate-cesium chloride centrifugation. For Northern blot analysis, RNA was denatured with 6% formaldehyde, size-fractionated by 1% agarose gel electrophoresis, and transferred to a Nytran membrane (Schleicher & Schuell) (Sambrook et al., 1989, Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, hereby incorporated by reference). The integrity and relative amounts of RNA were assessed by visualization of the ribosomal RNA by UV shadowing. Hybridizations were performed as above except that the formamide concentration was 50%, and the blots were washed in 0.2% SDS, 0.1x NaCl/citrate at 51°C. The probes used were either the full-length brain glucose transporter cDNA. (Birnbaum et al., 1986) or the 2.5 kb insert from pSM11-I. The Nytran membranes were exposed to Kodak XAR-5 film overnight at -80°C with a Quanta 111 intensifying screen.

The 131 kDa open reading frame of IRS-1 migrates as a 165 kDa protein during SDS-PAGE

- 71 -

The molecular size of IRS-1, 131 kDa, was somewhat smaller than expected for a protein that migrates near 180 kDa during SDS-PAGE. To determine whether the cDNA for the entire protein was obtained, a full length cDNA 5 encoding IRS-1 was constructed from several fragments, as described below, and inserted the contiguous cDNA into pBSII producing pBSII/IRS-1. The mRNA was transcribed in vitro using the t3 promoter, and the mRNA was translated in vitro in a reticulocyte lysate. Three different mRNA 10 species were produced to test the validity of the 131 kDa open reading frame, Fig. 14. A full length mRNA molecule (5365 bp) was synthesized from the pBSII/IRS-1 plasmid that was linearized beyond the 3' end with EcoRV. A shorter mRNA (4810 bp) was transcribed from a modified 15 plasmid linearized with EcoRV that lacked a 555 bp SpeI fragment from the 5'-untranslated region. The shortest mRNA molecule which contained the open reading frame (3754 bp) was transcribed from the plasmid lacking the 555 bp SpeI fragment but linearized slightly beyond the 20 first stop codon with AatII.

In the absence of added mRNA, no [³⁵S]methionine-labeled proteins were detected. Translation of the 4810 bp mRNA-B produced a 162 kDa protein. In contrast, the full length mRNA, which included three inframe stop 25 codons prior to the Kozac initiation site, produced very little of this protein product. Thus, the open reading frame most likely begins at nucleotide 589, Fig. 12. Moreover, deletion of 800 bp from the 3'-end of the cDNA had no effect on the size of the translation product, 30 suggesting that the actual stop site occurs at nucleotide 4392. Anti-peptide antibody, α Pep80, immunoprecipitated the major [³⁵S]methionine-labeled translation products, confirming that these protein were IRS-1.

Structural features of IRS-1

- 72 -

The amino acid sequence of IRS-1 shows no significant identity to known sequences in the translated Genbank. Serine is its most abundant residue (14.66%), followed by glycine (10.45%), proline (9.55%), and then 5 alanine (7.69%). IRS-1 is largely hydrophilic containing 41.78% polar residues, and nearly twice as many basic (14.41%) as acidic (8.83%) residues. It contains a few hydrophobic stretches, but none long enough to qualify as potential transmembrane spanning regions, Fig. 15A. (In 10 Fig. 15A the hydrophathicity of the deduced sequence of IRS-1 was analyzed by the Kyte-Doolittle algorigm.) This result is consistent with the presumed cytoplasmic location of the pp185 band, Daniel et al, 1987, J. Biol. Chem. 262:9778, hereby incorporated by reference. IRS-1 15 contains 5 consensus sequences for asparagine-linked glycosylation (Asn-Xxx-Ser/Thr), although there is no evidence that IRS-1 is glycosylated.

The consensus sequence for a nucleotide binding site, Gly-X-Gly-X-X-Gly (Seq. I.D. No. 25), is found 8 20 times in IRS-1 (Fig. 15B). This conserved sequence is proposed to join a β -sheet with an α -helix, forming an elbow around the nucleotide with the first glycine in contact with the ribose moiety and the second lying near the pyrophosphate, Wierenga et al., 1983, Nature 302:842 25 hereby incorporated by reference. This motif occurs once in IRS-1 beginning at Gly₁₃₇, and ending at Lys₁₅₆, which is located 14 amino acids beyond Gly₁₄₂, Fig. 15B. Lys₁₅₆ exists in the motif, Ala-X-Lys₁₅₆-X-Val, which is frequently found in protein kinases.

30 IRS-1 contains many potential phosphorylation sites, Fig. 15C. Based on typical motifs for cAMP-dependent protein kinase ([R,K]-[R,K]-X-[S,T], protein kinase C ([S,T]-X-[R,K]) and casein kinase ([S,T]-X-X-[E,D])), 33 putative Ser/Thr phosphorylation sites are 35 distributed throughout the protein. In addition, at

- 73 -

least 10 potential tyrosine phosphorylation sites can be identified, Fig. 15C. These sites were located by the presence of negatively charged amino acids adjacent to tyrosine residues, Kemp, et al., 1990, TIBS 15:342,
5 hereby incorporated by reference. Moreover, six of these putative tyrosine phosphorylation sites are located in the central region of the protein and contain the motif, YMXXM (Seq. I.D. No. 1), and one site has the sequence EYYE (Seq. I.D. No. 26), Fig. 16).

10 To test the validity of the YMXXM (Seq. I.D. No. 1) motif as a phosphorylation site for the insulin receptor, synthetic peptides were prepared containing the sequence of Tyr₄₆ (KK-Y₄₆-1), Tyr₆₀₈ (KK-Y₆₀₈-1) and Tyr₇₂₇ (KK-Y₆₅₈-1). The phosphorylation of these peptides by the
15 partially purified insulin receptor was compared to the phosphorylation of peptide IR1150, which includes the amino acid sequence around the major autophosphorylation sites of the insulin receptor, Y₁₁₄₆, Y₁₁₅₀ and Y₁₁₅₁, Fig.
20 17). The KK-Y₄₆-1 peptide (open circles) was a very poor substrate for the insulin receptor compared to the control IR1150 peptide. In contrast, the YMXXM-containing peptides, KK-Y₆₀₈-1 (solid rectangles) and KK-Y₆₅₈-1, were
25 at least as good as the IR1150 peptide. In each case, the YMXXM peptides displayed V_{max} values twice as high as the IR1150 peptide, but they had slightly higher K_m values. Although the phosphorylation sites actually used by the insulin receptor in the intact cell have not yet
30 been identified, these results suggest that IRS-1 contains several candidate sites with the interesting YMXXM motif.

In vitro kinase assays were performed as follows. The synthetic peptide substrate (IR₁₁₅₀), composed of
35 amino acids 1143-1152 of the human insulin receptor

- 74 -

(numbered as per Ullrich et al., 1984, *Nature* 309:418, hereby incorporated by reference, was purchased from Dr. David Coy, Tulane University, New Orleans, LA. Lectin-purified insulin receptors, normalized to insulin binding activity, were incubated for various periods of time in a final volume of 50 μ l containing 50 mM HEPES pH 7.5, 0.1 % Triton X-100, 5 mM MnCl₂, and the absence or presence of 100 nM insulin. Substrate phosphorylation was initiated by the addition of varying concentrations of peptide for 5 min at 22°C. Reactions were terminated by the sequential addition of 20 μ l 1% bovine serum albumin (BSA) and 50 μ l 10% trichloroacetic acid (TCA). Precipitated protein was removed by centrifugation, and the supernatant, containing the phosphorylated peptide, was applied to a 1 x 1 inch piece of phosphocellulose paper (Whatman). The papers were washed with 4 changes (1 liter each) of 75 mM phosphoric acid, and the retained radioactivity was measured by Cerenkov counting.

Phosphorylation of IRS-1 by the wild-type and mutant insulin receptor in CHO cells

CHO cells expressing the wild-type human insulin receptor were labeled with [³²P]orthophosphate for 2 h, and then stimulated with 100 nM insulin for 1 min. This time interval was chosen because in previous experiments, the pp185 band showed maximal phosphorylation after 20 s of insulin stimulation. In the absence of insulin, the antiphosphotyrosine antibody (α PY) immunoprecipitated several proteins which were also detected after insulin stimulation. However, insulin stimulated the tyrosine phosphorylation of 2 additional protein bands, the β -subunit of the insulin receptor (95 kDa) and pp185. The pp185 band from CHO cells was previously shown to migrate at 175 kDa during SDS-PAGE, Bjorge et al., 1990, *Proc. Natl. Acad. Sci. (USA)* 87, 3816-3820, hereby incorporated by reference.

- 75 -

Phosphoproteins from an equal portion of control and insulin-stimulated cell extract were immunoprecipitated with an antibody against Pep-80 (α Pep80). In the absence of insulin, the major phosphoprotein migrated at 165 kDa. Other minor proteins were also detected at 120 kDa, 100 kDa, and 55 kDa. Interestingly, these protein were also detected in the α PY immunoprecipitate and may constitute nonspecific binding; however, the 165 kDa protein, IRS-1, was the major phosphoprotein present in the α Pep80 immunoprecipitate. After insulin stimulation, the phosphorylation of IRS-1 protein increased about 2-fold and it migrated at a slightly higher molecular weight (170 kDa), consistent with insulin-stimulated phosphorylation occurring within 1 min. However, IRS-1 clearly migrated below the center of the pp185 band immunoprecipitated with the α PY.

As pp185 is a phosphotyrosine-containing protein, qualitative phosphoamino acid analysis was carried out. Before insulin stimulation, IRS-1 immunoprecipitated with the α Pep80 contained predominantly Ser(P) with a small amount of Thr(P), but no Tyr(P) was detectable; however, insulin stimulated the appearance of Tyr(P) in IRS-1. The corresponding analysis of the pp185 band

immunoprecipitated with α PY revealed Ser(P), Thr(P) and a small amount of Tyr(P) in the basal state, and a larger increase in Try(P) after insulin stimulation. The difference in the amount of Tyr(P) in the IRS-1 and the pp185 band after insulin stimulation is unknown.

It has previously been demonstrated that mutation of the insulin receptor in the juxtamembrane region of the β -subunit blocked the ability of insulin to stimulate tyrosine phosphorylation of pp185, whereas autophosphorylation of the mutant receptor was normal, White et al., 1988, Cell 54:641, hereby incorporated by

- 76 -

reference. CHO cells expressing the wild-type human insulin receptor (CHO/HIR_c), and mutant receptors containing point mutations (CHO/IR_{F960}) or a partial deletion (IR_{Δ960}) of the juxtamembrane region were labeled 5 with [³²P]orthophosphate. Insulin stimulated the tyrosine phosphorylation of the β-subunit of each receptor as shown by immunoprecipitation with the αPY. In contrast, the pp185 band was strongly phosphorylated only by the wild-type insulin receptor, whereas the IR_{F960} and IR_{Δ960} 10 showed no phosphorylation of the pp185 band. Similarly, immunoprecipitation of an equal amount of these cell extracts with αPep80 showed insulin-stimulated phosphorylation of the IRS-1 in the CHO/HIRc cells; insulin had no effect on the phosphorylation of IRS-1 in 15 the CHO/IR_{F960} and CHO/IR_{Δ960}. Thus the mutant receptors were not stimulating the phosphorylation or molecular weight shift of IRS-1 suggesting that IRS-1 interacts with the wild-type and mutant insulin receptor in a similar fashion to the components of the pp185 band. 20 Based on these results, we conclude that IRS-1 is a substrate of the insulin receptor and is a component of the pp185 band.

In vivo phosphorylation and phosphoamino acid analysis were performed as follows. CHO cells were grown 25 in 10 cm dishes in F12 medium containing 10% fetal bovine serum (Gibco). Subconfluent CHO cells (10^6) were transfected by calcium phosphate precipitation with 1 μg pSVEneo alone or together with 10 μg of pCVSVHIRc, pCVSVHIRc/F960, or pCVSVHIRc/Δ960 as previously described 30 (10-11). After 72 h, 800 μg/ml of geneticin (GIBCO) was added to the medium to select for neomycin-resistant cells. Surviving cells were cultured in the presence of geneticin to amplify the cell line. CHO cells that expressed high levels of surface insulin receptors were 35 selected by fluorescence-activated cell sorting (13), and

- 77 -

clonal cell lines were obtained by plating at limiting dilution.

Insulin receptor mutants were constructed, using oligonucleotide-directed mutagenesis, in which Tyr₉₆₀ was substituted with phenylalanine (IR_{F960}) or 12 amino acids (A954-D965) were deleted from the juxtamembrane region (IR_{Δ960}). CHO/neo cells, expressing only pSVEneo,

5 contained about 3,000 hamster insulin receptors.

Following transfection and selection by fluorescence-activated cell sorting, clonal lines of CHO/IR cells and mutant CHO/IR_{F960}, and CHO/IR_{Δ960} cells were obtained which expressed approximately 80,000 receptors/cell. Scatchard analysis of CHO/IR_{F960} and CHO/IR_{Δ960} cells has been previously described, and indicated that binding was

10 normal (10-11). The insulin dose response of *in vitro* autophosphorylation by partially purified receptors from CHO/IR, CHO/_{F960} and CHO/_{Δ960} cells was identical; a half-maximal response was obtained at approximately 3 nM insulin for all three lines, identical to the insulin

15 binding affinity of the receptors. Thus, despite mutations near the transmembrane domain, the coupling of insulin binding to receptor autophosphorylation was

20 normal in the IR_{F960} and IR_{Δ960}.

Confluent monolayers of transfected CHO cells in

25 10 or 15 cm dishes (Nunc) at 37°C were labeled for 2 h with 0.5 mCi/ml with [³²P]phosphate (New England Nuclear) as previously described (Backer et al., 1990). The cells were incubated for additional periods of time in the presence of 100 nM insulin, rapidly frozen with liquid

30 nitrogen, and solubilized in 100 mM Tris, pH 8.2, containing 2 mM sodium vanadate, 3.4 mg/ml PMSF, 100 μg/ml aprotinin, 1 μg/ml leupeptin, and 1% Triton-X-100. Tyr(P)-containing proteins were immunoprecipitated with antiphosphotyrosine antibody (αPY); precipitated proteins

35 were reduced with dithiothreitol and analyzed by SDS-

- 78 -

PAGE. Immunoprecipitated proteins were identified by autoradiography and the radioactivity in the insulin receptor subunits was quantified by liquid scintillation counting.

5 Immunoprecipitates of IRS-1 contain phosphatidyl inositol 3-kinase activity The phosphatidyl inositol 3-kinase (PtdIns 3-kinase) is activated by several growth factor receptor tyrosine kinases and is thought to be involved in the regulation of DNA synthesis, Kaplan et al., 1987, Cell 50:1021, hereby incorporated by reference. Several reports suggest that it is a 85 kDa protein which undergoes tyrosine phosphorylation or associates tightly with phosphotyrosine-containing proteins, Kaplan et al., 1987, supra. However, it is not 10 clear whether direct tyrosine phosphorylation of the PtdIns 3-kinase or its association with Tyr(P)-containing proteins is required for its activation.

15 Insulin stimulated the PtdIns 3-kinase was detected in α PY immunoprecipitates and in anti-insulin receptor immunoprecipitates as, Ruderman et al., 1990, Proc. Natl. Acad. Sci. (USA), 87:1411, hereby incorporated by reference, and Endemann et al., 1990, J. Biol. Chem 265:396, hereby incorporated by reference. Extracts from basal or insulin-stimulated CHO/HIRC cells 20 were incubated with α PY, two preparations of anti-insulin receptor antibody (B2 or K-14), and α Pep80. The PtdIns 3-kinase activity was measured in each immunoprecipitate. Fig. 18 shows the insulin stimulation of phosphatidyl inositol 3-kinase. CHO/IR cells were stimulated with 25 insulin (100 nM) for 10 min and extracts were prepared. The PtdIns 3-kinase activity was assay in immunocomplexes prepared with α PY (Tyr(P)), two anti-insulin receptor antibodies (B2 and K-14) and α Pep80.

30 Phosphatidyl inositol 3-kinase activity was assayed as follows. *In vitro* phosphorylation of 35

- 79 -

phosphatidylinositol was measured as previously described (Ruderman et al., 1990, supra. Subconfluent CHO cells grown in 100 mm dishes were made quiescent by an overnight incubation in F-12 medium containing 0.5% BSA.

5 The cells were then incubated in the absence or presence of insulin (100 nM) for 10 min, and washed once with ice cold PBS and twice with 20 mM Tris (pH 7.5) containing 137 mM NaCl, 1 mM MgCl₂, 1 mM CaCl₂, and 100 μM Na₃VO₄ (Buffer A). The cells were solubilized in 1 ml Buffer A

10 containing 1% NP-40 (Sigma) and 10% glycerol, and insoluble material was removed by centrifugation at 13,000 × g for 10 min. Tyrosyl phosphoproteins were immunoprecipitated from the supernatant with αPY and protein A-sepharose (Pharmacia). Alternatively, anti-

15 insulin receptor or control antibodies were used as described in the text. The immunoprecipitates were washed successively in PBS containing 1% NP-40 and 100 μM Na₃VO₄ (3 times), and 10 mM Tris (pH 7.5) containing 100 mM NaCl, 1 mM EDTA and 100 μM Na₃VO₄ (2 times). The

20 pellets were resuspended in 50 μl of 10 mM Tris (pH 7.5) containing 100 mM NaCl and 1 mM EDTA. To each pellet was added 10 μl 100 mM MnCl₂ and 10 μl of phosphatidylinositol (2 μg/μl) sonicated in 10 mM Tris (pH 7.5)/1 mM EGTA. The reaction was started by the

25 addition of 10 μl of 440 μM ATP containing 30 μCi [³²P]ATP. After 10 min at 22°C, the reaction was stopped by the addition of 20 μl 8N HCl and 160 μl CHCl₃:methanol (1:1). The samples were centrifuged, and the lower organic phase was removed and applied to a silica gel TLC

30 plate (Merck) which had been coated with 1% potassium oxalate. TLC plates were developed in CHCl₃:CH₃OH:H₂O:NH₄OH (60:47:11.3:2), dried and visualized by autoradiography. The radioactivity in spots which co-migrated with PtdIns-4P standard (Sigma) was measured by

- 80 -

Cerenkov counting as previously described (Ruderman et al., 1990).

Structure and Function of IRS-1

Insulin stimulates tyrosine phosphorylation of

- 5 IRS-1 in CHO cells expressing wild-type human insulin receptor. This leads to a slight retardation of its migration during SDS-PAGE, which is a typical finding following protein phosphorylation. Moreover, most of the immunoprecipitated IRS-1 migrates more slowly after 1 min
10 of insulin stimulation, suggesting the cellular IRS-1 reacts quickly and completely with the insulin receptor. Thus IRS-1 is expected to be a physiologically relevant substrate of the insulin receptor. Phosphoamino acid analysis reveals that both IRS-1 and the pp185 band
15 contain Ser(P) and a small amount of Thr(P) before and after insulin stimulation. In addition, the pp185 band contains a small amount of Tyr(P) before insulin stimulation. The amount of Tyr(P) in IRS-1 is detectable only after insulin stimulation, and is relatively low
20 compared to the Tyr(P) in the pp185 band following insulin stimulation. This disparity is consistent with the presence of additional Tyr(P)-containing proteins in the pp185 band, or the inability of α Pep80 to recognize the highly tyrosine phosphorylated form of the IRS-1.
25 Expression of the IRS-1 cDNA in CHO cells and the preparation of other antibodies will be necessary to resolve this question.

Several structural features of the insulin receptor are required for tyrosine phosphorylation of the pp185 band in CHO cells including a functional ATP binding site, an intact regulatory region which contains the major autophosphorylation sites, and a normal juxtamembrane region. Point mutations or a deletion of a portion of the juxtamembrane region inhibits insulin
35 signal transmission and phosphorylation of the pp185

- 81 -

band, without altering autophosphorylation of the insulin receptor. Two insulin receptor molecules containing juxtamembrane mutations, IR_{F960} and IR_{A960}, did not phosphorylate IRS-1 during insulin stimulation of 5 transfected CHO cells. Thus, IRS-1 shows a similar dependance on an intact juxtamembrane region of the insulin receptor for insulin-stimulated phosphorylation. These results demonstrate that IRS-1 has the expected characteristics of a pp185 component.

10 IRS-1 mRNA is in very low abundance. The 0.5 kbs doublet detected during Northern analysis is difficult to observe and required several day exposure with a probe of high specific activity. Based on parallel blots with rat liver insulin receptor probes, it is estimated that IRS-15 1 is about 5% as abundant as the insulin receptor. IRS-1 mRNA may be unstable, because the 3'-untranslated region containing the sequence motif ATTTA which has been implicated as a destabilizing motif in other mRNA molecules. Northern analysis of mRNA from rat liver, 20 muscle, spleen, brain and kidney indicates that IRS-1 is found in all of these cell types, suggesting that it may play an essential role of insulin signaling in all tissues. This is consistent with results with α PY in previous studies which indicate the pp185 band is found 25 in all cell types evaluated, Rosen, 1987, Science 237:1452, hereby incorporated by reference. Partial sequence analysis of IRS-1 from a human muscle cDNA library indicates the IRS-1 is extremely well conserved between rat liver and human skeletal muscle. These 30 results support the hypothesis that IRS-1 plays an essential and conserved role in cellular regulation by insulin.

The deduced amino acid sequence of IRS-1 is unique, which hampers attempts to deduce its function by 35 comparison with homologous proteins. IRS-1 is a

- 82 -

hydrophilic protein with no stretch of hydrophobic residues long enough to provide a transmembrane spanning region. It contains an abundance of glycine and proline residues which leads frequently to the motif Gly-Pro-Y,
5 which leads to a weak alignment between IRS-1 and collagen; however, the proteins are clearly distinct. Several structural motifs are found in IRS-1 which may provides clues regarding its role in insulin action including, 8 nucleotide binding motifs, a kinase-like
10 ATP-binding site, tyrosine phosphorylation sites with the motif YMXM, multiple serine and threonine phosphorylation sites, and a run of 10 glutamine residues.

Insulin action is thought to be mediated through a cascade of protein phosphorylation and dephosphorylation.
15 Whether IRS-1 plays a direct role in this mechanism as a protein kinase is unknown. Our previous attempts to label the components of the pp185 band with ATP affinity reagents have been unsuccessful. However, one of the eight nucleotide binding motifs in IRS-1 has the clear appearance of a ATP binding site. The nucleotide binding component has the structure Gly₁₃₇-Val-Gly-Glu-Ala-Gly and 14 (Seq. I.D. No. 27) amino acids away is the essential catalytic lys₁₅₆. In addition, the lysine reside is in an Ala-Xxx-Lys-Ile (Seq. I.D. No. 28) motif, which is
20 conserved among many protein kinases, Hanks et al., 1990, Science 241:42, hereby incorporated by reference. None of the other nucleotide binding motifs show this additional homology. Hanks et al. recently described 11 conserved subdomains commonly found in protein kinase
25 catalytic domains. The ATP binding site is located in region I, and all protein kinases evaluated contain a glutamic acid residue in region II, 13 to 42 residues down-stream from the catalytic lysine residue of region I. Consistent with this model, IRS-1 contains Clu₁₉₄ 38
30 residues away from Lys₁₅₆. Region III of kinase catalytic
35

- 83 -

domains contains a conserved leucine or isoleucine 10 to 17 residues away from the conserved glutamic acid of region II; IRS-1 has Ile₂₀₆, 11 residues beyond Glu₁₉₄. However, IRS-1 lacks the Asp-Phe-Gly motif of region VII, 5 and the Ala-Pro-Glu motif of region VIII, which are absolutely predictive of a protein kinase. The Ala-Pro-Glu motif is essential for catalytic activity in pp60^c-src and is located about 20 residues down-stream from the autophosphorylation sites in protein kinases. The 10 absence of these motifs from IRS-1 rules out the possibility that the IRS-1 is a typical protein kinase.

Tyrosine phosphorylation links IRS-1 to this insulin receptor. At least 10 potential tyrosine phosphorylation sites were detected by eye in the deduced 15 sequence, as any Tyr residue with an Asp or Glu residue nearby was considered a possibility. Interestingly six of these Tyr residues resided in a YM XM motif, which is also found in the polyoma middle T antigen (MTag), Carmichael et al., 1980, J. Biol. Chem., 255:230, hereby 20 incorporated by reference, and receptor tyrosine kinases for PDGF, Yarden et al., 1986, Nature 323, 226-232, hereby incorporated by reference, CSF-1, Sherr et al., 1985, Cell, 41, 665-676, hereby incorporated by reference, and EGF, Yarden et al., 1986, Nature, 323, 226-232, hereby 25 incorporated by reference; Ullrich et al., 1984, Nature, 309, 418-425, hereby incorporated by reference. IRS-1 synthetic peptides containing the YM XM motif are good substrates for the insulin receptor as their K_m values are nearly the same as insulin receptor peptide4. 30 Although we have no information about in vivo sites, all of the YM XM motifs look like good possibilities. In contrast, the motif Glu-Tyr-Tyr-Glu, is not phosphorylated well by the insulin receptor, suggesting that the presence of a Tyr in the YM XM motif with 35 adjacent negatively charged amino acids may define the

- 84 -

preferred substrate of the insulin receptor tyrosine kinase.

Recently, tyrosine phosphorylation sites in MTag and various growth factor receptors, in particular the PDGF and EGF receptors, have been shown to bind specifically to the Src homology-2 (SH2) domain in certain signal transduction proteins, including phosphoinositide-specific phospholipase C (PLC 1), GTPase activating protein (GAP), phosphatidyl inositol 3-kinase (PtdIns 3'-kinase) and p74^{raf}, Anderson et al., 1990, Nature, 250, 979-982, hereby incorporated by reference. The SH2 domain was first identified in nonreceptor protein tyrosine kinases like Src and Fps, by its apparent ability to interact with the kinase domain and phosphorylated substrates. Several motifs are highly conserved within the SH2 domain which typically begins with the sequence W-(Y/F)-(H/F)-G-K. Bacterially expressed SH2 domains from PLC 1 or GAP immobilized on Sepharose precipitate the PDGF and EGF receptor, suggesting that ligand-stimulated tyrosine phosphorylation may regulate the interaction between the receptor and cellular protein. Thus, tyrosine phosphorylation enable certain proteins to bind to cellular protein containing SH2 domains and potentially altering their activity.

Although the insulin receptor contains Tyr(P), it has not been shown to bind PLC 1, GAP, and p74^{raf}. Although insulin activates PtdIns 3'-kinase which is found in α PY immunoprecipitates, the IR weakly binds PtdIns 3'-kinase {}. This suggests that all Tyr(P) residues are not in the proper configuration to interact with SH2 domains; moreover, the insulin receptor does not contain any tyrosine phosphorylation sites in the YM XM motif, which appears to be strongly recognized by SH2 domains. Thus, IRS-1, which contains 6 tyrosine

- 85 -

phosphorylation sites in YM XM motifs may serve as a link between the insulin receptor and cellular proteins involved in the regulation of growth and metabolism. This conclusion is supported by the strong

5 immunoprecipitations of PtdIns 3'-kinase from insulin stimulation cells with our relatively weak IRS-1 antibodies. Thus, IRS-1 may serve as a cytoplasmic ligand that links the insulin receptor to SH2 domain-containing enzymes involved in cellular regulation.

10 The regulation of IRS-1 phosphorylation is potentially very complex. IRS-1 contains many potential serine and threonine phosphorylation sites, and it is serine phosphorylated in the basal state. The pp185 band in Fao hepatoma cells undergoes serine/ threonine 15 phosphorylation during stimulation with TPA, which inhibits partially the stimulation of DNA and glycogen synthesis by insulin. Moreover, IRS-1 contains 8 putative nucleotide binding sites which could provide additional regulation through other mechanisms. Thus 20 IRS-1 provides a common intermediate through which multiple protein kinases and other signal transduction systems may communicate.

IRS-1 contains a run of 10 glutamine residues beginning at Gln₈₇₁. Glutamine-rich regions have been 25 found in amino acid sequences of several eukaryotic regulatory proteins including the androgen receptor Lubahn et. al., 1988, Mol. Endocrin. 2:1265, hereby incorporated by reference, mineralocorticoid receptor Arriza et. al., 1987, Science 237:268, hereby 30 incorporated by reference, glucocorticoid receptor Hollenberg et. al., 1991, Nature 318:635, hereby incorporated by reference, human c-myc oncogene Rabbitts et. al., 1983, Nature 306:760, hereby incorporated by reference, the transcription factor SP1 Courey et. al., 35 1988, Cell 55:887, hereby incorporated by reference,

- 86 -

Drosophila zeste gene which binds and activates the Ubx promoter Pirrotta et. al., 1987, EMBO J. 6:791, hereby incorporated by reference, and products of the homoeobox containing genes such as Antp and Cut. The sequence 5 similarity is limited at most to the run of glutamines and a few adjacent amino acids. However, the role and specificity of the glutamine residues is unclear Courey et. al., 1988, Cell 55:887, hereby incorporated by reference. IRS-1 lacks other characteristics suggestive 10 of a DNA binding protein.

In summary, IRS-1 may provide a molecular link between the insulin receptor and cellular enzymes involved in regulation of cellular growth and metabolism. The amino acid deduced sequence of IRS-1 does not contain 15 any obvious enzymatic function; however, its low abundance, general distribution, and the presence of several common motifs in the sequence suggest that it may play an important role in insulin action. Provisionally, we propose that IRS-1 acts a molecular link between the 20 insulin receptor and cellular proteins which contain the SH2 domain. Other tyrosine kinases may also phosphorylated IRS-1, and other signaling systems such as serine/threonine kinases and nucleotides may regulate the signal flux.

25 Human IRS-1
Human IRS-1 encoding DNA can be obtained by the methods of the invention or, preferably, by homology to DNA encoding rat IRS-1, by methods known to those skilled in the art, e.g., by probing a human genomic or cDNA 30 library, preferably a liver cDNA library, with nucleic acid encoding rat IRS-1.

Human IRS-1 can be obtained by the protein purification methods described herein, or more preferably, by expression from recombinant human DNA

- 87 -

encoding IRS-1, by methods known to those skilled in the art.

Use

Dosages of tyrosine kinase inhibiting substances 5 and other therapeutic substance will vary, depending on factors such as, the disease being treated, the half life of the substance, potency, route of administration, and the condition of the patient.

Other Embodiments

10 Other embodiments are within the following claims, e.g., the molecules and methods of the invention can be used to diagnose insulin related diseases, e.g., diseases characterized by insulin resistance, e.g., Type II diabetes. These diagnostic tests can be based on the use 15 of antibodies to IRS-1 to determine the levels of IRS-1 in a tissue sample taken from a patient. Alternatively they can measure some other significant aspect of IRS-1 metabolism expression or action, e.g., the extent of IRS-1 phosphorylation, or the cellular or intracellular 20 distribution of IRS-1. Cloned DNA homologous to DNA that encodes IRS-1 can also be used to measure levels of IRS-1 expression, e.g., by measuring levels of IRS-1 encoding mRNA. Levels of any of these parameters that deviate significantly from normal are diagnostic of disease. 25 Normal and disease state levels of IRS-1, IRS-1 RNA, IRS-1 phosphorylation, or other significant parameters of IRS-1 metabolism expression, or action, can be determined by methods known to those skilled in the art.

Insulin related-disease states, e.g., insulin-
30 resistant diseases, e.g., Type II diabetes, that are caused by a structural defect in the insulin receptor substrate gene can be diagnosed by using DNA homologous to the IRS-1 gene to discover the structural defect. Structural defects in a gene can be discovered by methods

- 88 -

known to those skilled in the art, e.g., by restriction fragment length polymorphism or DNA sequence analysis.

What is claimed is:

- 89 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Kahn, G. Ronald
White, Morris F.
Rothenberg, Paul Louis

(ii) TITLE OF INVENTION: INSULIN RECEPTOR SUBSTRATE

(iii) NUMBER OF SEQUENCES: 28

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Richardson
(B) STREET: 225 Franklin Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP: 02110-2804

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
(D) SOFTWARE: WordPerfect (Version 5.0)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 07/643,982
(B) FILING DATE: 01/18/1991
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Freeman, John W.
(B) REGISTRATION NUMBER: 29,066
(C) REFERENCE/DOCKET NUMBER: 00303/013WO1

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 542-5070
(B) TELEFAX: (617) 542-8906
(C) TELEX: 200154

- 90 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Tyr Met Xaa Met
4

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TCTGCTGTGA CAGGCCCGG CGAGTTCTGG ATGCAGGTGG ATGACTCTGT GGTGGCCAG	60
AACATG	66

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TACATCCCTG GCGCCACCAT GGGCACCTCC CCTGCCCTGA CAGGCGATGA GGCC	54
---	----

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5125

- 91 -

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GGAATTCCCT GGTATTTGGG CGGCCTGGTGG CGGCAGGGGAC TGTTGGAGGG TGGGAGGAGG	60
CAGAGGAGGA GGAGGAGAAG GAGGAGGAGG GAGAACCCCCG TGCAACGTTG GGACTTGGCA	120
GCCCGCCTCC CCCTGCCCAA GGATATTTAA TTTGCCTGGG GAATCGCTAC TTCCAGAGGG	180
GAACTCGGGA GGGAAAGGAGC GCGCGCCTGG AGGGCCAAGC GGGGACTCCT CCGGTCGTCT	240
CTGCCTCCCT GCATCGGACT CTACCAGGGG CGGCAAGGGA TGCACCATAG CTCCCTCTCT	300
GCTGCAAGGA CTGGGGGAGA CTTAGTCCTC GGAAGATTGC GGCTGCACTC ACCCTAGACC	360
CACTGCCTTT CCCTCTGGC ATGAAACGCC CTTAAACTCG GATCAGGCTA TCTTCCTTTG	420
GCGCAGCTAC CTCGTCCCTC GGCTGCCCT CCCCAGCGCC AGGAACGGCG TGAATTCGG	480
AGTCAGGATT TCTGCTTGCT TCCTCCAGCC CGGAGTGCAT GTGCGGGGCC GCACCGAGAA	540
GCCACCCCTC ACCCAGTTT TCGACACCTC CCTCTGCTCC GCAGCAGC ATG GCG AGC CCT	600
Met Ala Ser Pro 1	
CCG GAT ACC GAT GCC TTC TCA GAC GTG CGC AAG GTG GGT TAC CTG CGC	648
Pro Asp Thr Asp Gly Phe Ser Asp Val Arg Lys Val Gly Tyr Leu Arg	
5 10 15 20	
AAA CCC AAG AGT ATG CAT AAG CGC TTT TTC GTG CTG CCG GCG GCC AGC	696
Lys Pro Lys Ser Met His Lys Arg Phe Phe Val Leu Arg Ala Ala Ser	
25 30 35	
GAG GCC GGG GGC CCG GCG CGC CTG GAG TAT TAT GAG AAC GAG AAG AAG	744
Glu Ala Gly Gly Pro Ala Arg Leu Glu Tyr Tyr Glu Asn Glu Lys Lys	
40 45 50	
TGG CGG CAC AAG TCG AGC GCC CCC AAA CGC TCG ATC CCC CTC GAG AGC	792
Trp Arg His Lys Ser Ser Ala Pro Lys Arg Ser Ile Pro Leu Glu Ser	
55 60 65	
TGT TTC AAC ATC AAC AAG CGG GCT GAC TCC AAG AAC AAG CAC CTG GTG	840
Cys Phe Asn Ile Asn Lys Arg Ala Asp Ser Lys Asn Lys His Leu Val	
70 75 80	
GCT CTC TAC ACC CGA GAC GAA CAC TTT GCC ATT GCG GCG GAT ACG GAG	888
Ala Leu Tyr Thr Arg Asp Glu His Phe Ala Ile Ala Ala Asp Ser Glu	
85 90 95 100	

- 92 -

GCT GAA CAA GAC ACG TGG TAC CAG GCT CTT CTG CAG CTG CAT AAT CGG Ala Glu Gln Asp Ser Trp Tyr Gln Ala Leu Leu Gln Leu His Asn Arg 105 110 115	936
GCA AAG GCC CAC CAT GAC GGG GCT GGA GGA GGC TGC GGT GGT AGC TGC Ala Lys Ala His His Asp Gly Ala Gly Gly Cys Gly Ser Cys 120 125 130	984
AGC GGC AGC TCT GGC GTC GGA GAG GCA GGG GAG GAC TTG AGC TAT GAC Ser Gly Ser Ser Gly Val Gly Glu Ala Gly Glu Asp Leu Ser Tyr Asp 135 140 145	1032
ACG GGC CCA GGA CCC GCG TTC AAG GAG GTC TGG CAG GTT ATC CTG AAA Thr Gly Pro Gly Pro Ala Phe Lys Glu Val Trp Gln Val Ile Leu Lys 150 155 160	1080
CCC AAG GGC TTA GGT CAG ACA AAG AAC TTG ATT GGT ATC TAC CGC CTC Pro Lys Gly Leu Gly Gln Thr Lys Asn Leu Ile Gly Ile Tyr Arg Leu 165 170 175 180	1128
TCG CTG ACC AGC AAG ACC ATC AGC TTT GTG AAG CTC AAC TCT GAG GCT Cys Leu Thr Ser Lys Thr Ile Ser Phe Val Lys Leu Asn Ser Glu Ala 185 190 195	1176
GCC GCT GTG GTG CTG CAG CTG ATG AAC ATC AGA CGC TGT GGC CAC TCA Ala Ala Val Val Leu Gln Leu Met His Glu Thr Ile Leu Glu Ala Met 200 205 210	1224
CGG GCC ATG AGC CAT GAG TTT CGC CCG CGC ACG AAA AGC CAA TCT TCA Arg Ala Met Ser Asp Glu Phe Arg Pro Arg Thr Lys Ser Gln Ser Ser 215 220 225	1272
TCC AGT TGC TCC AAC CCC ATC AGT GTT CCC CTG CGC AGG CAC CAT CTC Ser Ser Cys Ser Asn Pro Ile Ser Val Pro Leu Arg Arg His His Leu 230 235 240	1320
AAC AAT CCT CCG CCC AGC CAA GTG GGG CTG ACT CGG AGA TCT CGA ACT Asn Asn Pro Pro Pro Ser Gln Val Gly Leu Thr Arg Arg Ser Arg Thr 245 250 255 260	1368
GAG AGC ATC ACT GCC ACC TCC CCT GCC AGT ATG GTG GGT GGG AAA CCA Glu Ser Ile Thr Ala Thr Ser Pro Ala Ser Met Val Gly Gly Lys Pro 265 270 275	1416
GGT TCC TTC AGG GTG CGT GCC TCC AGC GAT GGC GAA GGC ACC ATG TCC Gly Ser Phe Arg Val Arg Ala Ser Ser Asp Gly Glu Gly Thr Met Ser 280 285 290	1464
CGT CCA GCA TCA GTG GAT GGC AGT CCT GTG AGC CCT AGC ACC AAC AGG Arg Pro Ala Ser Val Asp Gly Ser Pro Val Ser Pro Ser Thr Asn Arg 295 300 305	1512

- 93 -

ACC CAC GCC CAT CGG CAT CGA GGC AGC TCC AGG TTG CAC CCC CCA CTC Thr His Ala His Arg His Arg Gly Ser Ser Arg Leu His Pro Pro Leu 310 315 320	1560
AAC CAC AGC CGC TCC ATC CCT ATG CCT TCT TCA CGA TGC TCC CCT TCA Asn His Ser Arg Ser Ile Pro Met Pro Ser Ser Arg Cys Ser Pro Ser 325 330 335 340	1608
GCC ACC AGC CCA GTG AGC CTG TCA TCC AGT AGT ACC AGT GGC CAC GGC Ala Thr Ser Pro Val Ser Leu Ser Ser Ser Thr Ser Gly His Gly 345 350 355	1656
TCC ACT TCA GAC TGT CTC TTC CCG AGG CGC TCT AGT GCT TCC GTG TCC Ser Thr Ser Asp Cys Leu Phe Pro Arg Arg Ser Ser Ala Ser Val Ser 360 365 370	1704
GGT TCT CCT AGC GAT GGC GGT TTC ATC TCT TCT GAT GAG TAT GGC TCT Gly Ser Pro Ser Asp Gly Gly Phe Ile Ser Ser Asp Glu Tyr Gly Ser 375 380 385	1752
AGT CCC TGC GAT TTC CGA AGT TCC TTC CGC AGT GTC ACC CCA GAT TCC Ser Pro Cys Asp Phe Arg Ser Ser Phe Arg Ser Val Thr Pro Asp Ser 390 395 400	1800
CTG GGC CAC ACC CCA CCA GCC AGG GGT GAG GAG GAG CTG AGC AAC TAT Leu Gly His Thr Pro Pro Ala Arg Gly Glu Glu Leu Ser Asn Tyr 405 410 415 420	1848
ATC TGC ATG GGT GGC AAG GGA GCC TCC ACC TTG ACA GCT CCC AAT GGT Ile Cys Met Gly Lys Gly Ala Ser Thr Leu Thr Ala Pro Asn Gly 425 430 435	1896
CAC TAC ATT TTG TCT AGG GGT GGC AAC GGC CAT CGC TAC ATC CCA GGT His Tyr Ile Leu Ser Arg Gly Gly Asn Gly His Arg Tyr Ile Pro Gly 440 445 450	1944
GCT ACC ATG GGG ACA AGC CCG GCG CTG ACT GGA GAC GAA GCC GCT GGT Ala Thr Met Gly Thr Ser Pro Ala Leu Thr Gly Asp Glu Ala Ala Gly 455 460 465	1992
GCA GCA GAT CTG GAT AAC CGG TTT CCG AAG AGA ACT CAC TCG GCT GGC Ala Ala Asp Leu Asp Asn Arg Phe Arg Lys Arg Thr His Ser Ala Gly 470 475 480	2040
ACG TCC CCC ACC ATA TCC CAC CAG AAG ACC CCC TCG CAG TCC TCA GTG Thr Ser Pro Thr Ile Ser His Gln Lys Thr Pro Ser Gln Ser Ser Val 485 490 495 500	2088
GTT TCT ATT GAG GAA TAT ACA GAG ATG ATG CCC GCT GCC TAC CCA CCA Val Ser Ile Glu Glu Tyr Thr Glu Met Met Pro Ala Ala Tyr Pro Pro 505 510 515	2136

- 94 -

GGA GGT GGC ACT GGA GGC CGA CTG CCC GGC TAC CGG CAT TCC GCC TTC Gly Gly Gly Ser Gly Arg Leu Pro Gly Tyr Arg His Ser Ala Phe 520 525 530	2184
GTG CCC ACC CAC TCC TAT CCC GAG GAG GGT CTA GAG ATG CAC CAC TTG Val Pro Thr His Ser Tyr Pro Glu Glu Gly Leu Glu Met His His Leu 535 540 545	2232
GAA CGT CGT GGG GGC CAC CAC CGT CCA GAC TCC TCC AAC CTC CAC ACC Glu Arg Arg Gly Gly His His Arg Pro Asp Ser Ser Asn Leu His Thr 550 555 560	2280
GAT GAT GGC TAC ATG CCC ATG TCT CCC GGA GTG GCT CCA GTG CCC AGC Asp Asp Gly Tyr Met Pro Met Ser Pro Gly Val Ala Pro Val Pro Ser 565 570 575 580	2328
AAC CGC AAA GGA AAT GGG GAC TAT ATG CCC ATG AGC CCC AAG AGT GTA Asn Arg Lys Gly Asn Gly Asp Tyr Met Pro Met Ser Pro Lys Ser Val 585 590 595	2376
TCT GCC CCC CAG CAG ATC ATT AAC CCC ATC AGG CGC CAC CCA CAG AGA Ser Ala Pro Gln Gln Ile Ile Asn Pro Ile Arg Arg His Pro Gln Arg 600 605 610	2424
GTG GAC CCC AAT GGC TAC ATG ATG ATG TCT CCC AGT GGT AGT TGC TCT Val Asp Pro Asn Gly Tyr Met Met Ser Pro Ser Gly Ser Cys Ser 615 620 625	2472
CCT GAC ATT GGA GGT GGG TCT TGC AGC AGT AGC AGC ATC AGC GCA GCC Pro Asp Ile Gly Gly Ser Cys Ser Ser Ser Ile Ser Ala Ala 630 635 640	2520
CCT TCT GGG AGC AGC TAT GGG AAG CCA TGG ACA AAC GGA GTA GGG GGG Pro Ser Gly Ser Ser Tyr Gly Lys Pro Trp Thr Asn Gly Val Gly Gly 645 650 655 660	2568
CAC CAT ACC CAT GCC CTT CCC CAT GCC AAA CCT CCT GTT GAG AGC GGT His His Thr His Ala Leu Pro His Ala Lys Pro Pro Val Glu Ser Gly 665 670 675	2616
GGT GGT AAG CTC TTG CCT TGC ACT GGT GAC TAC ATG AAC ATG TCG CCA Gly Gly Lys Leu Leu Pro Cys Thr Gly Asp Tyr Met Asn Met Ser Pro 680 685 690	2664
GTG GGA GAT TCC AAC ACC AGC AGC CCC TCA GAA TGC TAC TAT GGC CCA Val Gly Asp Ser Asn Thr Ser Ser Pro Ser Glu Cys Tyr Tyr Gly Pro 695 700 705	2712
GAA GAT CCC CAG CAC AAG CCT GTC CTC TCC TAC TAC TCA TTA CCA AGG Glu Asp Pro Gln His Lys Pro Val Leu Ser Tyr Tyr Ser Leu Pro Arg 710 715 720	2760
TCC TTT AAG CAC ACC CAG CGC CCT GGG GAG CCA GAG GAG GGT GCC AGG	2808

- 95 -

Ser Phe Lys His Thr Gln Arg Pro Gly Glu Pro Glu Glu Gly Ala Arg			
725	730	735	740
CAC CAG CAT CTT CGT CTC TCT TCA AGC TCT GGA CGC CTT CGC TAT ACC			2856
His Gln His Leu Arg Leu Ser Ser Ser Gly Arg Leu Arg Tyr Thr			
745	750	755	
GCA ACT GCC GAA GAT TCC TCC TCT TCC ACC AGC AGC GAC AGC CTG GGT			2904
Ala Thr Ala Glu Asp Ser Ser Ser Thr Ser Ser Asp Ser Leu Gly			
760	765	770	
GGG GGT TAC TGT GGG GCT AGG CCA GAG TCT AGC GTC ACA CAT CCC CAC			2952
Gly Gly Tyr Cys Gly Ala Arg Pro Glu Ser Ser Val Thr His Pro His			
775.	780	785	
CAC CAT GCC TTG CAG CCC CAT CTG CCT CGA AAG GTA GAC ACA GCT GCA			3000
His His Ala Leu Gln Pro His Leu Pro Arg Lys Val Asp Thr Ala Ala			
790	795	800	
CAG ACC AAC AGC CGC CTG GCT CGA CCC ACA AGG CTG TCC TTG GGG GAT			3048
Gln Thr Asn Ser Arg Leu Ala Arg Pro Thr Arg Leu Ser Leu Gly Asp			
805	810	815	820
CCC AAG GCA AGC ACT TTA CCC CGG GTA CGA GAG CAA CAG CAG CAG CAG			3096
Pro Lys Ala Ser Thr Leu Pro Arg Val Arg Glu Gln Gln Gln Gln Gln			
825	830	835	
CAA CAG CAG CAG CAG TCT TCC CTG CAC CCT CCC GAG CCC AAA AGC CCA			3144
Gln Gln Gln Gln Ser Ser Leu His Pro Pro Glu Pro Lys Ser Pro			
840	845	850	
GGA GAA TAT GTG AAT ATT GAA TTC GGG AGT GGC CAG CCA GGC TAT TTA			3192
Gly Glu Tyr Val Asn Ile Glu Phe Gly Ser Gly Gln Pro Gly Tyr Leu			
855	860	865	
GCT GGC CCT GCA ACT TCC CGT AGC TCC CCT TCA GTT CGA TGT CTA CCC			3240
Ala Gly Pro Ala Thr Ser Arg Ser Ser Pro Ser Val Arg Cys Leu Pro			
870	875	880	
CAG CTC CAC CCA GCT CCC AGA GAA GAG ACT GGC TCG GAA GAG TAC ATG			3288
Gln Leu His Pro Ala Pro Arg Glu Glu Thr Gly Ser Glu Glu Tyr Met			
885	890	895	900
AAC ATG GAC TTG GGG CCA GGC CGG AGG GCA ACC TGG CAG GAG AGT GGT			3336
Asn Met Asp Leu Gly Pro Gly Arg Arg Ala Thr Trp Gln Glu Ser Gly			
905	910	915	
GGA GTT GAG TTG GGC AGA GTA GGC CCT GCA CCT CCA GGG GCT GCT TCC			3384
Gly Val Glu Leu Gly Arg Val Gly Pro Ala Pro Pro Gly Ala Ala Ser			
920	925	930	
ATT TGT AGG CCA ACC CGG TCG GTG CCA AAT AGC CGT GGT GAT TAC ATG			3432
Ile Cys Arg Pro Thr Arg Ser Val Pro Asn Ser Arg Gly Asp Tyr Met			

- 96 -

935	940	945	
ACC ATG CAG ATA GGT TGT CCT CGT CAA AGC TAT GTG GAT ACC TCA CCA Thr Met Gln Ile Gly Cys Pro Arg Gln Ser Tyr Val Asp Thr Ser Pro	950	955	3480
GTG GCC CCA GTC AGC TAT GCT GAC ATG CGG ACA GGC ATT GCT GCA GAG Val Ala Pro Val Ser Tyr Ala Asp Met Arg Thr Gly Ile Ala Ala Glu	965	970	3528
AAG GTG AGC CTG CCC AGA ACC ACA GGA GCT GCC CCC CCT CCA TCC TCC Lys Val Ser Leu Pro Arg Thr Thr Gly Ala Ala Pro Pro Pro Ser Ser	985	990	3576
ACA GCC TCT TCT GCT TCT GTT AAA GTG ATT CGT GCA GAC ACT CAA Thr Ala Ser Ala Ser Ala Ser Val Lys Val Ile Arg Ala Asp Thr Gln	1000	1005	3624
GGC TGC CGG AGG AGG CAC AGC TCC GAG ACC TTC TCG GCG CCT ACG CGG Gly Cys Arg Arg Arg His Ser Ser Glu Thr Phe Ser Ala Pro Thr Arg	1015	1020	3672
GCT GCC AAC ACA GTG TCT TTT GGA GCA GGG GCT GCA GGA GGG GGC AGC Ala Ala Asn Thr Val Ser Phe Gly Ala Gly Ala Gly Gly Ser	1030	1035	3720
GGT GGT GGC AGT GAG GAT GTG AAA CGC CAC AGC TCT GCA TCC TTT GAG Gly Gly Ser Glu Asp Val Lys Arg His Ser Ser Ala Ser Phe Glu	1045	1050	3768
AAT GTG TGG CTG AGA CCC GGG GAT CTA GGG GGA GCA TCC AAG GAG TCG Asn Val Trp Leu Arg Pro Gly Asp Leu Gly Ala Ser Lys Glu Ser	1065	1070	3816
GCT CCA GGG TGC GGG GCT GCC GGG GGA TTG GAG AAG AGT CTT AAC TAT Ala Pro Gly Cys Gly Ala Ala Gly Gly Leu Glu Lys Ser Leu Asn Tyr	1080	1085	3864
ATA GAC TTG GAT TTG GTC AAG GAT GTT AAG CAG CAC CCT CAA GAC TGC Ile Asp Leu Asp Leu Val Lys Asp Val Lys Gln His Pro Gln Asp Cys	1095	2000	3912
CCC TCT CAA CAG CAG TCC CTG CCA CCC CCT CCC CCT CAC CAA CCC TTA Pro Ser Gln Gln Gln Ser Leu Pro Pro Pro His Gln Pro Leu	2010	2015	3960
GGC AGC AAT GAG GGC AGC TCC CCA AGA CGC TCC AGT GAG GAT TTA AGC Gly Ser Asn Glu Gly Ser Ser Pro Arg Arg Ser Ser Glu Asp Leu Ser	2025	2030	4008
ACC TAT GCC AGC ATC AAC TTC CAG AAG CAA CCA GAG GAC CGT CAA Thr Tyr Ala Ser Ile Asn Phe Gln Lys Gln Pro Glu Asp Arg Gln	2040	2045	4053
		2050	

- 97 -

TAGCTTAACT GGACGTCACA GGCAGAATGA AAGACCTAAA TGACCTCAGC AATCCTCCTT	4113
TTAACTCAT GGGTACCCAG ACTCGAACTC TTTCACGATT CACAACCAGG ACCTCACGTC	4173
TTCCTCCTCA GTAGATGGTA CGATGCATCC CTTACAGTTT GTTTACTTG TACAATCCTC	4233
AGGAGTTCAT TGACTGAACT GCACGTTCTT TATTGTGCCA AGCAACAAGA AAGCACTGTG	4293
ACACCGAAC AATGAGTGTG CATAAAACTTC ATCTTGAAC TTAAGGACAG CTGGCCACGA	4353
AGAGCCAGTG TGCTCCCTGC CACGCCGAAA GAGGATGGGT TTACTCTCGT CAAATTACA	4413
AGCATAACGGT TCCTCTGCTC TGAAACCGTG TTCCATGACA CGCCGCTGTA AATTATTTCA	4473
TATGGAACTG TTCGCGTTGG GTGGAGAGAG TATTAAATAT TTAACATAGG TCTTCATTAA	4533
TATATGTAAT TTTTTAATGA AAATGTAAC TTCCCTCACAG CACATTTTT TTCTCTTGGAA	4593
ATGTGAACT GAGGTATTCA ATGTTTGTT TTAAAGAGTG GGAAGAATAC TTAAAACAAG	4653
GCTAAAAAGA GTAGACTAGG AGATGATCCT TGTTTTAAGA TTCTAATTCA GAAAAATAAT	4713
ATAATATGAA TCATAGTGCC ATAGAAGGTT CTGGACTGTA TAGTTGTACT TGCTGATGCT	4773
GTCTCTTGTA ATATAAACTT GATGTCGAGC TGAGTTCCCTT TTAAGAATTAA AGCTAAGTTT	4833
TGTAATTTTT TTTTTTCCA AACCGAAGGA GGATGTATTG TACTGGGGTG TTTTCAAGTG	4893
TCGGCTTAGA ATTGGAAGTT GAATGGAAGC AAAGTTCAAC AAAGAGAGGA AGCCACAGAC	4953
TTCCATTGTA AATACTGTAG AGAGAGACAT GAGCGATCCC TTCAAGTCAA AAATCTCTCT	5013
TTGGAATGAA GAATGTGGGT GTTTATAAAAT TCTGAAAATG TCTTCTGTT CATAATAAAC	5073
TAGACACTGT TGGTCCCTCC CCACCCCCAC TTCTATAAGC CTTTCCCCCG GA	5125

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Leu Glu Tyr Tyr Glu Asn Glu Lys

- 98 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Glu Gln Gln.Gln Gln Gln Gln Gln Gln Ser
5 10

Ile Leu Xaa Pro Pro Glu
15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Leu Ser Ser Glu Thr Phe Ser Ala Pro Xaa Pro
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Val Val Ala Val Asp Xaa Gly Ile Lys
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 9:

- 99 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Glu Glu Thr Gly Ser Thr Xaa Tyr Met Asn Met Asp
5 10

Leu Gly Pro Gly Glu Ala
15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Xaa Leu Pro Asp Ala Glu Met Gly Xaa Ser Pro Ala Xaa Thr
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Ser Val Ser Ala Pro Gln Gln Ile Ile Asn Pro Ile
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 12:

(i) SEQUENCE CHARACTERISTICS:

- 100 -

- (A) LENGTH: 6
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Asn Leu Ile Gly Ile Tyr
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Gly Gln Xaa Leu Thr Met Ala Asn
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Tyr Ile Pro Gly Ala Thr Met Thr Gly Ser Pro Ala
5 10

Leu Thr Gly Asp Glu Ala Arg
15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6

- 101 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

Ser Phe Ala Phe Val Ser
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Xaa Ile Ser His Ala Ile Ser Glu His Val Glu Asp
5 10

Ser Gly Val His Ser
15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Xaa Leu Gly Ala Ser Pro Pro Asn Ala Xaa Thr Ala
5 10

Pro Xaa Xaa Xaa Arg
15

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 18:

(i) SEQUENCE CHARACTERISTICS:

- 102 -

- (A) LENGTH: 12
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Xaa Pro Pro Xaa Thr Phe Gln Xaa Val Xaa Xaa Pro
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

Ser Ala Val Thr Gly Pro Gly Glu Phe Xaa Met Gln Val Asp Asp Ser
5 10 15

Val Val Ala Gln Asn Met Xaa Glu
20

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Gln Ala Asp Ala Val Tyr Phe Leu Pro Ile Thr Pro Gln Phe Val Thr
5 10 15

Glu Val Ile Xaa
20

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 21:

(i) SEQUENCE CHARACTERISTICS:

- 103 -

- (A) LENGTH: 8
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

Thr Phe Glu Glu Ser Phe Gln Lys
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Leu Phe Ala Thr Glu Ala Thr Ser Asp Xaa
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

Thr Ala Asp Asp Ser Xaa Ile Xaa Leu Leu
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 104 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Thr Arg Asp Ile Tyr Glu Thr Asp Tyr Tyr Arg Lys
5 10

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Gly Xaa Gly Xaa Xaa Gly
5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Glu Tyr Tyr Glu
4

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Gly Val Gly Glu Ala Gly

- 105 -

5

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Ala Xaa Lys Ile

4

- 106 -

Claims

1. A purified nucleic acid consisting essentially of nucleic acid encoding IRS-1.
2. The purified nucleic acid of claim 1, said 5 purified nucleic acid being present in a vector.
3. The purified nucleic acid of claim 1, said purified nucleic acid being present in a cell.
4. The purified nucleic acid of claim 1, said nucleic acid being under the transcriptional control of a 10 heterologous promoter.
5. A homogeneous population of cells, wherein each of said cells comprises cloned nucleic acid encoding IRS-1.
6. The homogenous population of cells of claim 15 5, wherein each cell is a eukaryotic cell.
7. A purified preparation of IRS-1.
8. The purified preparation of IRS-1 produced from nucleic acid encoding IRS-1.
9. A method of producing IRS-1, comprising the 20 steps of:
culturing the cell of claim 3 in medium to form a population of cells which expresses IRS-1, and purifying IRS-1 from said cells or from said culture medium.
10. A method of purifying a phosphoprotein 25 comprising in the following order:

- 107 -

- (a) providing a sample comprising said phosphoprotein in the phosphorylated state;
- (b) contacting said sample with boiling denaturant and a reducing agent under conditions that 5 inhibit the removal of phosphate groups from said phosphoprotein;
- (c) decreasing the concentration of said denaturant sufficiently to allow an anti-phospho-amino antibody to bind to said phosphoprotein; and
- 10 (d) contacting said phosphoprotein with an anti-phosphoamino antibody and purifying said phosphoprotein by virtue of its affinity for said antibody.

11. The method of claim 10, wherein in (d), said antibody is bound to a substrate, said sample is 15 contacted with said bound antibody, and said phosphoprotein is eluted from said bound antibody.

12. A method of diagnosing an insulin-related disease in a patient comprising measuring an aspect of IRS-1 metabolism in said patient, an abnormal level of 20 said aspect of metabolism being diagnostic of said disease.

13. The method of claim 12, wherein said disease is characterized by resistance to insulin.

14. The method of claim 12, wherein said disease 25 is Type II diabetes.

15. The method of claim 12, wherein said measurement comprises measuring the level of IRS-1 in a tissue sample taken from said patient, an abnormal level of expression being diagnostic of said disease.

- 108 -

16. The method of claim 12, wherein said measurement comprises measuring the level of phosphorylation of the IRS-1 in a tissue sample taken from said patient, an abnormal level of phosphorylation being diagnostic of said disease.

17. The method of claim 12, wherein said measurement comprises measuring the level of kinase activity of IRS-1.

18. The method of claim 12, wherein said measurement comprises measuring the amount of IRS-1 encoding RNA in a tissue sample taken from said patient, an abnormal level of IRS-1 encoding mRNA being diagnostic of said disease.

19. A method of diagnosing an insulin-related disease in a patient comprising determining the structure of the gene which expresses IRS-1, an abnormal structure being diagnostic of said disease.

20. The method of claim 19, wherein said diagnosis is performed prenatally.

21. The method of claim 19, wherein said disease is characterized by resistance to insulin.

22. The method of claim 19, wherein said disease is Type II diabetes.

23. A method of assaying an effect of a therapeutic agent on IRS-1 metabolism comprising administering said agent to a test organism and measuring the effect of said agent on an aspect of IRS-1

- 109 -

metabolism, a change in said aspect of IRS-1 metabolism indicating an effect of said agent.

24. The method of claim 2, wherein said aspect of IRS-1 metabolism is IRS-1 phosphorylation.

5 25. The method of claim 21, wherein said aspect of IRS-1 metabolism is the kinase activity of IRS-1.

26. The method of claim 20, wherein said insulin related disease is an insulin resistant state and said change in an aspect of metabolism is the level of IRS-1
10 phosphorylation.

27. A method of assaying the effects of a therapeutic agent which mimics a first effect of insulin, said first effect mediated by IRS-1, without mimicking a second effect of insulin comprising administering said
15 agent to a test organism and measuring a change in an aspect of IRS-1 metabolism.

28. A method of assaying an effect of a therapeutic agent which alters the ability of a tyrosine kinase to phosphorylate a substrate comprising the amino
20 acid sequence YM XM comprising administering said agent to a test organism and measuring the level of phosphorylation of a substrate which comprises the amino acid sequence YM XM.

29. The method of claim 28, wherein said
25 substrate is a naturally occurring substrate of said tyrosine kinase.

- 110 -

30. The method of claim 28, wherein said substrate is a synthetic substrate comprising the amino acid sequence YM XM.

31. A method of treating a mammal suffering from 5 a disease caused by the phosphorylation of a substrate of a tyrosine kinase, said substrate comprising the amino acid sequence YM XM comprising administering a therapeutically effective amount of a substance comprising the amino acid sequence YM XM.

10 32. A method of treating a mammal suffering from a disease caused by IRS-1 metabolism comprising administering to said mammal a therapeutically effective amount of a therapeutic agent which alters an aspect of the metabolism of IRS-1.

15 33. The method of claim 32, wherein said aspect of IRS-1 metabolism is the level of phosphorylation.

34. The method of claim 32, wherein said aspect of IRS-1 metabolism is the level of kinase activity of IRS-1.

20 35. The method of claim 32, wherein said abnormality comprises the inability of the insulin receptor to respond to insulin by phosphorylating IRS-1.

36. The method of claim 32, wherein said agent increases the phosphorylation of IRS-1.

25 37. The method of claim 32, wherein said agent decreases the phosphorylation of IRS-1.

- 111 -

38. The method of claim 32, wherein said disease is a cachectic disease.

39. The method of claim 32, wherein said agent is IRS-1.

5 40. A method of treating a mammal suffering from a disease caused by a tyrosine kinase comprising administering to said mammal a therapeutically effective amount of a therapeutic agent which modifies the ability of IRS-1 to alter the phosphorylation of said tyrosine 10 kinase, thereby altering the activity of said tyrosine kinase.

41. The method of claim 35, wherein said tyrosine kinase is the product of an oncogene.

42. A method of treating a mammal suffering from 15 a disease characterized by abnormal cell proliferation comprising administering to said mammal a therapeutically effective amount of a therapeutic agent which alters an aspect of IRS-1 metabolism.

43. The method of claim 37, wherein said aspect 20 of IRS-1 metabolism is IRS-1 phosphorylation.

44. The method of claim 38, wherein said aspect of IRS-1 metabolism is the level of kinase activity of IRS-1.

1/17




FIG. 1






FIG. 2

SUBSTITUTE SHEET

2/17

**FIG. 3****FIG. 4****SUBSTITUTE SHEET**

3/17




FIG. 5




FIG. 6

4/17




FIG. 7




FIG. 8

SUBSTITUTE SHEET

5/17




FIG. 9





FIG. 10

6/17



SUBSTITUTE SHEET

7/17

GGAATTCCCT	GGTATTTGGG	CGGCTGGTGG	CGGCAGGGAC	TGTTGGAGGG	TGGGAGGAGG	60
CAGAGGAGGA	GGAGGAGAAG	GAGGAGGAGG	GAGAACCCCG	TGCAACGTTG	GGACTTGGCA	120
GCCCCGCTCC	CCCTGCCAA	GGATATTTAA	TTTGCCTGGG	GAATCGCTAC	TTCCAGAGGG	180
GAACTCGGGA	GGGAAGGAGC	GCGCGCCTGG	AGGGCCAAGC	GGGGACTCCT	CCGGTCGTCT	240
CTGCCTCCCT	GCATCGGACT	CTACCAGGGG	CGGCAAGGGA	TGCACCATAG	CTCCTTCTCT	300
GCTGCAAGGA	CTGGGGAGA	CTTAGTCCTC	GGAAGATTGC	GGCTGCACTC	ACCCCTAGACC	360
CACTGCCTTT	CCCTCTGGGC	ATGAAACGCC	CTTAAACTCG	GATCAGGCTA	TCTTCCTTTG	420
GCGCAGCTAC	CTCGTCCTTC	GGCTGCCCT	CCCCAGCGCC	AGGAACGGCG	TGAATTCGG	480
AGTCAGGATT	TCTGCTTGCT	TCCTCCAGCC	CGGAGTGCAT	GTGCGGGGCC	GCACCGAGAA	540
GCCACCCCTC	ACCCAGTTTT	TCGACACCTC	CCTCTGCTCC	GCAGCAGC	ATG GCG AGC CCT	600
				Met	Ala Ser Pro	
				1		
CCG GAT ACC GAT GGC TTC TCA GAC GTG CGC AAG GTG GGT TAC CTG CGC						648
Pro Asp Thr Asp Gly Phe Ser Asp Val Arg Lys Val Gly Tyr Leu Arg						
5	10	15	20			
AAA CCC AAG AGT ATG CAT AAG CGC TTT TTC GTG CTG CCG GCG GCC AGC						696
Lys Pro Lys Ser Met His Lys Arg Phe Phe Val Leu Arg Ala Ala Ser						
25	30	35				
GAG GCC GGG GGC CCG GCG CGC CTG GAG TAT TAT GAG AAC GAG AAG AAG						744
Glu Ala Gly Pro Ala Arg Leu Glu Tyr Tyr Glu Asn Glu Lys Lys						
40	45	50				
TGG CGG CAC AAG TCG AGC GCC CCC AAA CGC TCG ATC CCC CTC GAG AGC						792
Trp Arg His Lys Ser Ser Ala Pro Lys Arg Ser Ile Pro Leu Glu Ser						
55	60	65				
TGT TTC AAC ATC AAC AAG CGG GCT GAC TCC AAG AAC AAG CAC CTG GTG						840
Cys Phe Asn Ile Asn Lys Arg Ala Asp Ser Lys Asn Lys His Leu Val						
70	75	80				
GCT CTC TAC ACC CGA GAC GAA CAC TTT GCC ATT GCG GCG GAT ACG GAG						888
Ala Leu Tyr Thr Arg Asp Glu His Phe Ala Ile Ala Ala Asp Ser Glu						
85	90	95	100			

FIG. 12
(PAGE 1 OF 7)

SUBSTITUTE SHEET

8/17

GCT GAA CAA GAC ACG TGG TAC CAG GCT CTT CTG CAG CTG CAT AAT CGG Ala Glu Gln Asp Ser Trp Tyr Gln Ala Leu Leu Gln Leu His Asn Arg 105 110 115	936
GCA AAG GCC CAC CAT GAC GGG GCT GGA GGA GGC TGC GGT GGT AGC TGC Ala Lys Ala His His Asp Gly Ala Gly Gly Gly Cys Gly Ser Cys 120 125 130	984
AGC GGC AGC TCT GGC GTC GGA GAG GCA GGG GAG GAC TTG AGC TAT GAC Ser Gly Ser Ser Gly Val Gly Glu Ala Gly Glu Asp Leu Ser Tyr Asp 135 140 145	1032
ACG GGC CCA GGA CCC GCG TTC AAG GAG GTC TGG CAG GTT ATC CTG AAA Thr Gly Pro Gly Pro Ala Phe Lys Glu Val Trp Gln Val Ile Leu Lys 150 155 160	1080
CCC AAG GGC TTA GGT CAG ACA AAG AAC TTG ATT GGT ATC TAC TAC CGC CTC Pro Lys Gly Leu Gly Gln Thr Lys Asn Leu Ile Gly Ile Tyr Arg Leu 165 170 175 180	1128
TCG CTG ACC AGC AAG ACC ATC AGC TTT GTG AAG CTC AAC TCT GAG GCT Cys Leu Thr Ser Lys Thr Ile Ser Phe Val Lys Leu Asn Ser Glu Ala 185 190 195	1176
GCC GCT GTG GTG CTG CAG CTG ATG AAC ATC AGA CGC TGT GGC CAC TCA Ala Ala Val Val Leu Gln Leu Met His Glu Thr Ile Leu Glu Ala Met 200 205 210	1224
CGG GCC ATG AGC CAT GAG TTT CGC CCG CGC ACG AAA AGC CAA TCT TCA Arg Ala Met Ser Asp Glu Phe Arg Pro Arg Thr Lys Ser Cln Ser Ser 215 220 225	1272
TCC AGT TGC TCC AAC CCC ATC AGT GTT CCC CTG CGC AGG CAC CAT CTC Ser Ser Cys Ser Asn Pro Ile Ser Val Pro Leu Arg Arg His His Leu 230 235 240	1320
AAC AAT CCT CCG CCC AGC CAA GTG GGG CTG ACT CCG AGA TCT CGA ACT Asn Asn Pro Pro Pro Ser Gln Val Gly Leu Thr Arg Arg Ser Arg Thr 245 250 255 260	1368
GAG AGC ATC ACT GCC ACC TCC CCT GCC AGT ATG GTG GGT GGG AAA CCA Glu Ser Ile Thr Ala Thr Ser Pro Ala Ser Met Val Gly Gly Lys Pro 265 270 275	1416
GGT TCC TTC AGG GTG CGT GCC TCC AGC GAT GGC GAA GGC ACC ATG TCC Gly Ser Phe Arg Val Arg Ala Ser Ser Asp Gly Glu Gly Thr Met Ser 280 285 290	1464
CGT CCA GCA TCA GTG GAT GGC AGT CCT GTG AGC CCT AGC ACC AAC AGG Arg Pro Ala Ser Val Asp Gly Ser Pro Val Ser Pro Ser Thr Asn Arg 295 300 305	1512

FIG. 12
(PAGE 2 OF 7)

SUBSTITUTE SHEET

9/17

ACC CAC GCC CAT CGG CAT CGA GGC AGC TCC AGG TTG CAC CCC CCA CTC Thr His Ala His Arg His Arg Gly Ser Ser Arg Leu His Pro Pro Leu 310 315 320	1560
AAC CAC AGC CGC TCC ATC CCT ATG CCT TCT TCA CGA TGC TCC CCT TCA Asn His Ser Arg Ser Ile Pro Met Pro Ser Ser Arg Cys Ser Pro Ser 325 330 335 340	1608
GCC ACC AGC CCA GTG AGC CTG TCA TCC AGT AGT ACC AGT GGC CAC GGC Ala Thr Ser Pro Val Ser Leu Ser Ser Ser Thr Ser Gly His Gly 345 350 355	1656
TCC ACT TCA GAC TGT CTC TTC CCG AGG CGC TCT AGT GCT TCC GTG TCC Ser Thr Ser Asp Cys Leu Phe Pro Arg Arg Ser Ser Ala Ser Val Ser 360 365 370	1704
GGT TCT CCT AGC GAT GGC GGT TTC ATC TCT TCT GAT GAG TAT GGC TCT Gly Ser Pro Ser Asp Gly Gly Ile Ser Ser Asp Glu Tyr Gly Ser 375 380 385	1752
AGT CCC TGC GAT TTC CGA AGT TCC TTC CGC AGT GTC ACC CCA GAT TCC Ser Pro Cys Asp Phe Arg Ser Ser Phe Arg Ser Val Thr Pro Asp Ser 390 395 400	1800
CTG GGC CAC ACC CCA CCA GCC AGG GGT GAG GAG GAG CTG AGC AAC TAT Leu Gly His Thr Pro Pro Ala Arg Gly Glu Glu Glu Leu Ser Asn Tyr 405 410 415 420	1848
ATC TGC ATG GGT GGC AAG GGA GCC TCC ACC TTG ACA GCT CCC AAT GGT Ile Cys Met Gly Gly Lys Gly Ala Ser Thr Leu Thr Ala Pro Asn Gly 425 430 435	1896
CAC TAC ATT TTG TCT AGG GGT GGC AAC GGC CAT CGC TAC ATC CCA GGT His Tyr Ile Leu Ser Arg Gly Gly Asn Gly His Arg Tyr Ile Pro Gly 440 445 450	1944
GCT ACC ATG GGG ACA ACC CCG GCG CTG ACT GGA GAC GAA GCC GCT GGT Ala Thr Met Gly Thr Ser Pro Ala Leu Thr Gly Asp Glu Ala Ala Gly 455 460 465	1992
GCA GCA GAT CTG GAT AAC CGG TTT CGG AAG AGA ACT CAC TCG GCT GGC Ala Ala Asp Leu Asp Asn Arg Phe Arg Lys Arg Thr His Ser Ala Gly 470 475 480	2040
ACG TCC CCC ACC ATA TCC CAC CAG AAG ACC CCC TCG CAG TCC TCA GTG Thr Ser Pro Thr Ile Ser His Gln Lys Thr Pro Ser Gln Ser Ser Val 485 490 495 500	2088
GTT TCT ATT GAG GAA TAT ACA GAG ATG ATG CCC GCT GCC TAC CCA CCA Val Ser Ile Glu Glu Tyr Thr Glu Met Met Pro Ala Ala Tyr Pro Pro 505 510 515	2136

FIG. 12
(PAGE 3 OF 7)

SUBSTITUTE SHEET

10/17

GGA GGT GGC AGT GGA GGC CGA CTG CCC GGC TAC CGG CAT TCC GCC TTC Gly Gly Gly Ser Gly Gly Arg Leu Pro Gly Tyr Arg His Ser Ala Phe 520 525 530	2184
GTG CCC ACC CAC TCC TAT CCC GAG GAG GGT CTA GAG ATG CAC CAC TTG Val Pro Thr His Ser Tyr Pro Glu Glu Gly Leu Glu Met His His Leu 535 540 545	2232
GAA CGT CGT GGG GGC CAC CAC CGT CCA GAC TCC TCC AAC CTC CAC ACC Glu Arg Arg Gly Gly His His Arg Pro Asp Ser Ser Asn Leu His Thr 550 555 560	2280
GAT GAT GGC TAC ATG CCC ATG TCT CCC GGA GTG GCT CCA GTG CCC AGC Asp Asp Gly Tyr Met Pro Met Ser Pro Gly Val Ala Pro Val Pro Ser 565 570 575 580	2328
AAC CGC AAA GGA AAT GGG GAC TAT ATG CCC ATG AGC CCC AAG AGT GTA Asn Arg Lys Gly Asn Gly Asp Tyr Met Pro Met Ser Pro Lys Ser Val 585 590 595	2376
TCT GCC CCC CAG CAG ATC ATT AAC CCC ATC AGG CGC CAC CCA CAG AGA Ser Ala Pro Gln Gln Ile Ile Asn Pro Ile Arg Arg His Pro Gln Arg 600 605 610	2424
GTG GAC CCC AAT GGC TAC ATG ATG ATG TCT CCC AGT GGT AGT TGC TCT Val Asp Pro Asn Gly Tyr Met Met Ser Pro Ser Gly Ser Cys Ser 615 620 625	2472
CCT GAC ATT GGA GGT GGG TCT TGC AGC AGT AGC AGC ATC AGC GCA GCC Pro Asp Ile Gly Gly Ser Cys Ser Ser Ser Ile Ser Ala Ala 630 635 640	2520
CCT TCT GGG AGC AGC TAT GGG AAG CCA TGG ACA AAC GGA GTA GGG GGG Pro Ser Gly Ser Ser Tyr Gly Lys Pro Trp Thr Asn Gly Val Gly Gly 645 650 655 660	2568
CAC CAT ACC CAT GCC CTT CCC CAT GCC AAA CCT CCT GTT GAG AGC GGT His His Thr His Ala Leu Pro His Ala Lys Pro Pro Val Glu Ser Gly 665 670 675	2616
GGT GGT AAG CTC TTG CCT TGC ACT GGT GAC TAC ATG AAC ATG TCG CCA Gly Gly Lys Leu Leu Pro Cys Thr Gly Asp Tyr Met Asn Met Ser Pro 680 685 690	2664
GTG GGA GAT TCC AAC ACC AGC AGC CCC TCA GAA TGC TAC TAT GGC CCA Val Gly Asp Ser Asn Thr Ser Ser Pro Ser Glu Cys Tyr Tyr Gly Pro 695 700 705	2712
GAA GAT CCC CAG CAC AAG CCT GTC CTC TCC TAC TAC TCA TTA CCA AGG Glu Asp Pro Gln His Lys Pro Val Leu Ser Tyr Tyr Ser Leu Pro Arg 710 715 720	2760
TCC TTT AAG CAC ACC CAG CGC CCT GGG GAG CCA GAG GAG GGT GCC AGG	2808

11/17

Ser Phe Lys His Thr Gln Arg Pro Gly Glu Pro Glu Glu Gly Ala Arg 725 730 735 740	
CAC CAG CAT CTT CGT CTC TCT TCA AGC TCT GGA CGC CTT CGC TAT ACC His Gln His Leu Arg Leu Ser Ser Ser Gly Arg Leu Arg Tyr Thr 745 750 755	2856
GCA ACT GCC GAA GAT TCC TCC TCT TCC ACC AGC AGC GAC AGC CTG GGT Ala Thr Ala Glu Asp Ser Ser Ser Thr Ser Ser Asp Ser Leu Gly 760 765 770	2904
GGG GGT TAC TGT GGG GCT AGG CCA GAG TCT AGC GTC ACA CAT CCC CAC Gly Gly Tyr Cys Gly Ala Arg Pro Glu Ser Ser Val Thr His Pro His 775 780 785	2952
CAC CAT GCC TTG CAG CCC CAT CTG CCT CGA AAG GTA GAC ACA GCT GCA His His Ala Leu Gln Pro His Leu Pro Arg Lys Val Asp Thr Ala Ala 790 795 800	3000
CAG ACC AAC AGC CGC CTG GCT CGA CCC ACA AGG CTG TCC TTG GGG GAT Gln Thr Asn Ser Arg Leu Ala Arg Pro Thr Arg Leu Ser Leu Gly Asp 805 810 815 820	3048
CCC AAG GCA AGC ACT TTA CCC CGG GTA CGA GAG CAA CAG CAG CAG CAG Pro Lys Ala Ser Thr Leu Pro Arg Val Arg Glu Gln Gln Gln Gln Gln 825 830 835	3096
CAA CAG CAG CAG TCT TCC CTG CAC CCT CCC GAG CCC AAA AGC CCA Gln Gln Gln Gln Ser Ser Leu His Pro Pro Glu Pro Lys Ser Pro 840 845 850	3144
GGA GAA TAT GTG AAT ATT GAA TTC GGG AGT GGC CAG CCA GGC TAT TTA Gly Glu Tyr Val Asn Ile Glu Phe Gly Ser Gly Gln Pro Gly Tyr Leu 855 860 865	3192
GCT GGC CCT GCA ACT TCC CGT AGC TCC CCT TCA GTT CGA TGT CTA CCC Ala Gly Pro Ala Thr Ser Arg Ser Pro Ser Val Arg Cys Leu Pro 870 875 880	3240
CAG CTC CAC CCA GCT CCC AGA GAA GAG ACT GGC TCG GAA GAG TAC ATG Gln Leu His Pro Ala Pro Arg Glu Glu Thr Gly Ser Glu Glu Tyr Met 885 890 895 900	3288
AAC ATG GAC TTG GGG CCA GGC CGG AGG GCA ACC TGG CAG GAG AGT GGT Asn Met Asp Leu Gly Pro Gly Arg Arg Ala Thr Trp Gln Glu Ser Gly 905 910 915	3336
GGA GTT GAG TTG GGC AGA GTA GGC CCT GCA CCT CCA GGG GCT GCT TCC Gly Val Glu Leu Gly Arg Val Gly Pro Ala Pro Pro Gly Ala Ala Ser 920 925 930	3384
ATT TGT AGG CCA ACC CGG TCG GTG CCA AAT AGC CGT GGT GAT TAC ATG Ile Cys Arg Pro Thr Arg Ser Val Pro Asn Ser Arg Gly Asp Tyr Met	3432

FIG. 12
(PAGE 5 OF 7)

12/17

935	940	945	
ACC ATG CAG ATA GGT TGT CCT CGT CAA AGC TAT GTG GAT ACC TCA CCA Thr Met Gln Ile Gly Cys Pro Arg Gln Ser Tyr Val Asp Thr Ser Pro	950	955	3480
960			
GTG GCC CCA GTC AGC TAT GCT GAC ATG CGG ACA GGC ATT GCT GCA GAG Val Ala Pro Val Ser Tyr Ala Asp Met Arg Thr Gly Ile Ala Ala Glu	965	970	3528
975			
980			
AAG GTG AGC CTG CCC AGA ACC ACA GGA GCT GCC CCC CCT CCA TCC TCC Lys Val Ser Leu Pro Arg Thr Thr Gly Ala Ala Pro Pro Pro Ser Ser	985	990	3576
995			
ACA GCC TCT TCT GCT TCT GTT AAA GTG ATT CGT GCA GAC ACT CAA Thr Ala Ser Ala Ser Val Lys Val Ile Arg Ala Asp Thr Gln	1000	1005	3624
1010			
GGC TGC CGG AGG AGG CAC AGC TCC GAG ACC TTC TCG GCG CCT ACG CGG Gly Cys Arg Arg His Ser Ser Glu Thr Phe Ser Ala Pro Thr Arg	1015	1020	3672
1025			
GCT GCC AAC ACA GTG TCT TTT GGA GCA GGG GCT GCA GGA GGG GGC AGC Ala Ala Asn Thr Val Ser Phe Gly Ala Gly Ala Gly Gly Ser	1030	1035	3720
1040			
GGT GGT GGC AGT GAG GAT GTG AAA CGC CAC AGC TCT GCA TCC TTT GAG Gly Gly Gly Ser Glu Asp Val Lys Arg His Ser Ser Ala Ser Phe Glu	1045	1050	3768
1055			
1060			
AAT GTG TGG CTG AGA CCC GGG GAT CTA GGG GGA GCA TCC AAG GAG TCG Asn Val Trp Leu Arg Pro Gly Asp Leu Gly Gly Ala Ser Lys Glu Ser	1065	1070	3816
1075			
GCT CCA GGG TGC GGG GCT GCC GGG GGA TTG GAG AAG AGT CTT AAC TAT Ala Pro Gly Cys Gly Ala Ala Gly Gly Leu Glu Lys Ser Leu Asn Tyr	1080	1085	3864
1090			
ATA GAC TTG GAT TTG GTC AAG GAT GTT AAG CAG CAC CCT CAA GAC TGC Ile Asp Leu Asp Leu Val Lys Asp Val Lys Gln His Pro Gln Asp Cys	1095	2000	3912
2005			
CCC TCT CAA CAG CAG TCC CTG CCA CCC CCT CCC CAC CAA CCC TTA Pro Ser Gln Gln Ser Leu Pro Pro Pro Pro His Gln Pro Leu	2010	2015	3960
2020			
GGC AGC AAT GAG GGC AGC TCC CCA AGA CGC TCC AGT GAG GAT TTA AGC Gly Ser Asn Glu Gly Ser Ser Pro Arg Arg Ser Ser Glu Asp Leu Ser	2025	2030	4008
2035			
2040			
ACC TAT GCC AGC ATC AAC TTC CAG AAG CAA CCA GAG GAC CGT CAA Thr Tyr Ala Ser Ile Asn Phe Gln Lys Gln Pro Glu Asp Arg Gln	2040	2045	4053
2050			

FIG. 12
(PAGE 6 OF 7)

13/17

TAGCTTAACT GGACGTCACA GCCAGAATGA AAGACCTAAA TGACCTCAGC AATCCTCCTT	4113
TTAACTCAT GGGTACCCAG ACTCGAACTC TTTCACGATT CACAACCAGG ACCTCACGTC	4173
TTCCCTCCTCA GTAGATGGTA CGATGCATCC CTTACAGTTT GTTTACTTTG TACAATCCTC	4233
AGGAGTTCAT TGACTGAACT GCACGTTCTT TATTGTGCCA AGCAACAAGA AAGCACTGTG	4293
ACACCGAAC AATGAGTGTG CATAAACTTC ATCTGAACT TTAAGGACAG CTGGCCACGA	4353
AGAGCCAGTG TGCTCCCTGC CACGCCGAAA GAGGATGGGT TTACTCTCGT CAAATTACAA	4413
AGCATAACGGT TCCTCTGCTC TGAAACCGTG TTCCATGACA CGCCGCTGTA AATTATTCA	4473
TATGGAACTG TTCGCGTTGG GTGGAGAGAG TATTAATAT TTAACATAGG TCTTCATTAA	4533
TATATGTAAT TTTTTAATGA AAATGTAAC TTCCTCACAG CACATTTTT TTCTCTGGAA	4593
ATGTGGAACG GAGGTATTCA ATGTTTGTT TTAAAGAGTG GGAAGAATAC TTAAAACAAG	4653
GCTAAAAAGA GTAGACTAGG AGATGATCCT TGTTTAAGA TTCTAATTCA GAAAAATAAT	4713
ATAATATGAA TCATAGTGCC ATAGAAGGTT CTGGACTGTA TAGTTGACT TGCTGATGCT	4773
GTCTCTTGTAA ATATAAACTT GATGTCGAGC TGAGTTCTT TTAAGAATTA AGCTAAGTTT	4833
TGTAATTTTT TTTTTTCCA AACCGAAGGA GGATGTATTG TACTGGGTG TTTTCAAGTG	4893
TCGGCTTAGA ATTGGAAGTT GAATGGAAGC AAAGTTCAAC AAAGAGAGGA AGCCACAGAC	4953
TTCCATTGTA AATACTGTAG AGAGAGACAT GAGCGATCCC TTCAAGTCAA AAATCTCTCT	5013
TTGGAATGAA GAATGTGGGT GTTTATAAAT TCTGAAAATG TCTTTCTGTT CATAATAAAC	5073
TAGACACTGT TGGTCCCTCC CCACCCCCAC TTCTATAAGC CTTTCCCCCG GA	5125

FIG. 12
(PAGE 7 OF 7)

14/17




FIG. 13

15/17




FIG. 14




FIG. 15a





FIG. 15b



RESIDUE FIG. 15c

SUBSTITUTE SHEET

16/17




FIG. 16

17/17




FIG. 17




FIG. 18

SHIRSTITIITE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US92/00437

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5): C12P 1/00, 1/25, 1/68, 21/00 US CL : 536/22; 435/7.1, 172.3; 436/63; 530/413; 514/12.		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	536/22; 435/7.1, 172.3; 436/63; 530/413; 514/12.	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁶		
cas online, medline, aps		
III. DOCUMENTS CONSIDERED TO BE RELEVANT¹⁴		
Category ⁷	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	nature, volume 318, issued 14 November 1985, M.F. White et al, "Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells" pages 183-188, see entire document.	1-44
X	Archives of Biochemistry and Biophysics, Volume 242, No. 1, issued 01 October 1985, D.T. Pang et al, "Purification of the Catalytically active phosphorylated form of insulin receptor kinase by affinity chromatography with O-phosphotyrosyl-binding antibodies" pages 176-186, see entire document.	1-11
Y	Biochemistry, Volume 12, No. 24, issued 20 November 1973, B.A. Cunningham et al, "The complete amino acid sequence of beta2-microglobulin" pages 4811-4822, see entire document.	1-11
Y	Proceedings of the National Academy of Sciences, Volume 78, No. 11, issued 01 November 1981, S.V. Suggs et al, "Use of synthetic oligonucleotides as hybridization probes" pages 6613-6617, see entire document.	1-11
<p>[*] Special categories of cited documents:¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
02 APRIL 1992	37 APR 1992	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	Gregory P. Einhorn	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

P,X	Nature, volume 352, issued 04 July 1991, X.J. Sun et al, "Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein" pages 73-77, see entire document.	1-44
P,X	Biochemical and biophysical research communications, Volume 180, No. 2, issued 31 October 1991, H.J. Goren et al, "The 180000 molecular weight plasma membrane insulin receptor substrate is a protein tyrosine phosphatase and is elevated in diabetic plasma membranes" pages 463-469, see entire document.	1-44

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers , because they relate to subject matter (1) not required to be searched by this Authority, namely:

2. Claim numbers , because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out (1), specifically:

3. Claim numbers , because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

Please See Attached Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Search Authority did not invite payment of any additional fee.

Remark on protest

- The additional search fees were accompanied by applicant's protest.

- No protest accompanied the payment of additional search fees.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
P,X	The Journal of Biological Chemistry, Volume 266, no. 12, issued 05 May 1991, P.L. Rothenberg et al, "Purification and partial sequence analysis of pp185, the major cellular substrate of the insulin receptor tyrosine kinase" pages 8302-8311, see entire document.	1-44
A,P	The New England Journal of Medicine, volume 325, No. 13, issued 26 September 1991, F.H. Epstein et al, "Insulin resistance - mechanisms, syndromes, and implications" pages 938-948, see entire document.	1-44

FURTHER INFORMATION CONTINUED FROM PREVIOUS SHEETS

VI. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

- I. Claims 1-6, 8, 9, 12-18 drawn to a first composition and a first method of making and a first method of use, classified in Class 536/22, 435/172.3, 436/63.
- II. Claim 7, drawn to a second composition, classified in Class 530/350.
- III. Claims 19-22, drawn to a second method of use, classified in Class 436/63.
- IV. Claims 23-34, drawn to a third method of use, classified in Class 435/7.1.
- V. Claim 27, drawn to a fourth method of use, classified in Class 435/7.1.
- VI. Claims 28-30, drawn to a fifth method of use, classified in Class 435/7.1.
- VII. Claim 31, drawn to sixth method of use, classified in Class 514/12.
- VIII. Claims 32-39, 41, 43, 44, drawn to a seventh method of use, classified in Class 514/12.
- IX. Claim 40, drawn to an eighth method of use, classified in Class 514/12.
- X. Claim 42, drawn to a ninth method of use, classified in Class 514/12.